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Abstract 
 
In a forever busy pharmaceutical market, the need for analgesic and anti-inflammatory drugs 
is still in high demand. Various conditions such as rheumatoid arthritis, diabetes or viral 
infections are frequently associated with persistent and unalleviated pain, therefore 
uncovering novel pharmacological targets is deemed necessary.  
Store-operated calcium entry (SOCE), a complex mechanism orchestrated by calcium release 
activated calcium (CRAC) channels, has been recently associated with neuropathic and 
inflammatory pain. Moreover, several attempts to describe the presence of CRAC channel 
molecular components in pain-sensing DRG and dorsal horn neurons have been made. Yet, 
the exact identity of CRAC channel complex components, the function of junctional proteins 
in CRAC channel assembly and the exact role of SOCE within primary afferent neurons 
remains poorly understood. Here I hypothesized that SOCE functions as a facilitator of Ca2+ 
signalling in inflammatory pain conditions and that junctional proteins offer a supportive role 
of the CRAC channels assembly in DRG neurons. 
To test this, I characterized the localization pattern of CRAC components within DRG neurons 
by immunohistrochemistry. STIM (1 and 2) and Orai (1 and 3) isoforms were all expressed 
within primary afferent neurons of different sensory modalities. STIM1 and Orai1 were 
expressed to a higher degree as compared to their family members and co-localized into puncta 
upon SOCE activation as demonstrated by proximity ligation assay (PLA). Interestingly, 
STIM2 revealed a higher preference in large-diameter (presumed mechanosensory) neurons, 
as compared to STIM1. 
To confirm the presence of SOCE, the effect of CRAC inhibitors YM58483 and Synta66 in 
DRG neurons was also investigated. Both compounds significantly reduced SOCE in DRG 
neurons; the efficacy of inhibition was dramatically increased by pre-incubation suggesting 
that these CRAC inhibitors may not act as direct ion channel pore blockers but rather interfere 
with the CRAC complex functional assembly. 
v 
 
CRAC channel complex assembly relies on the close proximity of the cellular plasma 
membrane and endoplasmic reticulum, yet, nothing is known thus far about how these 
membrane junctions are maintained in DRG. This thesis brings evidence of the expression of 
Junctophilin (JPH) proteins within primary sensory neurons. Amongst the family members, 
JPH4 was expressed the highest, followed by JPH1 and JPH3, while no expression of JPH2 
was observed.  
Moreover, experiments using immunocytochemistry revealed that JPH4 is co-expressed with 
Orai1 and STIM1 in pain-sensing neurons, while PLA demonstrated that both Orai1 and 
STIM1 co-localize with JPH4 at endoplasmic reticulum (ER)-plasma membrane (PM) 
junctions upon bradykinin (BK) -induced SOCE. 
To test whether JPH4 is a SOCE facilitator, several experiments were performed. Thus, it was 
demonstrated that STIM1 directly interacts with JPH4 upon ER Ca2+ store depletion using 
immunoprecipitation. Furthermore, knocking-down JPH4 disrupted the Orai1-STIM1 
clustering and coupling at the ER-PM junctions as observed by PLA. Interestingly, silencing 
JPH4 in DRG neurons inhibited SOCE without altering the basal Ca2+ pool levels and impaired 
the subsequent ER Ca2+ store refill, as demonstrated by calcium imaging experiments. These 
observations taken together strengthen the role of JPH4 in facilitating SOCE in DRG neurons. 
CRAC channels have been previously considered attractive targets for treatment of 
inflammatory conditions and more pharmaceutical companies showed an increased interest in 
developing CRAC modulators in the past decade. The high expression of JPH4 in peripheral 
sensory neurons, its importance in promoting the CRAC channel assembly and its role on the 
oscillatory ER Ca2+ refill provide evidence for considering JPH proteins as putative targets for 
treating inflammatory pain.  
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 Chapter 1. Introduction 
 
At some point in life, everyone should experience the sensation called pain; the ability to feel 
it is critical for survival. Patients with congenital insensitivity to pain (CIP), first described by 
Swanson in 1963, represent rare clinical cases when undetectable body injuries can become 
fatal. Pain protects us against harmful external stimuli (noxious heat or cold, physical tissue 
damage or chemical irritants) and internal threats (such as broken bones or infections) 
(Stemkowski et al. 2012). Thus, without the ability to sense it, our body will not be able to 
acknowledge trauma and to further protect itself from harm. 
Researchers continuously invest resources to attain an in depth understanding of pain 
mechanisms as well as supporting the demand for analgesics that we are facing nowadays. 
While acute pain is attenuated once the injured tissue is healed (such as postoperative pain), 
chronic pain is persistent and its management is challenging. Chronic pain has a multifactorial 
etiology and is not an extension of acute pain (Mao et al. 2017). For this reason, patients with 
various conditions such as diabetes, arthritis, neuropathic or cancer-related pain still suffer 
from unalleviated pain. The current treatments are not sufficient to attenuate pain in certain 
clinical cases and this affects greatly the quality of patients’ lives. For a correct diagnosis and 
an efficient treatment, the development of novel diagnostic tools and analgesics is extremely 
necessary and in very high demand.   
 
The following chapter is a review of the most recent and relevant research publications to 
support the objectives of this thesis. Firstly, I will offer an overview of the general aspects of 
pain signaling, followed by discussing the importance of store-operated calcium-entry in 
inflammatory pain and, finally, outlining the role of junctophilin proteins in modulating 
calcium dynamics. 
 
2 
 
1.1 Nociception 
Our skin and internal organs contain unspecialized peripheral nerve endings of neurons that 
are responsible for responding to sensorial stimuli (Stemkowski et al. 2012). An interesting 
characteristic of these neurons is their morphology: a pseudo-unipolar axon projecting from 
the soma and bifurcating towards the periphery where the stimuli is detected and towards the 
spinal horn, where they synapse with secondary neurons which in-turn further project signals 
to the relevant structures in the brain (Devor et al. 1999; Tandrup et al. 1995).  
The process by which noxious stimuli are detected is called nociception and the primary 
afferent neurons that respond to it are referred to as nociceptors (Dubin and Patapoutian, 
2010). The somata of primary nociceptors reside in the trigeminal ganglia (TG; 1 pair, for 
detecting cephalic stimuli) and the dorsal root ganglia (DRG; 29 pairs at each vertebra in 
humans) (Basbaum et al. 2009).  
The nociceptive terminal expresses different proteins that are selectively activated in response 
to external stimuli. Types of proteins that are most frequently activated during this detection 
phase are: receptor-activated channels, ROC (e.g. the heat sensor TRPV1), G-protein coupled 
receptors, GPCR (e.g. bradykinin or histamine receptor), or voltage-operated channels, VOC 
(e.g. voltage-gated sodium channels) (Bourinet et al. 2014, Stemkowski et al. 2012). 
 
Nociceptors are typically categorized based on fiber size, the type of the sensory stimuli they 
detect and how fast they conduct an action potential. The three main classes of sensory fibers 
are: 
i) Aβ fibers, large myelinated fibers with fast conductivity; they respond to light touch and 
pressure 
ii) Aδ fibers, medium thinly myelinated fibers with lower conductivity; they respond to 
mechanical and/or thermal stimuli 
iii) C fibers, small non-myelinated fibers with slow conductivity; they respond to 
mechanical, thermal and/or chemical stimuli.  
3 
 
The myelination of fibers determines the speed of action potential conduction through the 
axon. Regarding pain, Aδ fibers are responsible for mediating the first component of pain, 
whereas C fibers detect and propagate the secondary slow pain. Table 1.1 shows the 
classification of nerve fibers based on diameter, conduction velocity myelination and function. 
 
Table 1.1 The classification on sensory fibers based on conduction velocity and size 
 
Other ways to classify peripheral sensory neurons also exist. For instance, C fibers are further 
subcategorized in two groups: i) ‘peptidergic’ fibers that express nerve growth factor (NGF) 
receptor, tyrosine kinase A (TrkA), calcitonin-gene related peptide (CGRP) and Substance P 
(SP); and ii) ‘non-peptidergic’ fibers that express the purinergic receptor P2X3 while lacking 
CGRP or SP (Basbaum et al. 1999, Vuchanova et al. 1998). Recently, sequencing studies have 
also been used to further subdivide nociceptors however, this is outside the scope of the current 
thesis. (Usoskin et al. 2015; Li et al. 2016).  
 
 
 
Type of sensory fiber Diameter 
(µm) 
Conduction 
velocity (m/s) 
Myelinated? Function 
Aβ fiber 5-12 30-70 Myelinated fine touch 
Aδ fiber 2-5 12-30 Thinly 
myelinated 
light touch 
fast pain 
temperature 
C fiber 0.5-1 0.5-2 Not 
myelinated 
slow pain 
temperature 
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1.2 The ascending pathway of pain 
An external stimulus, such as noxious heat, activates a sensory receptor found at the nerve 
endings of nociceptors. This first event is called a receptor potential which involves 
depolarization of the membrane due to an inward current flow (Basbaum et al. 2009). The 
receptor potential leads to the the activation of voltage-gated ion channels (such as voltage-
gated calcium, sodium and potassium channels) that play a key role in both neurotransmitter 
release and generation of action potentials (Fletcher A. 2011). 
Upon action potential generation, the signal is propagated through the neuronal fiber (axon), 
thus enabling communication with postsynaptic neurons found in the dorsal horn (Dubin et al. 
2010) (Figure 1.1). The dorsal horn of the spinal cord is organized into distinct laminae where 
nociceptors of different sensory modalities terminate (Figure 1.1). As such, Aβ fibers 
terminate deeper in the dorsal horn (laminae III, IV, V) whereas Aδ afferents project to both 
lamina I and lamina V. Interestingly, C fibers reveal distinct projection patterns depending on 
their subtype: most peptidergic C nociceptors terminate in lamina I and deeper lamina II, while 
non-peptidergic fibers project in the ventral part of lamina II (Basbaum et al. 2009) (Figure 
1.1). Therefore, neurons within laminae I and II are responsive to noxious stimuli (through Aδ 
and C afferents), neurons in laminae III and IV respond to innocuous stimulation (via Aβ 
fibers) and neurons in lamina V respond to both noxious and non-noxious stimuli.   
Dorsal horn (second order) neurons ascend via the spinothalamic tract and project to different 
areas of the brain such as the thalamus and the parabrachial nucleus (Figure 1.1). From these 
areas, third order neurons project to the somatosensory cortex and amygdala, and further to 
the insular and cingulate cortices where the emotional component of pain is processed 
(Basbaum et al. 2009) (Figure 1.1). Other second order neurons terminate at the rostral ventral 
medulla and parabrachial nucleus where descending modulation takes place. Orofacial 
noxious stimuli detected by the TG nociceptors follow a similar pathway, but via the TG nerve 
and the subsequent trigemino-thalamic pathway (Basbaum et al. 2009). 
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Figure 1.1 Anatomy of the pain pathway. The noxious stimulus is detected at the nociceptive terminal 
of the primary afferent neurons. These reside in the dorsal root ganglia (DRG) and the trigeminal 
ganglia (TG, not shown). The dorsal horn reveals a laminar organization where nociceptors terminate. 
Peptidergic C fibers (green) and Aδ fibers (blue) project superficially in the lamina I of the dorsal horn, 
while the non-peptidergic C fibers (dark green) terminate in the inner part of lamina II. Laminae III and 
IV receive input from Aβ fibers, while lamina V neurons are responsive to both noxious and non-
noxious stimuli via Aδ and Aβ nociceptors, respectively. Second order neurons project further to 
different areas of the brain: to the thalamus where information about the location and the intensity of 
the stimulus is transmitted, to the amygdala via the parabrachial nucleus, where the emotional 
component of the pain is generated and to the periaqueductal gray and rostral ventral medulla regions 
where the descending feedback occurs. Figure based on Basbaum et al. 2009. 
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1.3 Types of pain 
Despite the critical role of pain to protect us from harm, not all types of pain are beneficial to 
the body. Differentiating pain is necessary for diagnostics and treatment, therefore many 
(sometimes overlapping) classifications have been generated based on various factors such as 
time course, physiology of pain, intensity and location /type of tissue.  
Based on physiology, pain can be classified as nociceptive (transient, acute) pain, neuropathic 
(nervous system injury) pain and inflammatory (tissue injury) pain. Interestingly, more than 
one mechanism can be present at once and a patient can suffer more than one type of pain. For 
example, inflammatory pain signalling is also involved in neuropathic pain (Xu et al. 2011). 
Nociceptive pain occurs as a result of noxious stimulation in an otherwise healthy tissue and 
is based on nociceptor specialization in sensing heat, chemical or mechanical stimuli (Carr et 
al. 1999). It is characterized as being the physiological, acute type of pain produced by the 
activation of nociceptors found in internal organs or skin (Carr et al. 1999). This can be 
referred to as ‘healthy pain’ which is emplaced to provide protection to the body (see above).  
Conversely, Neuropathic pain is defined as pain “initiated or caused by a primary lesion or 
dysfunction in the nervous system” (IASP definition, www.iasp-pain.org) and it appears as 
hyperalgesia (exaggerated pain sensation subsequent to a noxious stimulus) or allodynia (pain 
sensation following an innocuous stimulus). (Bridges et al. 2001) Persistent pain secondary to 
nerve injury is a very complex phenomenon and comprises of pathological remodelling of 
peripheral afferents and central sensitisation in both the spinal cord and the brain. (Campbell 
et al.2006). The neuropathic pain signalling pathways have been intensely studied and the 
ongoing focus on the proteins involved (ion channels, receptors, enzymes) led to some success 
in the development of targeted pain therapies. Yet, the complexity of neuropathic pain poses 
substantial challenges to both researchers and clinicians. Viral infections (e.g. with Herpes 
zoster), cancer therapies (e.g. chemotherapy agents such as paclitaxel) or various diseases (e.g. 
diabetes) can generate nerve damage and therefore become the main source of unalleviated 
persistent pain (Campbell et al. 2006). At the moment, the sufferers can only benefit from 
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drugs that temporary reduce the pain secondary to the nerve injury. As personalised healthcare 
is moving forward, we are looking towards a future of individual targeted therapies and novel 
pharmacological targets to be discovered. However, despite the importance of such studies, 
neuropathic pain is outside the scope of this thesis.  
Inflammatory pain is usually generated by a tissue lesion and is one of the five characteristics 
of inflammation: heat (calor), swelling (tumor), pain (dolor), redness (rubor) and loss-of-
function (function laesa). (Kidd et al. 2001). Inflammation generates an immune response 
which involves the release of numerous signalling factors by immune cells (e.g. leukocytes, 
neutrophils) and damaged tissue (Figure 1.2). At the injury site, mediators are released from 
damaged cells into the extracellular space which act on the peripheral terminals of nociceptive 
afferents by directly activating or sensitizing them to other chemical and physical stimuli (Das 
V. 2015) (Table 1.2).  The receptors they activate fall into three main categories: i) G-protein 
coupled receptors (GPCR), ii) receptor tyrosine kinases (Trk) and iii) ion channels (Linley et 
al. 2010). 
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Figure 1.2. Mechanisms of inflammatory pain pathways in peripheral sensory neurons. A tissue 
lesion generates an immune response and the subsequent release of pro-inflammatory mediators (such 
as BK). These mediators further act on local peripheral nociceptors (e.g. BK receptors B1, B2) and 
trigger internal cascades responsible for the generation of an action potential. Figure adapted from Das 
V. 2015. 
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Table 1.2 Summary of key inflammatory mediators released during an immune response (This 
list has been adapted from Jeske NA 2015) 
 
Mediator  
and its source 
Tissue target Receptor Somatic target 
Bradykinin 
(immune cells, 
plasma) 
Blood vessels 
 Nociceptors 
B1R 
B2R 
Thermal 
Mechanical 
Substance P 
(nociceptors) 
Immune cells 
Blood vessels 
Nociceptors 
NK1R Thermal 
Mechanical 
Glutamate 
(microglia, 
nociceptors) 
Nociceptors mGluR1  
mGlu2/3  
mGluR5 
Thermal 
Mechanical 
Serine proteases 
(immune cells, 
nociceptors) 
Nociceptors PAR1 
PAR2 
PAR4 
Thermal 
Mechanical 
Endothelin 
(endothelial cells) 
Blood vessels 
 Nociceptors 
ETaR 
ETbR 
Thermal 
Mechanical 
Chemical 
Serotonin 
(immune cells) 
Nociceptors 5-HT1A 
2A, 2B 
3, 4, 7 
Thermal 
Mechanical 
Chemical 
Prostaglandin 
(microglia, 
nociceptors) 
Nociceptors EP1, 2 
EP3B, 3C 
EP4 
DP1, 2 
Thermal 
Mechanical 
Chemical 
CGRP 
(nociceptors) 
Blood vessels 
Nociceptors 
Endothelial cells 
CRLR 
RAMP1 
Thermal 
Mechanical 
 
ATP 
(microglia, 
nociceptors) 
Nociceptors 
Immune cells 
Microglia 
P2X2, 3, 4, 7 
P2Y 
Thermal 
Mechanical 
 
NGF 
(immune cells, 
nociceptors) 
Nociceptors 
Immune cells 
TrkA 
GPR30 
Thermal 
Mechanical 
 
10 
 
1.4 G-protein coupled receptors  
G-protein coupled receptors (GPCRs) form the largest family signalling proteins with 
approximately 850 members (Geppetti et al. 2015). They are highly involved in mediating 
pain and itch as they reside in the nerve terminal of sensory neurons. GPCRs sense and respond 
to stimuli from immune cells, epithelial tissue or the circulation and also have a key role in 
neurogenic inflammation (Geppetti et al. 2015). G-proteins are generally classified as 
monomeric G-proteins (or small G-proteins) and heterotrimeric G-proteins (composed of three 
different subunits α, β and γ) (Geppetti et al. 2015, Purves et al. 2001). G-protein activation 
alters the function of different downstream effectors, mainly enzymes such as adenylyl cyclase 
(AC) or phospholipase C (PLC) (Figure 1.3). In turn, these enzymes produce second 
messengers that activate different intracellular signalling cascades (Purves et al. 2001). 
Interestingly, specific G-protein subunits trigger different cascades, and therefore the 
signalling pathway is receptor-dependent (Figure 1.3). As such: 
i) Activation of Gs proteins triggers the stimulation of adenylyl cyclase (AC) with cyclic 
adenosine monophosphate (cAMP) being generated. Furthermore, protein kinase A 
(PKA) is activated and modulates other proteins through phosphorylation, such as voltage 
gated sodium channels (NaV1.7) (Figure 1.2). These channels are responsible for the 
depolarization phase of the action potential in various excitable cells (Linley et al. 2010; 
Bhave et al. 2002). Among the inflammatory GPCR coupled to Gs are prostaglandin 
receptors EP2, 4 and DP1, prostacyclin (IP) receptor, serotonin (5-HT) receptors and 
endothelin (ET) receptor A 
ii) Opioid receptors, GABAB, dopamine D2 and some other receptors are coupled to Gi/o 
proteins; once activated, they promote an analgesic effect by reducing the cAMP levels 
and further inhibiting presynaptic NaV1.7 channels. Interestingly, it has been shown that 
bradykinin (BK) has a role in the insertion of delta-opioid receptors in the plasma 
membrane of peripheral sensory neurons (Linley et al. 2010) 
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iii) Receptors coupled to Gq/11  subunits stimulate the plasma membrane 
phosphatidylinositol-4,5-biphosphate (PIP2) cleavage by phospholipase C (PLC). This 
generates two metabolites: inositol triphosphate (IP3) and diacylglycerol (DAG). DAG 
activates the protein kinase C (PKC) that targets various ion channels such as the heat 
sensor, TRPV1, while IP3 binds to IP3 receptors (IP3R) found in the endoplasmic 
reticulum (ER) membrane, further generating a calcium release from the ER pool into the 
cytosol (Jung et al. 2004). Among inflammatory GPCR expressed in nociceptors are 
histamine receptor H1, BK receptor 2 (B2R), prostaglandin receptor EP1, substance P 
receptor NK1 and purinergic receptor P2Y. 
 
 
 
Figure 1.3 Intracellular signalling cascades associated with GPCRs. In all three examples, binding 
a GPCR agonist to its specific receptor leads to the activation of the G-protein. Further on, downstream 
effector proteins recruit second messengers and trigger specific pathways (from left to right: Gs, Gq 
and Gi as examples for heterotrimeric G-proteins). Figure adapted from Purves et al. 2001. 
 
12 
 
1.5 Ca2+ signalling 
In the remaining pages of this chapter I will focus on Ca2+ signalling as this is the main topic 
of the current study.  Ca2+ acts as a ubiquitous secondary messenger regulating a plethora of 
cellular functions, ranging from gene expression to contractility and from synaptic transition 
to cell death (Cerella et al. 2010). One recognised role of Ca2+ in the nervous system is 
facilitation of synaptic transmission.  Due to the steep Ca2+ gradient present between the inside 
and outside of the cell, voltage-gated Ca2+ channel (VGCC) activation allows Ca2+ to flood 
into the cell and increase the cytoplasmic concentration of Ca2+.  Further on, Ca2+ binds to 
synaptotagmin-1 (a protein localized to synaptic vesicles) and triggers exocytosis (Clapham 
et al. 2007). There are multiple calcium-permeable channels involved in pain signalling and 
VGCCs represent the dominant pathway of calcium entry through depolarization. (Bourinet 
et al. 2014). These channels can be categorized depending on their mode of action: high 
voltage activated channels (further classified as L-, N-, P-, Q- and R- types) and low voltage 
activated channels (T-type) (Bourinet et al. 2014). 
Other Ca2+-permeable channels such as N-methyl-D-aspartate (NMDA), transient receptor 
potential (TRP) or P2X receptors are non-selective calcium-permeable cation channels shown 
to be expressed in nociceptive neurons and play key roles in pain signalling. (Bourinet et al. 
2014). Despite these various channels being important in nociceptive signal transduction, they 
are outside the scope of this thesis, so they will not be discussed further. 
Not all intracellular Ca2+ signals are mediated by Ca2+ entry from the outside of the cell. A 
robust Ca2+ signalling ‘hub’ is represented by intracellular Ca2+ stores, such as endoplasmic 
reticulum (ER), mitochondria and Golgi apparatus (Ashby and Tepikin, 2001). In relation to 
inflammatory pain mechanisms, of particular importance are ER Ca2+ stores as these are 
mobilised downstream of the Gq/11-coupled GPCR and some other relevant pathways 
(Geppetti et al. 2015).  An important mechanism for the maintenance of ER Ca2+ load is 
through the so-called calcium-release activated-calcium (CRAC) channels. These are 
activated upon depletion of Ca2+ from ER and generate a small inward calcium current called 
13 
 
ICRAC (Parekh 2010, Luik et al. 2006). Activation of ER membrane residents IP3 and/or 
ryanodine receptors (RyR) leads to initiation of this process, which was amply named as Store 
Operated Ca2+ Entry (SOCE) (Parekh and Putney 2005) 
The following chapter will offer an in depth understanding of this mechanism, its origins and 
role in excitable and non-excitable cells. 
 
1.5.1 Store operated calcium entry (SOCE) 
The concept of SOCE dates to JW Putney’s manuscript published in 1986, describing the term 
“capacitative” calcium entry as the mechanism by which plasma membrane Ca2+ channels are 
activated by intracellular store discharge (Putney JW 1986). Previous studies in the field 
showed that cytosolic Ca2+ can be increased by two main methods: i) cationic influx from the 
extracellular compartment into the cytoplasm, and ii) depletion of intracellular Ca2+ stores. 
(Bohr et al. 1963; Breemen et al. 1969, Putney et al. 1981). Also, a secondary messenger has 
been identified to mobilize internal Ca2+ release from nonmitochondrial intracellular stores in 
pancreatic cells; this was found to be the inositol 4,5-trisphosphate (IP3) (Berridge 1983). 
Further studies demonstrated that a sesquiterpene lactone, thapsigargin, was able to release 
Ca2+ from the internal stores independently of IP3 formation (Jackson et al. 1988). After the 
development of the cytosolic Ca2+ indicator fura-2 (Grynkiewics et al. 1986), a report 
described a transient rise in [Ca2+]i using thapsigargin as a model of SOCE activation 
(Takemura et al. 1989). The activity of thapsigargin was attributed to the blockade of the 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pumps which were subsequently defined 
as being responsible for refilling the ER stores (Thastrup et al.1990).  
JW Putney further investigated the relationship between three key elements of calcium 
signaling in excitable and non-excitable cells: calcium entry into the cell, calcium release from 
internal stores and refilling these stores (Putney JW 1986). Similarly, in 1983, Fabiato firstly 
described the concept of calcium-induced calcium-release (CICR) via ryanodine receptors in 
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cardiac cells (Fabiato 1983). Altogether, the findings around SOCE were later summarized in 
2005 (Parekh AB and Putney JW, 2005) when several mechanisms thought to activate SOCE 
were reported: i) the presence of diffusible messengers that could link store depletion to 
replenishment stimulation (Takemura et al. 1989), ii) vesicular fusion suggesting that store-
operated calcium channels (SOCC) are diffused in the PM after store depletion 
(Somasundaram et al. 1995) and iii) conformational coupling: IP3Rs bind to plasma membrane 
Ca²⁺ channels in skeletal muscles (Irvine et al. 1990). Later, the molecular identity of the 
proteins involved in modulating SOCE was revealed. 
 
1.5.2 STIM, Orai and TRPC. Key players in activating SOCE 
In 1992, Hoth and Penner reported for the first time recordings of a whole-cell current 
generated by Ca2+ store depletion. They called this Ca2+ release-activated Ca2+ current, ICRAC 
(Hoth and Penner 1992). ICRAC was shown to be a small (in the range of few pA/pF) inward 
rectifying and with a positive reversal potential current. The authors hypothesized that 
emptying Ca2+ stores could generate the activation of a PM current either through a second 
messenger or by the direct interaction between ER and PM (Hoth and Penner 1992). While 
most Ca2+ channels are permeant to other divalent cations, CRAC channels seemed to be 
highly Ca2+ selective and to be blocked by Ba2+ and Mn2+ (Hoth and Penner 1992) (Figure 
1.4).   
At that time, the Drosophila TRP channel was the first non-voltage Ca2+ channel known to 
reside in the PM and to be activated by Ca2+ store depletion, but the mechanism underlying 
this process remained unelucidated (Wes et al. 1995). Later, after the TRPC1-7 family member 
were identified, TRPC1 was channel thought to contribute to SOCE (Liu et al. 2003). 
However, the electrophysiological properties of TRPC1-mediated Ca2+ currents did not 
resemble those of ICRAC (e.g. the current is relatively Ca
2+ selective) and other TRP channels 
also failed to conduct ICRAC described by Hoth and Penner (Liu et al. 2003). Thus separately, 
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ISOC was defined as the nonselective current occurring after the activation and opening of PM 
ion channels in response to ER Ca2+ store depletion (Roos et al. 2005, Feske et al. 2006).  
 
Figure 1.4 Permeability of ICRAC to divalent cations ICRAC was activated by IP3 and EGTA in a 
standard buffer containing 10 mM Ca2+. This solution that was then changed to a) Ca2+ free solution, 
b)10 mM Ba2+ and c) 10 mM Mn2+ in 1mM EGTA. The circles mark the current-voltage relationships 
during the inward current at 10mM Ca2+ (white) and during the application of the test solution (black). 
Image taken from Hoth and Penner 1992. 
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A decade later, Roos and colleagues identified the stromal interacting molecule (STIM, 
initially called SIM) as being key component of SOCE (Roos et al. 2005). Calcium imaging 
and whole-cell patch clamp single cell recordings showed a decrease in SOCE driven by 
thapsigargin in RNAi induced knockdown of STIM1 in Drosophila S2 cells (Roos et al 2005). 
Knocking down the human STIM1 in Jurkat T cells as well as its overexpression in human 
embryonic kidney (HEK) 293 cells cumulatively confirmed its role in promoting thapsigargin-
induced Ca2+ entry (Roos et al 2005). The authors highlighted that while STIM1 can trigger 
SOCE, it cannot form the channel itself. Its main role is to sense changes in the ER Ca2+ levels 
thereby triggering Ca2+ entry through plasma membrane channels when these levels drop 
(Roos et al 2005). 
One year later, a genetic screening study revealed that a mutation in human Orai1 caused a 
severe combined immunodeficiency disorder (SCID) (Feske et al. 2006). It was also the first 
channelopathy of the immune system ever described at that time. More importantly, in a 
mechanistic manner, the same study showed that Orai1 mutations in human T cells led to a 
complete loss of ICRAC (Feske et al. 2006). Orai1 (initially called CRACM1) was thus 
confirmed as the primary pore-forming component of CRAC channels able to conduct ICRAC 
upon ER store depletion (Feske et al. 2006, Vig et al. 2006). Vig and colleagues confirmed 
the role of Orai1 in mediating thapsigargin-induced ICRAC by knockdown experiments in 
HEK293 and Jurkat T cells (Figure 1.5). 
 Later, three key properties of Orai1 were described: i) it is sensitive to 2APB (2-
aminoethyldiphenyl borate, a non-selective ICRAC inhibitor), ii) it is dependent on calcium 
concentration, and iii) it is well expressed in human T cells (Lis et al. 2007). 
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Figure 1.5:  Inhibition of ICRAC by CRACM1 (Orai1) siRNAs. Normalized time course of IP3-
induced ICRAC in HEK293 cells (A) and Jurkat cells (C). 10mM BAPTA was used to clamp [Ca2+]i to 
near zero. Data shown as average for Scramble and CRACM1-KD with siRNA1 and siRNA2. 
Representative current-voltage traces of ICRAC at 60 s evoked by 50 ms voltage ramps in HEK293 cells 
(B) and Jurkat cells (C). Image taken from Vig et al. 2006. 
 
 
 
 
 
 
 
 
 
18 
 
The discovery of STIM, Orai and TRPC proteins led to a further characterization of SOCE: 
STIM1 is the ER Ca2+ sensor, plasma membrane TRPC channels are responsible for the 
nonselective cation current ISOC and Orai1 channels mediate ICRAC, the highly Ca
2+ selective 
current (Roos et al 2005, Feske et al. 2006, Zhang et al. 2006). STIM1 is required to activate 
calcium entry through both channel types (Roos et al 2005). 
 
1.5.3 STIM isoforms 
STIM1 was initially identified in Drosophila S2 cells, but in mammals a second homologue, 
STIM2, was also described (Roos et al. 2005; Prakriya M 2013).  They are both ER-membrane 
residents highly involved in SOCE. 
STIM1 is a 685 amino acid long, 77 kDa in size, protein residing in the ER/SR membrane and 
has two properties critical for activating SOCE: i) it senses the ER Ca2+ store discharge, and 
ii) after store depletion, it communicates with plasma membrane TRPC or Orai channels to 
activate ISOC or ICRAC, respectively (Prakriya M 2013). Two splice variants have been 
determined: STIM1S (S for small, the well-known STIM1 that slowly clusters and form 
CRAC channels with Orai1) and STIM1L (L for long, 110 kDa variant that interacts with actin 
and forms permanent clusters with Orai1 independent of SOCE) (Darbellay et al. 2011). 
For STIM1 to function as a sensor and Ca2+ entry facilitator, several domains important for its 
role were identified (Figure 1.4). In the ER-luminal N-terminus, STIM1 contains a canonical 
but hidden EF-hand as well as a sterile-α motif (SAM) (Stathopulos et al. 2006). As previously 
mentioned, STIM1 is responsible for initializing the first step of SOCE, thus when the ER 
Ca2+ pool is depleted, Ca2+ dissociates from the EF hand, followed by the destabilization of 
the EF-SAM domain, which means it becomes less compact (Fahrner et al. 2013). Extended 
STIM1 monomers further form oligomers and consequently redistribute into puncta located 
at ER-PM junctions (Baba et al. 2006).  
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Figure 1.6. The architecture of STIM1 and STIM2 proteins The ER luminal region consists of the 
N-terminus which includes the signalling peptide, the canonical EF1 hand, the noncanonical EF2 hand 
and the SAM domain. The transmembrane domain (T) separates the EF-SAM region from the cytosolic 
domain. The cytosolic region comprises of three coiled-coil domain (CC1, 2 and 3), a serine-proline 
rich segment (SP) and a lysine rich polybasic domain (K). Figure adapted from Zhu et al. 2017. 
 
In the cytosolic strand, the C-terminus contains three coiled-coil domains (CC1, CC2 and 
CC3), a serine/proline and a lysine-rich region as well as a CRAC-modulatory-domain (CMD) 
(Muik et al. 2009; Fahrner et al. 2013). Previous studies identified key regions of the C-
terminus sufficient to activate the PM Orai channels: the CRAC activation domain (CAD), 
STIM1-Orai1 activating region (SOAR), ORAI1-activating small fragment (OASF) and 
Coiled-coil domain b9 (Ccb9) (Muik et al. 2009; Park et al. 2009). These domains have CC2 
and CC3 regions in common, as well as 19 other residues and a STIM1 homomerization 
domain (SHD) (Fahrner et al. 2013). Interestingly, the deletion of the SHD fragment in the 
OASF region abolishes the activation of CRAC channels as showed in patch clamp recordings 
(Muik et al. 2009). 
STIM2 (84 kDa molecular weight) differs from STIM1 in the variable domain downstream of 
the second C-terminal coiled-coil region and does not have a short N-terminal signal peptide 
sequence as STIM1 does (Johnstone et al. 2010, Soboloff et al. 2012).  
Interestingly, the STIM2 EF-hand has a low affinity for Ca2+ (Kd~500 µM) and its monomer 
has a more stable EF-hand than that of STIM1. This observation led to the conclusion that 
STIM1 is able convert from mono- to oligomeric state in a faster manner (Stathopulos et al. 
2006; Zheng et al. 2009). 
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The C terminus of STIM2 has an additional polybasic domain and a shorter acidic region of 
an unknown function which was shown to interact with both PIP2 and PIP3, while STIM1 has 
a preference for PIP2 (Ercang et al. 2009, 2012; Mullins and Park 2009). Moreover, the SOCE-
associated regulatory factor (SARAF protein, encoded by the SARAF gene, formerly named 
transmembrane protein 66 or TMEM66) responds to cytosolic Ca2+ elevation after ER Ca2+ 
refill, generating a slow inactivation of STIM2-dependent basal SOCE (Palty et al. 2012). 
SARAF is an ER resident protein that inhibits SOCE through an unknown mechanism (Palty 
et al. 2012). Another group reported that the depletion of the acidic Ca2+ stores in platelets 
expressing both STIM1 and STIM2 enhanced both their interactions and the association of 
STIM2 with the SERCA3 isoform (Zbidi et al. 2011). 
There are three different prost-translationally modified STIM2 proteins, as follows: 
a) ER-localized hSTIM2: it is a fully cleaved signal peptide and contains the previously 
identified N-terminus peptide sequence. 
b) Cytosolic non-glycosylated pre-STIM2: a full-length version that escapes ER targeting; 
is responsible for store-independent activation of Orai1 (Graham et al.2011). 
c) ER-localized fragment of STIM2: its cleavage results in releasing the N-terminus signal 
peptide fragment (SPF) into the cytoplasm and it contains a calmodulin binding site (Shen 
et al. 2005; Graham et al. 2011). Other studies showed that STIM2 has a second, low 
affinity (1 µm) calmodulin binding site at the lysine-rich C-terminus that is involved in 
the reduced plasma membrane phospholipase interaction (Bauer et al. 2008; Bhardwaj et 
al. 2013). 
Soboloff and colleagues investigated the role of STIM2 and found that it has an inhibitory 
effect on SOCE (Soboloff et al. 2006). Brandman and colleagues also showed that knocking-
down STIM2 in HEK293, HeLa and HUVEC cells reduced the basal level of cytosolic Ca2+ 
and overexpressing STIM2 led to an increased level of basal Ca2+ (Brandman et al. 2007) 
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1.5.4 Role of STIM isoforms in disease 
While the role of STIM and Orai proteins has been intensely studied in relation to various 
diseases, SOCE has been shown to contribute to normal skeletal muscle function, fatigue or 
even aging (Thornton et al., Brotto M. 2011).  Evidences also show that SOCE is important in 
muscle contraction during exercise or tetanic stimulations (Pan et al. 2014). 
A decade before its role in SOCE was established, the STIM1 gene was initially reported as 
being highly expressed in skeletal muscle tumors as well as in child malignancies (Sabbioni 
et al 1997).  
Moreover, recent studies have shown that STIM1 is required for platelet activation and 
mutations might be responsible for the Stormorken (rare disease characterized by mild 
bleeding) and York (CRAC channelopathy characterized by thrombocytopenia) syndromes in 
humans (Misceo et al 2014, Markello et al 2015). A missense mutation leading to the 
replacement of Arginine 304 with tryptophan affects the CC1 fragment of STIM1, which is 
responsible for maintaining in its STIM1 inactive form. This mutation has been correlated 
with excessive Ca2+ entry, leading to premature platelet activation and subsequent bleeding 
disorders (Misceo et al 2014). Similarly, mutations in the canonical EF-hand of STIM1 have 
also been associated with tubular aggregate myopathy in humans (Bohm et al 2013). Other 
studies have reported that high-calorie diet in pigs increases STIM1 expression in coronary 
smooth cells, leading to coronary atherosclerosis (Edwards et al 2010). 
Studies done in mice lacking STIM1 in smooth muscle cells showed tissue growth deficiency, 
thus providing evidence for the role of STIM1 in smooth muscle development (Mancarella et 
al 2013). Recent advances in clinical research confirmed that serum STIM1 levels can be used 
as a biomarker for restenosis (Li et al 2015). 
STIM1/Orai1 mediated SOCE has been associated with breast cancer cell migration in triple 
negative MDA-MB231 cells, regulating their migration but not proliferation (Yang et al. 
2009). Several studies confirmed that STIM1/Orai1 SOCE is involved in breast cancer 
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metastasis (Yang et al. 2009, Davis et al. 2012). Recent findings reported that STIM1 
expression is increased in colorectal cancer tissue samples and further associated with tumour 
invasion and metastasis (Wang et al. 2015). The same group showed that STIM1 regulates 
COX-2 but not COX-1 expression in colorectal cancer cells and NSAIDS indomethacin and 
ibuprofen almost completely reduced STIM1-regulated cell migration. 
STIM2 was shown to be highly expressed in different melanoma cells, again having a potential 
role in metastasis and tumour migration (Stanisz et al. 2014). Other studies reported an 
increased expression of STIM2 in colorectal as well as in oesophageal squamous cancer cells 
(Zhu et al. 2014, Sobradillo et al. 2014). 
Altered Ca2+ signalling has been associated with neurodegeneration and subsequent loss of 
neuronal function leading to diseases such as Alzheimer’s, Huntington’s, HIV-induced 
dementia or Parkinson’s. Several studies showed that during oxidative stress, ROS production 
increases SOCE, leading to cell injury due to excessive Ca2+ entry (Nunes and Demaurex 
2014). Oxidative stress reduces the affinity of STIM1 for Ca2+, thus facilitating a store-
independent activation of STIM1 and an increase in ISOC (Nunes and Demaurex 2014). 
The second isoform, STIM2, may also have an important role in mediating neuronal SOCE. 
Contradictory data suggest that depending on the type of cells, STIM2 might have a conflicting 
role: STIM2 KD mice were protected from neuronal damage secondary to a cerebral ischemic 
stroke (Berna-Erro et al. 2009) while another study showed that loss of STIM2 determines 
hippocampal neuronal loss in mice (Sun et al 2014). 
 
1.5.5 Orai proteins. Structure and function 
Plasma membrane resident Orai1 is a 33 kDa molecule with four transmembrane domains; 
and intracellular N- and C-terminal regions (Feske et al. 2006) As described previously, Orai 
proteins (particularly Orai1 isoform) are responsible for forming the CRAC channel pore 
(Mercer et al. 2006, Yamashita et al.2007). The concurrent discovery of both Orai and STIM 
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proteins led to a wave of interest in these proteins and their role in different excitable and non-
excitable cells. 
In 2012, Hou X and colleagues answered a widely asked question regarding the structure of 
Orai1, its multimerization and ability to form contacts with the cytosolic region of STIM1. 
The group elucidated the crystal structure of the Drosophila CRAC channel pore. Figure 4 
shows the channel’s hexameric assembly of Orai proteins. Each subunit of Orai1 contains four 
transmembrane (TM) domains and a helix following TM4 that expands into the cytoplasm 
(Hou X et al. 2012). The TM helices are arranged in three concentric circles: TM4 helices 
form the outer ring, the TM2 and TM3 helices form the middle ring, while TM1 helices 
constitute the inner circle and outline the ion pore (Hou X et al. 2012). Recently, contacts 
between the TM1 helix and the TM2/3 helices have been reported as critical for STIM1/Orai1 
channel gating (Yeung P. S-W et al. 2018). E106 residues found in the TM1 region constitute 
the Ca2+ pore binding site and reflects the main difference between CRAC channels and 
VGCCs. The E106 ring binds Ca2+ specifically and blocks Na+ currents through the channels 
at lower micromolar Ca2+ concentrations (Prakriya and Lewis 2006; Gudlur and Hogan 2017; 
Yang et al. 1993).  
Multiple binding models have been described; some models show that Orai1 C-terminal 
helices are able to interact with STIM1, while other models reflect the binding between a pair 
of Orai1 TM4 helices and a STIM1 dimer (Hou et al. 2012, Palty et al.2015, Stathopulos et 
al.2013). Moreover, studies showed that STIM1 also binds to the N-terminal segment of 
Orai1, thus indicating that this contact might be necessary to modulate the open conformation 
of the pore (Zhou et al. 2015, 2016). 
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Figure 1.7. The architecture of Orai1. A representation of the structure of the channel showing in a 
color coded format the four trasmembrane domains of the Orai1 pore: TM1 in blue, TM2 in red, TM3 
in green and TM4 in brown. The yellow and grey subunits are extensions of TM4. Figure adapted from 
Hou et al. 2012. 
 
There are other two isoforms of within this protein family: Orai2 and Orai3, found in 
mammalian cells. Studies showed that all three proteins are capable to form CRAC-like 
channels, but Orai1 remains the best-studied protein until now (Lis et al. 2007, Prakriya 2013). 
Structurally, these homologues differ in their C-terminal site and the TM3-TM4 loop sequence 
(Lis et al. 2007). Orai1 contains two glutamates in the C-terminal region, while Orai2 and 
Orai3 contain three (Lis et al.2007; Frischauf et al. 2009). This structural difference might be 
responsible for the reduced fast inactivation observed in Orai1 but not in Orai2 or Orai3 
(Frischauf et al. 2009; Hoth and Niemeyer 2013). Orai3 also contains the longest extracellular 
TM3-TM4 loop between the three isoforms (Frischauf et al. 2011). Orai2 displays a moderate 
level of fast Ca2+ dependent inactivation as compared with Orai1 (low) and Orai3 (high) 
(Zweifach and Lewis 1995). Even-though the crystal structure of Orai1 established in 2012 
highlights its hexameric constitution, contradicting studies state that Orai1 may function as a 
tetramer (Hou and Pedi 2012). Moreover, a ratio of 8 STIM1 to one Orai1 tetramer seems to 
result in a maximal current density through the CRAC channel, and it is not known whether 
such dependence exists for other STIM and Orai homologs (Hoover and Lewis 2011, Lis et 
al. 2011). Other studies reported that Orai2 gives rise to smaller currents than Orai1 and that 
it may also be able to reduce Orai1 functionality when co-expressed in Jurkat T cells (Alansary 
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et al. 2014, DeHaven et al. 2007, Inayama et al. 2015).  Additionally, Ca2+ signals were 
unchanged in siRNA induced Orai2 or Orai3 knock-out human aortic smooth muscle 
(hASMC) cells, suggesting that Orai1 plays a key role in SOCE activation while its isoforms 
may not contribute directly to SOCE (Baryshnikov et al. 2009). Interestingly, high Orai2 
expression might correlate with high STIM2 expression in some cells (Hoth and Niemeyer, 
2013). 
Experiments on HEK293 cells showed that over-expressing Orai3 with STIM1 failed to 
generate an increase in ISOC, but it moderately increased when Orai2 was over-expressed. The 
highest ISOC was achieved in the presence of Orai1 (Mercer, 2006). As previously discussed, 
the N-terminus of Orai1 is key for activating SOCE. This was confirmed by replacing the 
Orai3 N-terminus region with that of Orai1, resulting in a higher magnitude of ISOC. Vice versa, 
when the Orai3 N-terminus was inserted into the Orai1 channel, the current was completely 
abolished (Shuttleworth, 2012). 
At this moment in time, there is no definite evidence of the functional role of Orai2 or 3, but 
it has been proposed that they might mediate SOCE, to a minimal extent, in cells lacking 
functional Orai1 (Mercer et al. 2006).  
 
1.5.6 Role of Orai isoforms in disease 
As mentioned previously, in 2006 a study reported that R91W mutation of human Orai1 was 
associated with defective SOCE, CRAC channel function and the development of SCID 
(Feske et al 2006). Several groups then reported that Orai-1 deficient patients presented with 
a severe immunodeficiencies characterized by the weak T cell activation and impaired 
cytokine production (McCarl CA et al. 2009; Feske et al. 2009). Moreover, upon vaccination 
or infection, patients with Orai1 mutations could not mount antigen-specific antibodies (Feske 
et al. 2009). The question regarding whether other Orai isoforms are able to rescue SOCE in 
R91W mutant T cells and fibroblasts was also raised. Interestingly, neither Orai2 nor Orai3 
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was able to activate or maintain ISOC in Orai1 mutant cells of SCID patients (Gwack et al. 
2007). 
The group tested the effect of endogenously expressed Orai2 and Orai3 as well as that of 
efficiently delivered proteins to the plasma membrane and both scenarios failed to rescue ISOC. 
This suggests that, at least in these cell types, the Orai1 isoform plays a vital role in SOCE 
(Gwack et al. 2007). Interestingly, in some breast cancer cell lines, endogenous SOCE seems 
to be mediated by Orai3: while estrogen-receptor negative breast cancer cells showed an 
Orai1-dependent SOCE, the estrogen-receptor positive cells showed that ISOC is mediated 
through Orai3 (Motiani et al. 2010). 
The absence of Orai1 in humans has also been associated with different myopathies: one study 
reported global muscular hypotonia, reduced head control, decreased endurance and muscle 
strength as well as respiratory muscle insufficiency in Orai1-null patients (McCarl et al 2009). 
Orai1 deficient patients also presented a dental enamel defects and difficulties in sweating 
leading to dry skin and recurrent fever with heat intolerance (McCarl et al 2009; Feske er al. 
2009, Feske et al. 2010). As Ca2+ influx is required for normal secretion from sweat glands, 
the absence of Orai1 (resulting in impaired SOCE) has consequences on the function of sweat 
glands generating hypo- or anhidrosis (Feske et al. 2010).  
Similar to the role of STIM1 in thrombosis and haemostasis, Orai1-mediated SOCE is 
essential for platelet activation and thrombin-dependent coagulation (Bergmeier et al. 2009). 
Other studies have also shown that mice failed to form thrombus and promote artery occlusion 
in chemical injured arterial walls, this being associated with Orai1 and STIM1 deficiency 
(Braun et al. 2009; Varga-Szabo et al. 2008). 
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1.6 STIM-Orai coupling. CRAC channels 
CRAC current was initially observed in T and mast cells and was characterized as a highly 
selective Ca2+ current that is activated as a consequence of a reduction in ER Ca2+ levels 
(Lewis and Cahalan 1989, Zweifach and Lewis 1993). As described in previous sections, the 
CRAC current is a cationic influx from the extracellular compartment into the cytosol, through 
the PM resident CRAC channels that comprises of the ER Ca2+ sensor STIM and PM pore-
forming subunit, Orai. Thus, channel gating is dependent on the direct interaction between 
STIM and Orai proteins (Gudlur et al 2013). When the ER Ca2+ pool is depleted, a 
conformational rearrangement of STIM1 is induced when its EF hand releases the bound Ca2+ 
ions; the protein becomes more extended and is able to span the ER-PM distance (Muik et al. 
2011). Orai channels reside evenly distributed in the PM. STIM1 functions to recruit and 
cluster with them into forming the CRAC channel at ER-PM junctions (Luik et al. 2006). 
Studies showed that STIM proteins translocate within the ER membrane which can be 
optically monitored through so-called ‘puncta’ formation. This translocation occurs within ~1 
minute, is independent of Orai and precedes Orai gating and CRAC channel opening (Liou et 
al. 2005; Wu et al. 2006). Interestingly, the recruitment of Orai proteins at ER-PM junctions, 
into puncta, is dependent on STIM1 (Park et al. 2009). In the absence of ER store depletion, 
all three Orai channels are inactive until STIM1 binding occurs (Lis et al. 2007; Schindl et al. 
2009).  
However, few studies revealed that a long splice variant of STIM1 (STIM1L) may form 
clusters with Orai1, independent of store depletion, predominantly in excitable cells 
(Darbellay et al. 2011). STIM1L has been shown to be present in all skeletal muscles, brain, 
spleen, liver, lungs and heart, while STIM1S is ubiquitously expressed in all tissues (Darbellay 
et al. 2011). Simillarly, Sauc and colleagues showed that STIM1L is able to trap and gate 
Orai1 without the involvement of the ER in murine embryonic fibroblasts (Sauc et al. 2015). 
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Figure 1.8. Schematic representation of CRAC channel activation.Once triggered by factors such 
as GPCR agonists (Ligand, blue), ER Ca2+ pool starts to deplete and the EF hands of STIM1 release 
Ca2+ as a consequence to the store discharge. This triggers a conformational change in STIM1 structure, 
followed by its movement into clusters at ER-PM junctions. There it binds to Orai1, followed by the 
channel formation, pore opening and Ca2+ influx into the cytosol. ER residents SERCA pumps facilitate 
the Ca2+ store replenishment and once refilled, CRAC channels deactivate and STIM and Orai proteins 
return to their resting state. 
 
STIM1 directly binds to the N- and C-termini of Orai1 and recent studies have described the 
STIM1-Orai1 Association Pocket (SOAP) where leucines L273 and L276 of Orai1 are 
involved in hydrophobic interactions with STIM1 and negatively charged aspartate of Orai1 
further form electrostatic interactions with STIM1 regions (Hou et al. 2012, Stathopulos et al. 
2013). While STIM1 binding is primarily achieved by coupling to the Orai1 C-terminus 
region, studies have also shown that truncating N-terminus elicits an impairment in Orai1 
function (Derler et al. 2013, Zhou et al. 2016). Interestingly a STIM1-Orai1 interaction at the 
N-terminus was also detected, but with a weaker affinity (Derler et al. 2013). Since the crystal 
structure of Orai1 has been described, the hexameric structure of the channel has been widely 
accepted, but the stoichiometry of the STIM-Orai complex remains controversial (Hou et al. 
2012). A recent study showed that the number of STIM1 molecules is important for the degree 
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of inactivation of ICRAC, therefore the higher number of STIM1 molecules, the more 
pronounced ICRAC inactivation (Scrimgeour et el. 2014). 
While the structural complexity of the STIM-Orai machinery remains to be determined, it is 
widely accepted that STIM1 initially couples to the C-terminus of Orai1, involving a 
conformational rearrangement of its subdomains, including bridging the Orai1 N-terminus in 
order to fully activate the channel (Fahrner et al. 2017). Orai1, 2 and 3 can form hetero- or 
homomeric channels and once coupled with STIM1, the TM domains of Orai rearrange, form 
and open the pore, allowing Ca2+ influx. As previously explained, the TM4 of Orai1 forms the 
outer ring of the pore, TM2 and TM3 helices form the middle ring, while TM1 helix forms 
the inner pore that is permeable to Ca2+ (Hou et al. 2012, Zhou et al. 2010). Close to the 
external side of the CRAC channel, the so-called Ca2+ accumulation region (CAR) includes 
negatively charged amino acids found between TM1 and TM2 (Frischauf et al. 2015). CAR, 
found at 1 to 2 nanometres away from the selectivity filter, initially binds up to three Ca2+ 
ions, thus functioning as a Ca2+ driver into the pore by locally increasing Ca2+ levels (Frischauf 
et al. 2015; Jha and Muallem 2016). CAR is found in a flexible loop between TM1 and TM2, 
while the selectivity filter is located in the TM1 helix, comprising of six glutamates (Hou et 
al. 2012). In the centre of the pore, a hydrophobic segment forms the gate that blocks Ca2+ 
entry in the resting state (Hou et al. 2012).  
The activation process of CRAC channels is reversible and the hallmark of the channel is its 
fast calcium-dependent inactivation (CDI) mechanism. Patch-clamp recordings showed that 
when cells are hyperpolarized, CDI occurs within tens of milliseconds after the peak of ICRAC 
(Zweifach and Lewis 1995; Shaw 2013). Fast CDI was linked to a region of acidic residues 
close to the CAD domain of STIM1 (Lee et al. 2009). Interestingly, other studies showed that 
Orai1 is also involved in the fast CRAC channel inactivation, through a calmodulin-binding 
domain found in the N-terminus of Orai1 (Mullins et al. 2016). 
Despite the fast mechanism of CDI, the CRAC channel disassembly occurs within tens of 
seconds following their activation. This is called the slow CRAC inactivation and is triggered 
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by ER Ca2+ store refilling (Liou et al. 2007; Shaw 2013). Once Ca2+ ions are taken up by the 
ER-resident SERCA pumps, it then binds to the EF hand in the N-terminus of STIM1, causing 
STIM1 de-oligomerization, followed by Orai1-STIM1 disassembly, dissolution of puncta and 
STIM1’s diffusion away from the PM returning to the resting state (Liou et al. 2007). 
 
Figure 1.9. Total Internal Reflection Fluorescence (TIRF) imaging of one Jurkat T cell showing 
STIM1-Orai1 clustering during SOCE. A. At rest, ER located mCherry-STIM1 is widely distributed 
and out of focus, while GFP-myc-Orai1 is distributed throughout the cell, at the PM and in focus. B. 
Once SOCE is triggered with thapsigargin (TG) in Ca2+ free conditions, STIM1 clusters and expands 
to reach the PM. Orai1 also changed its initial position. The merged images show that at rest STIM1 
and Orai1 do not colocalize, but during SOCE, both proteins translocate and meet at the formed puncta. 
Figure adapted from Luik et al. 2006. 
 
   
Several studies found that the activity of CRAC channels could also be regulated through 
processes such as protein kinase C (PKC) dependent phosphorylation of the N-terminus of 
Orai1, or cyclin-dependent kinase 1 (CDK1) phosphorylation of STIM1 (Kawasaki et al. 
2010; Smyth et al. 2009). The importance of these mechanisms remains to be elucidated.  
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1.7 Pharmacology of CRAC channels 
Calcium influx through CRAC channels regulates different cellular functions such as cell 
proliferation, gene expression and exocytosis. Since the identification of Orai1-3 and STIM1-
2 proteins and their role in SOCE, researchers investigated ways to modulate these channels. 
As described in previous sections, defects in CRAC channel function were shown to be 
associated with different human diseases: immunodeficiency, myopathy, anhydrosis, cardiac 
or pulmonary deficiency. Taken together, the accumulating knowledge regarding the role of 
CRAC channels in these diseases led to an increased interest in the development of CRAC 
channel modulators. Due to the complex STIM-Orai machinery, alongside other endogenous 
proteins thought to be involved in modulating SOCE, multiple proteins have been targeted 
and several pharmacological agents have been developed. While most of them are still in 
preclinical studies, some may have the scientific profile to be taken further in to clinical 
development.  
 
1.7.1 Inducers 
The main mechanisms that induce ICRAC are: 
a) blockade of sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase pumps (with SERCA 
inhibitors, e.g. thapsigargin, cyclopiazonic acid);  
b) activating IP3 receptors with GPCR agonists; 
c) activating RyR with RyR agonists (e.g. caffeine), and  
d) using calcium ionophores (e.g. ionomycin).  
While plenty of endogenous compounds are putative SOCE inducers (such as GPCR agonists: 
ATP, histamine, epinephrine, BK etc.), 2-aminoethyl diphenyl borate (2-APB) is one of the 
few small-molecule CRAC activators used in research. This agent was initially obtained by 
the esterification of diphenylboronic acid with aminoethanol in ethanol. The procedure was 
published by Povlock TP and colleagues in 1958. Remarkably, 2-APB seems to be a direct 
activator of Orai3 channels at 50 µM, both in the presence or absence of STIM1, displaying 
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large outward low Ca2+ selective currents (Peinelt et al. 2008). Interestingly, it has been 
reported that 2-APB has a dual effect in such a way that it activates SOCE at lower 
concentrations (3-10 µM) but inhibits calcium influx at higher concentrations (30-50 µM) 
(DeHaven et al. 2008). This drug is considered a non-selective CRAC channel inhibitor as it 
acts on multiple other receptors and ion channels such as blocking IP3R, SERCA pumps, 
TRPC3, activating TRPV1,2 and 3 and potentiating TRPV6 (also known as CaT1) and 
TRPM6 (Maruyama et al. 2007, Hu et al. 2004, Missiaern et al. 2001).  
Calcium influx factor (CIF), whose molecular identity is still unknown, has been identified 
by in a variety of cells (Bolotina et al. 2005; Csutora et al. 1999; Kim et al. 1999). CIF is 
known to be produced in the ER, following Ca2+ depletion and its thought to induce the 
displacement of calmodulin from a PM Ca2+-independent phospholipase A2β (iPLA2β), thus 
leading to SOCE activation (Randriamampita et al. 1993; Smani T et al. 2004). Interestingly, 
a study showed that following ER Ca2+ depletion, STIM1 might initially function as a trigger 
for CIF production as well as facilitating CIF delivery to its PM target, iPLA2β (Csutora et 
al. 2008). The identity of CIF and its exact role in mediating ICRAC still remains subject of 
future research. 
Loperamide, a drug widely used for acute diarrhea, is a SOCE enhancer. While it has no 
direct effect on ICRAC, at 10 to 30 µM concentrations, it has been proposed to function as a 
CRAC potentiator in cultured HL-60 leukemic cells. (Harper et al. 1997). 
Nocodazole (an antineoplastic agent) and colchicine (an anti-inflammatory agent, commonly 
used to treat gout), both causing microtubule depolymerization, were also found to enhance 
ICRAC in STIM1 overexpressing cells (Smyth et al. 2007). Without any direct effect on ICRAC, 
colchicine substantially potentiated calcium influx in response to submaximal store depletion 
(Smyth et al. 2007). 
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While CRAC inducers are widely used as research tools to stimulate SOCE in experimental 
conditions, a global interest has been given to CRAC inhibitors as putative pharmacological 
targets especially in inflammatory disorders or autoimmune diseases. 
1.7.2 Inhibitors 
Similar to other calcium permeable channels, CRAC channels are inhibited by divalent and 
trivalent cations, possibly due to decreasing Ca²⁺ permeability. Even at low concentrations, 
Ni²⁺, La³⁺ and Gd³⁺ can fully block CRAC channels in cerebral arteriolar smooth muscle cells 
(Flemming et al. 2003). 
Widely known as the TRPV1 activator, capsaicin demonstrated an inhibitory effect on CRAC 
channels (Fischer et al. 2001; Wang et al. 2005). Capsaicin is able to block SOCE in Jurkat T 
cells in a dose-dependent manner with an IC50=32 µM (Fischer et al.2001). Indo-1 loaded cells 
showed that capsaicin inhibits SOCE in carbachol (CCh, an acetylcholine receptor activator) 
treated Jurkat T cells, and fura-2 measurements revealed a reduced capacitative calcium entry 
in thapsigargin treated P12 cells (Fischer et al. 2001). 
BTP2 (YM 58483), a pyrazole derivative, was developed as a tool to inhibit thapsigargin-
induced SOCE. It was initially tested in T-lymphocytes and showed a 30-fold selectivity for 
CRAC channels as compared to VOC channels, with an IC50 of 100 nM (Ishikawa et al. 2003). 
BTP2 might depend on the external calcium concentrations in such a way that the effect of 
SOCE inhibition was shown to be higher when extracellular Ca2+ levels were raised (Zitt et 
al. 2004). Interestingly, BTP2 seems to have an indirect mechanism on CRAC function as 
well, by stimulating the opening of TRPM4 channels, leading to membrane depolarization and 
indirectly reducing calcium influx through CRAC channels (Takezawa et al. 2006). 
Diethylstilbestrol, an estrogen receptor agonist, has been found to inhibit ICRAC in mast cells, 
platelets and aortic myocytes (Zakharov et al. 2004). It has a dose-dependent effect with IC50 
= 0.1µM. Its inhibitory effect was showed after triggering ICRAC using thapsigargin in whole-
cell patch-clamp recordings. 
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A recent study showed that oleic acid inhibits ICRAC in human colorectal adenocarcinoma cells. 
The inhibitory effect was protein kinase C-independent and it was restored by albumin. By 
contrast, stearic acid could not reduce ICRAC in colon carcinoma cells (Carrillo et al. 2012).  
Another putative CRAC channel blocker is nocodazole, an anti-neoplastic agent. Smyth and 
Putney studied its effects on HEK293 cell lines. Confocal images showed a dispersion of 
microtubules throughout the ER after nocodazole treatment, presumably preventing formation 
of the STIM1-Orai1 puncta. Interestingly, in STIM1 overexpressing cells, nocodazole 
enhanced the capacitative calcium entry through CRAC channels (Smyth et al.2007). 
Econazole, an imidazole derivative used as a fungal agent, demonstrated non-selective CRAC 
channel blocking effects in mast cells (Franzius et al. 1994). Similar to econazole, SKF96365, 
an imidazole antimycotic, was one of the first developed CRAC channel inhibitors (Franzius 
et al. 1994). Its effect has been tested in a range of cells with an IC50 values of 12 µM in Jurkat 
T cells (Chung et al. 1994). Both econazole and SKF96365 exhibit a non-specific CRAC 
channel profile as they also suppress the activity of non-selective cation channels, VGCC, as 
well as cyclic AMP-gated chloride channels (Chung et al. 1994, Singh et al. 2010). 
Several studies mentioned carboxyamidotriazole as being a potent SOCE inhibitor. It was 
proposed to generate mitochondrial depolarization which leads to greater calcium-dependent 
inactivation of the CRAC channels (Mignen et al. 2005). The use of carboxyamidotriazole has 
been associated with impaired cancer cell proliferation and invasion and this molecule reached 
several oncology clinical trials in diseases such as ovarian and cervical cancer, melanoma or 
renal cell carcinoma (Kohn et al. 1996). 
The pharmaceutical company GlaxoSmithKline (GSK) developed a list of novel pyrazole 
compounds identified as selective CRAC inhibitors, without affecting STIM1 aggregation or 
STIM1-Orai1 coupling. Among these, GSK-5498A inhibits ICRAC with an IC50 of 1 µM in 
HEK cells (Tian et al. 2016; Rice et al 2013), while GSK-7975A decreases the POAEE 
(palmitoleic acid ethyl ester, a mediator of alcohol-related pancreatitis)-evoked cytosolic Ca2+ 
rise in pancreatic acinar cells (Gerasimenko et al. 2013). This finding potentially indicates a 
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pharmacological role against acute pancreatitis which lacks effective treatment and is life-
threatening (Pandol et al. 2007).  
Synta Pharmaceuticals also developed a series of CRAC channel inhibitors, amongst which 
Synta66 has drawn attention in recent years (Tian et al. 2016). Despite its SOCE inhibitory 
effect demonstrated on red blood cells (IC50= 3µM), Synta 66 has been shown to reduce the 
expression of interleukins (IL)-2 and 17 in cells taken from inflamed areas of patients suffering 
from inflammatory bowel disease (IBD), suggesting its putative role in T-cell signaling 
(Sabatino et al. 2009).  
RO2959, a CRAC channel inhibitor developed by Roche, demonstrated an IC50 value of 
400nM in RBL-2H3 cells (Jairaman and Prakriya 2013). This molecule can inhibit Orai1 to a 
greater extent than the other Orai isoforms and can potentially inhibit cytokine production, 
gene expression and T-cell proliferation as shown in primary CD4+ T cells (Chen et al. 2013).  
CalciMedica is a biotech company focused on developing CRAC channel inhibitors for the 
treatment of inflammatory and autoimmune disorders. Their CM2489 compound seems to be 
the first CRAC channel blocker taken forward to human testing. CalciMedica completed a 
Phase I clinical trial for treating plaque psoriasis with this CRAC inhibitor, leading the exciting 
pathway of clinical development. In May 2017, the company also received fast-track 
designation from US FDA for another CRAC channel blocker, CM4620 which showed 
promising activity in animal models of pancreatic necrosis and systemic inflammation 
(CalciMedica, Inc, May24, 2017). 
ML-9, a drug known to inhibit myosin light chain kinase, inhibits ICRAC in thapsigargin treated 
HEK293 cells in a dose-dependent manner with an IC50 value of 10 μM (Smyth et al. 2008) 
Interestingly, confocal and TIRFM recordings showed that the inhibition of ICRAC by ML-9 is 
due to blocking STIM1 rearrangement, which leads to interrupting STIM1-Orai1 coupling and 
puncta formation. (Smyth et al. 2008).  
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1.8 Ca2+ microdomains 
Components of the Ca2+ signalling cascade are frequently organized into the so-called Ca2+ 
microdomains. These are regions within cells that occupy hundreds of nanometres where Ca2+ 
dynamics is locally modulated and Ca2+ permeable channels, such as VGCC or CRAC, reside 
(Berridge, 2006, Parekh, 2008) Microdomains at the ER-PM junctions can modulate Ca2+-
dependent processes related to SOCE in both excitable and non-excitable cells (Vaca et al. 
2010; Berridge et al. 2006).  
Store-Operated Calcium Influx Complex (SOCIC) is considered to be the functional unit of 
SOCE and is defined as a macromolecular complex that is assembled in response to ER Ca2+ 
depletion, with the purpose to promote Ca2+ influx from the extracellular space into the 
cytoplasm (Vaca et al. 2010). SOCIC comprises of different proteins that assemble and 
disassemble this complex to modulate Ca2+ dynamics. (Vaca et al. 2010). While the main 
proteins that form SOCIC are STIM1 (the ER Ca2+ sensor) and PM Ca2+ channels (Orai1 
and/or TRPC1), other molecules have been proposed to play a role in capacitive Ca2+ entry 
such as SERCA pumps, calmodulin, IP3 receptors or junctional proteins. (Putney et al. 2007; 
Mullins et al. 2009; Varnai et al. 2007). 
 
1.8.1 Sarco/endoplasmic reticulum Ca2+ ATP-ase (SERCA) 
SERCA pumps have been described as the third element of SOCE (Manjarrés et al. 2010). 
With high affinity for Ca2+, they have a key role in allowing cytosolic Ca2+ to enter the ER 
and refill the stores. Increased SERCA pumps density at Ca2+ microdomains is key to facilitate 
reloading of the ER Ca2+ pool. (Rizutto and Pozzan 2006).  Interestingly, it has been shown 
that SERCA pumps form an outer ring around CRAC channels, but whether they are localized 
near or exactly at the ER-PM junctions remains unknown. (Manjarres et al. 2010). Inhibitors 
of SERCA pumps, such as thapsigargin, are widely used by researchers as tools to induce 
capacitive Ca2+ entry. Recent studies highlighted that disrupting Ca2+ homeostasis by blocking 
SERCA can cause apoptosis possibly by extensive ER Ca2+ drainage (Sehgal et al. 2017).  
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1.8.2 Calmodulin 
Ca2+-induced Ca2+-release (CICR) takes place in narrow regions between the SR and the t-
tubule membrane of cardiac myocytes. These tight associated regions are known as dyads. 
(Winslow et al. 2011). Dyads have an estimated volume of 3×105 nm3, a diameter of 100 - 200 
nm and a height of 10-15 nm and are often referred to as nanodomains (Franzini et al. 1999; 
Hayashi et al. 2009). At this level, L-type Ca2+ channels (LTCCs) are located in the t-tubules 
of PM, juxtaposed to the RyRs residing in the SR membrane. LTCCs can sense both local and 
global Ca2+ signals through a secondary messenger called calmodulin (CaM) (Winslow et al. 
2012). CaM contains 4 EF-hands and binds Ca2+ to its C- or N-terminus (up to four ions in 
total), tethering to LTCCs and mediating Ca2+ dependent inactivation. (Winslow et al. 2011). 
Interestingly, Ca2+ dependent fast inactivation of SOCCs has been previously linked to the 
interaction of CaM to the N-terminus of Orai1 (Mullins et al. 2009). CaM also has a key role 
in preventing Ca2+ overload by competing with STIM proteins for PM lipids. (Bhardwaj et al. 
2013; Malli et al. 2008). A recent study showed that Ca2+-CaM is able to disassemble STIM1 
oligomers and therefore deactivate STIM1-Orai1 complexes in HEK293T cells. (Li et al. 
2017). SOCE activation causes a cytosolic Ca2+ rise through Orai1, therefore leading to 
charging CaM with Ca2+ and its movement closer to the ER-PM junctions where the STIM1-
Orai1 complexes are formed. Moreover, Ca2+-CaM has a high affinity for the SOAR of STIM1 
(site Orai1 binds to) (Li et al. 2017). Interestingly, the SOAR domain has been shown to have 
an affinity of approximately 200µM for the Orai1 channel and of 0.2 µM for the Ca2+-CaM 
which is 1000-fold higher (Li et al 2017, Yuan et al. 2009; Stathopulos et al. 2013). Therefore, 
in competing with Orai1 for the SOAR domain, Ca2+-CaM is able to pull STIM1 from Orai1 
and thus disrupting the CRAC channel assembly (Li et al 2017) 
 
 
 
38 
 
1.8.3 Ca2+ permeable channels of the intracellular stores 
Inositol 1,4,5-triphosphate (IP3) activates the ER-resident receptors IP3R by promoting Ca
2+ 
binding to a what was an unidentified stimulatory Ca2+ binding site, until recently. (Taylor et 
al. 2010). Hamada and colleagues recently unveiled the structure of the IP3R by mutagenesis 
and X-ray crystallography (Hamada et al. 2017). Over 2000 amino acids have been identified 
between the IP3 binding site and the channel itself and several residues have been proposed as 
candidates for mediating the gating (Hamada et al. 2017).  
Functional IP3R are homo- or hetero- tetrameric channels that allow Ca
2+ release from the ER 
into the cytosol (Alzayady et al. 2013). Each monomer is formed by three major domains: 1) 
the C-terminus comprising of six transmembrane regions; the final transmembrane pair (5-6) 
and the luminal loop forming the pore (Ramos-Franco et al 1999); 2) the N-terminus 
containing the IP3 binding site; and 3) an intervening sequence (Galvan et al 1999). 
Interestingly, they have modest Ca2+ permeability (PCa/PK=6) as compared to VGCCs or 
SOCCs (PCa/PK=1000) (Taylor and Tovey 2010). Several studies suggest that SOCE activation 
requires IP3R to be in close proximity to the CRAC channels at the PM-ER junctions and that 
their blockade deactivates already formed CRAC channels suggesting a conformational 
coupling model for SOCCs (Okeke et al. 2016). Our lab previously reported the importance 
of IP3R in the activation of the PM Cl
- channel ANO1. (Jin et al. 2013).  
Another important Ca2+ release channel found in the SR/ER membrane of cardiac and skeletal 
muscle cells is RyR (Lanner et al. 2010). There are three isoforms (RyR 1-3) and are the 
largest known ion channels with a molecular weight higher than 2MDa (Lanner et al. 2010). 
While they are mainly expressed in skeletal and cardiac muscle cells, RyR2 and RyR3 
isoforms has been also identified in areas of the brain such as hippocampus and thalamus (Lai 
et al. 1992). Similar to IP3R, RyR are located at Ca
2+ microdomains, can trigger spontaneous 
Ca2+ sparks and have a role in the excitation-contraction coupling (Lanner et al. 2010). 
Recently, a third family of intracellular Ca2+ channels has been reported, called two-pore 
channels (TPC) (Wang et al. 2012). These channels are activated by nicotinic acid adenine 
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dinucleotide phosphate (NAADP) resulting in Ca2+ release from the endo-lysosomal system 
(Patel et al. 2011; Zhu et al. 2010, Taylor et al. 2010). Interestingly, a number of transient 
receptor protein (TRP) channels have also been reported to mediate Ca2+ release from 
intracellular stores, in addition to their role in the PM. (Gees et al. 2010). 
 
1.8.4 Junctional proteins 
Proteins localised between the ER and PM membranes are known to support the regulation of 
SOCE and to form junctional membrane complexes (JMCs) (Várnai et al. 2007). Previous 
studies have identified various components of the JMCs such as junctin (expressed in muscle 
cells), junctate (a splice isoform of junctin, ubiquitously expressed), mitsugumin (detected in 
skeletal muscle), sarcalumenin (expressed in cardiac and skeletal muscle) or junctophilins 
(detected in skeletal and cardiac muscle, neurons and T-cells) (Correll et al. 2017; Srikanth et 
al. 2012; Hadad et al. 1999; Takeshima et al. 2015).  
ER-PM junctions are best understood and described in muscle cells, where JMCs are 
organized in dyads (in cardiac muscle cells) or triads (in skeletal muscle cells) and one of their 
key roles is to couple RyRs found in the ER membrane, to VGCCs in the PM membrane. 
(Berridge et al. 2003). In neurons, JMCs have firstly been described in 1962 as subsurface 
cisterns and their impairment was associated with different neurodegenerative diseases, 
including Huntington’s disease. (Rosenbluth et al. 1962; Krause et al. 2015). 
Junctophilins (JPHs) have been found in all excitable cells as part of JMCs and were 
intensively studied by Takeshima and colleagues since 2000 (Takeshima et al. 2000). Their 
first publication described JPHs as JMCs proteins with a hydrophobic segment spanning the 
ER membrane and a cytosolic domain with affinity for the PM. (Takeshima et al. 2000) The 
publication mentioned 3 family members and focused on the importance of JPH2 in regulating 
Ca2+ transients in cardiac myocytes, followed by a more thorough characterisation of tissue 
specific protein expression at mRNA level, later that year. The same research lab reported for 
the first time, in 2003, the presence of a 4th JPH subtype in both human and mouse genomes 
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(chromosome 14q11.1 and chromosome 14C1-2, respectively) (Nishi et al 2003). 
Interestingly, JPH3 and JPH4 were found to be similarly distributed in the brain, 
predominantly in the hippocampal pyramidal neurons as part of the subsurface cisterns. (Nishi 
et al. 2003, Moriguchi et al. 2006) 
Mammalian JPH family members are composed of eight repeats of the membrane occupation 
and recognition nexus (MORN) sequence in the cytosolic N-terminus and have high affinity 
for PM phospholipids. At the same time, their C-termini span the ER/SR membrane. 
(Kakizawa et al. 2008). 
 
 
 
 
Figure 1.10. The structure of junctophilin proteins. A. Hydropathicity profile of JPH1 (rabbit) 
showing the PM binding segment (caracterized by repeated MORN motifs) and the transmembrane 
(TM) segment (or ER/SR membrane spanning section). B. A proposed JPH structure in JMCs showing 
the C-terminus spanning region in the ER/SR membrane, the cytosolic domain and the N-terminus 
containing MORN motifs interacting with the PM. Figure adapted from Takeshima et al. 2015. 
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Junctophilin-1 (JPH1) 
JPH1 is a 90 kDa protein, highly expressed in skeletal muscle, identified also at a lower level 
in the heart, where JPH2 is expressed predominantly. (Takeshima et al. 2000; Phimister et al. 
2007). JPH1 was reported in 2000 as a component of PM-SR junctions of rabbit skeletal 
muscle (Takeshima et al. 2000) and it is now known to have a key role in maintaining the 
geometry of the muscle JMCs. (Block et al. 1988). It has been shown that silencing JPH1 
affects already-formed triads and reduces their overall number in muscle cells. (Hirata et al. 
2006). Fewer triads have led to a lower contractile force that concluded with pup death in mice 
lacking JPH1, presumably due to respiratory failure (Ito et al. 2001). Furthermore, JPH1 
proteolysis may contribute to skeletal muscle weakness as seen in a mouse model of muscular 
dystrophy (Murphy et al. 2013). JPH1 has other roles besides holding the close apposition 
between the SR membrane and the PM T-tubules: it regulates voltage gated Ca2+ entry through 
direct interactions with dihydropyridine receptors (DHPR) in skeletal muscle cells and also 
promotes SR stored Ca2+ release by interacting with ryanodine receptors (RyR1 isoform) 
(Golini et al. 2011; Phimister et al. 2007).  
Recently, David Pla-Martin and colleagues reported that mutations within JPH1 and 
ganglioside-induced differentiation-associated protein 1 (GDAP1) gene contribute to severe 
SOCE impairment (Pla-Martin et al. 2015). GDAP1 plays a role in neuronal development and 
mutations have been previously associated with neuropatic disorders and more specifically 
with Charcot-Marie-Tooth disease (CMT) (Pla-Martin et al. 2013). CMT is an inherited 
condition characterized by progressive muscle weakness and neuropathy. The authors 
described the case of a 29-year-old Spanish woman with diagnosed with CMT type 2K caused 
by a GDAP1 R120W mutation (inherited from her father) that also had a R213P mutation in 
the JPH1 gene (inherited from her mother). She presented a more severe disease phenotype in 
comparison with her relatives who had only GDAP1 gene mutation (Pla-Martin et al. 2015). 
Previous studies have shown that CMT neuropathies may also be associated with the impaired 
distribution of the mitochondria towards the junctional membrane complexes, resulting in a 
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decrease in SOCE and leading to impaired Ca2+ uptake by mitochondria (Pla-Martin et al. 
2013). 
 
Junctophilin 2 (JPH2) 
Cardiac excitation-contraction (EC) coupling governs the heart muscle contraction and at 
cellular level it requires a close relationship and precise communication between VGCC 
located on the T-Tubule and RyR residing on the SR membrane (Brette et al. 2003). Studies 
have shown that disruptions in this communication, such as changes in T-tubule morphology, 
are associated with heart failure (Balijepalli et al. 2003).  
JPH2, a 74 kDa protein of 696 amino acids, bridges the gap between PM and SR, maintaining 
the JMC in healthy cardiomyocytes (Takeshima et al. 2000). JPH2 deficiency have been 
associated with impairment of T-tubule maturation, suggesting that it plays an important role 
in maintaining the dyadic structure in cardiac muscle cells (Chen et al. 2013). Transgenic 
JPH2-null mice demonstrated a 90% increase of the distance between SR and sarcolemmal T-
tubules (Takeshima et al. 2000). This was associated with spontaneous cardiomyocyte 
contraction, a reduced amplitude of Ca2+ transients as well as irregular Ca2+ currents 
(Takeshima et al. 2000). Calcium-induced calcium-release (CICR) was also impaired in JPH2 
KO cardiac cells in vitro, with no effect on the expression or functionality of LTCC 
(Landstrom et al. 2011).  
JPH2 was linked to different types of cardiac disorders such as dilated and hypertrophic 
cardiomyopathy (HMC) seen in rodent genetic models, or HMC with left ventricular tract 
obstruction observed in humans (Minamisawa et al. 2004; Landstorm et al. 2011). Several 
studies have reported that JPH2-altered expression is more frequently associated with HMC 
incidence as compared to its mutations (<1% HMC) (Landstorm et al. 2012). Interestingly, 
JPH2-E169K mutation has been recently associated with supraventricular arrhythmia 
observed in a multi-generation family; a rodent model of this mutation revealed a decreased 
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RyR2-JPH2 interaction and consecutively an increase in spark frequency (Beavers et al. 
2013). 
Several studies described skeletal muscle function impairment associated with JPH2 
mutations as well (Landstorm et al. 2014). Over-expressing JPH2-S165F mutation resulted in 
reduced Ca2+ release via RyR1, thus reduced CICR followed by hypertrophy (Woo et al. 
2010). It was proposed that JPH2-S165F mutation might affect the TRPC3 phosphorylation 
mediated by PKC (Woo et al. 2008). As TRPC3 is known to modulate RyR1, the JPH2-S165F 
was considered to indirectly diminish RyR1 function and contribute to skeletal muscle 
hypertrophy (Woo et al. 20008, 2009, 2010). 
Interestingly, dysregulation of JPH2 was associated with microtubule densification due to 
enhanced polymerization (Zhang et al 2014). Cardiac stress leads to an increase in microtubule 
density which further results in JPH2 altered redistribution, T-tubule remodelling and EC 
dysfunction, potentially leading to heart failure (Zhang et al 2014). Furthermore, JPH2 
overexpression has been shown to prevent heart failure without affecting the baseline 
contractile function (Guo et al. 2014).  
Junctophilin 3 and 4 
Junctophilin 3 (748 amino acids, 81 kDa) and Junctophilin 4 (628 amino acids, 66 kDa) were 
primarily observed within the brain and studies suggested that their role might be in facilitating 
the Ca2+ crosstalk between PM P/Q-type VGCC and ER RyR (Moriguchi et al. 2006). 
Surprisingly, silencing either of the proteins in mice hippocampal neurons resulted in no 
abnormalities, but the loss of both proteins resulted in impaired Ca2+-dependent K+ channel 
(SK)-dependent afterhyperpolarization, further leading to reduced memory, impaired 
exploratory activity and death of 5 weeks old mice (Moriguchi et al. 2006). JPH3 seems to 
serve as a JMC stabiliser, regulating neuronal Ca2+ influx and its mutation was linked to 
Huntington’s Disease-like 2 (HDL2), a neurological disorder characterized by motor 
impairments and cognitive decline leading to dementia (Seixas et al. 2012). JPH3 was also 
44 
 
considered to function as a neuroprotector in elderly populations, hypothesis being confirmed 
by comparing young versus old JPH3-null mice; ROS dependent tissue oxidation in old mice 
led to a late-onset neurodegeneration similar to that observed in HDL2 patients (Seixas et al. 
2012). Abolished afterhyperpolarization was also observed in cerebellar Purkinje cells of 
JPH3/4 null mice (Kakizawa et al. 2007). The neuronal JPH3/4 KO resulted in 
hyperphosphorylation of PKCγ, an impairment in the synaptic maturation contributing to 
severe motor defects and impaired cerebellar plasticity (Ikeda et al. 2007). 
Since their discovery, JPH3 and 4 were mainly investigated in excitable cells, but a recent 
study reported the presence and the role of JPH4 in T cells (Woo et al. 2016). The authors 
proposed that in resting cells, JPH4 and junctate form a protein complex that allows STIM1 
recruitment after ER Ca2+ discharge. The proposed mechanism is that cytosolic CC1-CC2 
domains and the ER-luminal domain of STIM1 are interacting with the JPH4-junctate 
complex as observed in GST pulldown analysis of STIM1 fragments (Woo et al. 2016). The 
role of JPH4 in T cells may have a high benefit on the development of new pharmacological 
agents for inflammatory disorders and the presence of both JPH3 and 4 in different brain cells 
opens the door for further neurobiology research.  
 
1.9 SOCE in neurons 
Neurons have been thought to deliver Ca2+ influxes mostly through VGCC and receptor 
activated Ca2+ channels (e.g. glutamate or AMPA receptors), but since early 2000’s studies 
have shown the presence of SOCE in excitable cells, including neurons (Akbari et al. 2004; 
Emptage et al. 2001). The concept of capacitative calcium entry in neuronal cells was 
originally demonstrated three decades ago (Putney JW 2011), but only later its importance in 
the development of the nervous system was evidenced (Nishiyama et al. 2000). Altered Ca2+ 
signaling can have serious consequences leading to Ca2+ overload, oxidative stress and ROS 
production, unfolded protein response, autophagy inhibition as well as mitochondrial 
dysfunction (Bollimuntha et al. 2017). All these issues may further lead to neurological 
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disorders such as Alzheimer’s or Parkinson’s disease, HIV-induced dementia, Huntington’s, 
bipolar disorders, as well as ataxia and muscular dystrophy (Bollimuntha et al. 2017). 
Different ion channels have been proposed to mediate SOCE in neurons, but TRPC family 
members attracted interest due to their high expression in the central and peripheral nervous 
system. Studies have identified TRPC channels to be preferentially expressed in different 
neuronal populations and thus having distinct functional roles: TRPC1 regulates cell 
proliferation in neuronal stem cells, TRPC3 and 6 mediate brain-derived neurotrophic factor 
(BDNF) – dependent neuronal growth and TRPC5 triggers a platelet-derived growth factor 
(PDGF) medicated neuroprotection (Fiorio et al. 2005; Jia et al. 2007; Yao et al. 2009).  Later, 
Orai and STIM proteins have been shown to be expressed in distinct patterns in the brain and 
therefore the role of SOCE in neuropathophysiology gained more interest (Kraft et al. 2015). 
Orai and STIM isoforms have been identified in both human and murine brain (Kraft et al. 
2015). While STIM1 and 2 have similar expression in murine and human brain at mRNA 
level, Orai1 seems to be less present than Orai3, while Orai2 mRNA has been identified in 
murine but not in human brain tissue (Lalonde et al.2014). Interestingly, Orai2 and Orai3 seem 
to co-localize in murine Purkinje cells, STIM1 is highly present in cerebellum and low in the 
hippocampus, while STIM2 has the opposite expression pattern (Lalonde et al. 2014). In 
murine hippocampus, STIM1 is highly expressed in neuronal soma, while STIM2 both in 
soma and dendrites (Hooper et al. 2014). 
STIM1’s role in Purkinje neurons and cerebellar granule neurons might be to trigger slow 
glutamate receptor signal and gene transcription, while STIM2 might have a role in preventing 
memory loss in Alzheimer’s disease as it regulates the activity of calmodulin kinase 2 
(CAMKII) and stabilizes hippocampal mushroom spines (Hartman et al. 2014; Lalonde et al. 
2014; Sun et al. 2014).  
Increased expression of STIM1 and Orai1 may lead to neuronal death after an ischemic event, 
due to cytosolic Ca2+ accumulation (Zhang et al. 2014). This is consistent with the fact that 
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CRAC channels also play a crucial role in thrombus formation. Thus, inhibiting platelet 
activation with pharmacological agents that target SOCE may prevent or treat ischemic events 
(Varga-Szabo et al. 2008). A SOCE dysfunction was also associated with Charcot-Marie-
Tooth (CMT) disease, characterized by axonal neuropathy or demyelinating of motor and 
sensory peripheral nerves (Pareyson et al. 2013). This genetic disorder is caused by mutations 
in GDAP1, whose silencing triggers a partial depletion of the ER Ca2+ pool, further reducing 
the Ca2+ influx through SOCE (Barneo-Munoz et al. 2015). 
Outside CNS, molecular components of CRAC have been recently found in peripheral 
neurons, specifically in dorsal root-ganglia (DRG) and dorsal horn neurons (Gemes et al 2011, 
Munoz and Hu 2016). Previous studies showed that CRAC channels are fully functional in 
DRGs and that ICRAC is enhanced after nerve injury (Gemes et al. 2011). STIM1, 2 and Orai1, 
3 but not Orai2 were identified in DRG neurons and, interestingly, Orai1 and 3 are thought to 
play a key role in membrane depolarization and neuronal excitability, vital for inter-neuronal 
signaling and pain transmission (Wei et al. 2017). In a spinal nerve ligation (SNL) rat model, 
injured DRG L5 neurons revealed an increased ICRAC as compared to control neurons (Gemes 
et al. 2011). Moreover, while Orai1 and STIM1 expression is not affected after nerve damage, 
thapsigargin failed to trigger SOCE on injured neurons, suggesting that the nerve injury itself 
depletes the ER Ca2+ stores, activates and maintain ICRAC (Gemes et al. 2011). 
The ER Ca²⁺ concentration critically regulates calcium signaling in peripheral nervous system, 
but Ca²⁺ store replenishment in stimulated DRG neurons is still an undocumented area which 
requires further research. As previously highlighted, calcium signaling is strongly implicated 
in inflammatory and neuropathic pain mechanisms and the referenced studies suggest a 
potential role of CRAC channels in inflammatory GPCR signaling and pain. 
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1.10 Aims of this study 
The above review covered the progress that has been made in the past decade to elucidate the 
importance of SOCE in excitable and non-excitable cells, but also highlighted the limited 
knowledge of its role in pain signalling. The overall objective of this study was to characterize 
SOCE in primary afferent neurons and probe its role in inflammatory signalling cascades. 
Specific aims of this study are as follows 
a) Characterizing the expression of the CRAC components within DRGs. 
b) Determining the effect of CRAC inhibitors on ATP and/or BK-induced SOCE. 
c) Investigating expression and functional role of junctional proteins, Junctophilins in DRG 
d) Exploring the role of SOCE and its components in the maintenance of inflammatory 
signalling cascades in DRG. 
Most of this work was carried out on DRG neurons, but a separate aim was also to investigate 
whether the effect of CRAC inhibitors YM58483 and Synta66 is dependent on the type of 
cells, SOCE stage and/or duration of treatment. The overarching aim of this study was to 
develop mechanistic understanding of SOCE in nociceptive sensory neurons in order to 
provide new insights for the treatment of inflammatory pain.  
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Chapter 2. Materials and Methods 
 
2.1 Established cell lines 
Human embryonic kidney 293 (HEK 293) cells and Chinese hamster ovary (CHO) cells were 
used for fluorescent calcium imaging experiments. Cells were cultured on 100 mm culture 
dishes in Dulbecco’s Modified Eagle’s medium (DMEM-GlutaMAX, Life Technologies) 
supplemented with 10% Foetal Calf Serum (FCS, Sigma-Aldrich), 50 U/ml penicillin (Sigma-
Aldrich) and 50 µg/ml streptomycin (Sigma-Aldrich) and kept in a humidified incubator (set 
at 37°C and 5% CO2). Cells were passaged every 3 days by washing with 10 mL phosphate 
buffer saline (PBS, Sigma-Aldrich), followed by pipetting for mechanical detachment (for 
HEK 293 cells) or trypsinization (for CHO cells) with 1 ml Trypsin-EDTA (Invitrogen). Once 
isolated in a tube, cells were washed twice with fresh DMEM and centrifuged for 5 minutes 
at 800 rpm (25°C). The cell cone was re-suspended in fresh pre-warmed (37°C) DMEM and 
cells were seeded at a density of 106/ml. 
2.1.1 Cell line transfection 
For transfection, 24 well plates were prepared consisting of different dilutions of HEK293 or 
CHO cells. Once cells were adjudged to be ~50-90% confluent 24 hours post-seeding, they 
were transfected with 100-400 ng DNA using Fugene HD (Promega) according to the 
manufacturer’s instructions. The transfection protocol was optimized by treating the cells with 
different amounts of plasmid concentration and considering a variable cell confluency. As 
expected, an efficient transfection has been observed when 400 ng of cDNA plasmid was used 
and cells were 60-70% confluent. The following day, cells were detached (see above for 
method depending on cell type), collected and seeded on pre-coated coverslips. Imaging 
experiments were performed 48 hours post-seeding. 
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2.2 Primary culture of DRG neurons 
All animal work was performed under UK Home Office License and in accordance with the 
regulations of the UK Animals (Scientific Procedures) Act 1986. 
Wistar rats (7 to 14 days old) were sacrificed by exposure to isoflurane overdose, followed by 
cervical dislocation to confirm the death according to the Home Office Schedule I protocol. 
Rats were decapitated followed by removal of the spine, which was then sliced longitudinally 
to expose the spinal cord. Upon removal of the spinal cord, sphere-like DRGs were revealed 
between vertebras, which were extracted using fine forceps. Ganglia were stored in ice-cold 
Hanks Balanced Salt Saline (HBSS, Sigma-Aldrich) solution and then transferred into a 
dissociation solution containing 10 mg/ml dispase (Thermo Fisher Scientific) and 1 mg/ml 
type 1A collagenase (Sigma-Aldrich) in pre-warmed HBSS. During the dissociation, ganglia 
were kept in a humidified incubator at 37°C and 5% CO2 for 13 minutes, followed by gentle 
trituration to facilitate the dissociation and re-incubated for a further 2 minutes. This protocol 
has been optimized by previous members of Prof. Nikita Gamper’s lab to provide the efficient 
neuronal survival with regards to the fragility of DRG. A final mechanical dissociation by 
trituration was performed, followed by addition of ice-cold media (DMEM with GlutaMAX, 
10% FCS, penicillin 50 U/ml and streptomycin 50 µg/ml) to halt the dissociation process. 
Cells were then centrifuged and washed twice for 5 minutes at 800 rpm in ice-cold DMEM 
media. The cell cone was resuspended in pre-warmed media and 100 l droplets of  the high 
density cell suspension were placed on 10 mm glass coverslips which were pre-coated with 
poly-D-lysine (Millipore Ltd) and laminin (Insight Biotechnology) to provide adherence for 
DRG neurons. Dissociated cells were then incubated for 4 hours to facilitate adhesion and to 
reduce the risk of apoptosis. Following this, each coverslip was supplemented with 1 ml media 
for culturing and re-incubated for a minimum of 48 hours prior to experiments. 
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2.2.1 DRG transfection 
Attempts to transfect DRG neurons with either R- or G-CEPIA1er were made by choosing a 
non-viral gene transfer technique. Nucleofection has been shown to be more efficient in 
transfecting non-dividing cells with respect to other transfection methods (Kirton et al. 2013). 
This technique combines chemical transduction and electroporation to facilitate the plasmid 
entry into the nucleus of primary cultured or hard-to-transfect cells (Martinet W et at. 2003). 
For neurons that required transfection with calcium-measuring organelle-entrapped protein 
indicators (CEPIA; see below), a Nucleofector® I console (Lonza) was used to transfect DRG 
neurons. Prior to seeding, cells were resuspended in a rat neuron transfection buffer and mixed 
with 10 µg of DNA. The solution was then quickly transferred into a Lonza certified cuvette 
and placed into the nucleofector. Program O-03 was utilized for transfection after which the 
cells were resuspended in pre-warmed media and seeded onto coverslips. As for standard 
cultured DRGs, cells were incubated for minimum 48 hours prior to experiments. 
2.2.2 DRG knock-down with deliverable small interfering RNA 
For gene silencing experiments, small interfering RNA (siRNA) against JPH4 was delivered 
with Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific). To do so, 
DRG neurons were dissociated as previously described and 48 hours post-seeding the cells 
were approximately 70% confluent and ready for transfection. Briefly, the cultured neurons 
were washed with fresh pre-warmed DMEM (without FCS and antibiotics). The transfection 
reagent and siRNA were mixed in OptiMEM I reduced serum medium (Life Technologies) as 
per manufacturer’s instructions. A scrambled oligomer was also used as a negative control 
(Table 2.1). Two different siRNA products against JPH4 were used at various concentrations 
(from 5 to 10 pmol per well) 
ell) in both single use and in combination. The diluted siRNA-lipid complex was then added 
to cells followed by incubation at 37°C for 1 to 3 days. To determine the knock-down (KD) 
effect, the cells were lysed and analyzed by Western blot as described in Chapter 6. 
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Table 2.1: The list of siRNA products used for DRG knock-down experiments. 
 
2.3 Cytosolic calcium imaging using fura-2 AM 
Fura-2 is a high affinity calcium indicator, widely used to measure intracellular calcium levels 
by fluorescence imaging (Paredes et al. 2008). For the experiments detailed in this thesis, fura-
2 acetoxymethyl ester (fura-2 AM) was utilized, which is a membrane permeant form of the 
dye and delivers fura-2 inside the cell once cytosolic esterases remove the acetoxymethyl 
groups (Paredes et al. 2008). It is a ratiometric calcium indicator that is excited at both 340 
and 380 nm and emits at 510 nm. The fluorescence intensity ratio (R = F340/F380) is measured 
at wavelengths where the difference of fluorescence between bound (at 340 nm) and free 
indicator (at 380 nm) is maximum. This way, the risk of photobleaching or uneven dye loading 
is reduced as compared to other intensity-based calcium indicators such as Fluo-4. 
Prior to recording, plated cells were loaded with fura-2 by incubating them with a mixture of 
2 µM fura-2 AM (Thermo Fisher Scientific) and 0.01% pluronic acid (Sigma-Aldrich) in 
extracellular bath solution (EC, Table 2.3) for 1 hour. The mixture was then removed and cells 
were washed with EC solution. Fragments of coverslips were placed on the microscope 
perfusion chamber and EC solution was perfused over the cells through a gravity driven 
perfusion system at an approximate rate of 2 ml/min. The drug compounds were diluted in EC 
solution to the required concentration and applied via the perfusion system. 
Product name Referred to as Supplier 
Silencer Select siRNA against JPH4 
(s175513) 
siRNA #1 Life Technologies 
Silencer Select siRNA against JPH4 
(s175511) 
siRNA #2 Life Technologies 
Silencer Select Negative Control No.1 siRNA Scrambled oligomer Life Technologies 
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To visualize the cells, an inverted Nikon TE-2000 microscope was connected to a Till 
Photonics fluorescent imaging system comprising of a Polychrome V monochromator and an 
IMAGO CCD camera. TILL Vision 4.5.56 software (later upgraded to Live Acquisition 2.2.0) 
was used for image acquisition and processing. Cells were excited at 340 nm and 380 nm (50 
ms exposure) to confirm fura-2 loading and the emission was collected using a UV-2A filter 
(Nikon). Regions of interest (ROIs) were used to select neurons from snapshots taken to record 
from and for further post-hoc analysis. Prior to recording, further protocol details were also 
set (such as duration of excitation, total experiment duration, signal-to-noise parameters). 
Recordings made were exported and analysed in Microsoft Excel and Origin software. 
2.4 Intraorganellar calcium imaging with CEPIA 
Calcium-measuring organelle-entrapped protein indicators (CEPIA) are genetically encoded 
calmodulin-based Ca2+ indicators (Suzuki et al. 2014). CEPIAs have been recently described 
as a new sensitive tool to investigate organellar functions as they are engineered to emit red, 
green or blue/green fluorescence when binding Ca2+ at intraorganellar Ca2+ concentrations 
(Suzuki et al. 2014). 
SOCE has been previously investigated by measuring the increase in cytosolic Ca2+ levels 
after store depletion with either SERCA inhibitors or GPCR agonists (Suzuki et al. 2014). 
Calcium imaging in the ER is therefore another direct mean to analyze SOCE and indicators 
such as CEPIA allow to do so. I have used R-CEPIA1er (Kd = 565 ± 58 μm, Fmax/Fmin = 
8.8 ± 0.7) and G-CEPIA1er (Kd = 672 ± 23 μm, Fmax/Fmin = 4.7 ± 0.3) (Suzuki et al. 2014). 
Their high dynamic range proved to be efficient in cultured neurons where Ca2+ changes 
within the ER were mainly studied indirectly by cytosolic Ca2+ imaging (Suzuki et al. 2014). 
 
Imaging of ER calcium levels using G-CEPIA1er and R-CEPIA1er was done in the same 
manner as fura-2 calcium imaging however excitation was done using 488nm (GFP-B filter 
cube) and 560nm (G-2A filter cube), respectively. 
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2.5 CEPIA-cDNA preparation 
R- and G- CEPIA1er were purchased from Addgene as plasmids in bacteria agar stabs. An 
agar solution containing 100 µg/ml Ampicillin was prepared and poured in 100 mm diameter 
Petri dishes. A sterile pipette tip was used to extract the bacteria growing within the agar stab 
and spread over the solidified agar in the plates. Three different streaks were created to spread 
and dilute the bacteria. The plates were then incubated at 37°C for 16 to 24 hours and the 
following day, bacterial colonies were visible. One single colony was used to further prepare 
a culture of bacteria overnight in a Lysogeny broth (LB) solution containing 100 µg/ml 
Ampicillin. Plasmid DNA was isolated from the culture using a QIAGEN Plasmid Midi Kit, 
according to the manufacturer’s recommendations. Briefly, the bacterial culture was harvested 
by centrifugation at 7000 rpm for 15 minutes at 4°C. The bacterial pellet was resuspended in 
a lysis buffer provided and the supernatant containing plasmid DNA was collected, followed 
by DNA elution and further on precipitation with room-temperature isopropanol. The pellet 
DNA was then washed with 70% ethanol, air-dried and dissolved in a suitable volume of 
alkaline buffer. The plasmid DNA concentration was determined by measuring an absorbance 
at 260 nm using a NanoDrop spectrophotometer. 
 
 
Table 2.2: List of chemicals and drugs used for calcium imaging 
 
Drug Concentration Supplier 
Thapsigargin 1 µM LKT Laboratories 
ATP 30 µM Sigma-Aldrich 
BK 250 nM Calbiochem 
YM58483 1 µM Sigma-Aldrich 
Synta66 3 µM provided by Richard Foster, School of 
Chemistry, University of Leeds 
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Table 2.3: Solutions used for calcium imaging experiments and inducing SOCE 
 
2.6 Immunocytochemistry (ICC) 
Cultured DRG neurons were fixed with 4 % ice-cold paraformaldehyde (PFA, Sigma-Aldrich) 
for 20 minutes. After washing three times with 1x PBS, cells were incubated with a blocking 
buffer (containing 0.05% Tween 20, 0.25% Triton X-100 and 5% donkey and/ or goat serum 
in 1X PBS, all products from Sigma-Aldrich) for 1 hour at room temperature. The purpose of 
this step is to reduce nonspecific background noise and to improve the sensitivity of the assay. 
Following this, cells were incubated overnight at 4°C with a solution containing one or two 
primary antibodies, depending on the experimental design. The antibodies were diluted to the 
required concentration in 5% bovine serum albumin (BSA, Sigma-Aldrich) in 1x PBS. Next 
day, the cells were washed again with 1x PBS and further incubated with fluorochrome-
conjugated secondary antibodies (Table 2.4) diluted in 1 % BSA buffer for 2 hours at room 
temperature. Coverslips were then washed and mounted on microscope glass slides with 10 
µl Vectashield mounting medium supplemented with 4,6 diamidino-2-phenylindole (DAPI, 
Vector Laboratories). Samples were kept in the dark, at 4°C and imaged with a Carl Zeiss 
LSM880 inverted confocal microscope and processed with Zeiss ZEN imaging software. For 
Extracellular bath solution (mM) Ca
2+
 free solution (mM) 
NaCl 160 NaCl 165 
KCl 2.5 KCl 2.5 
MgCl2 1 MgCl2 1 
CaCl2 2 EGTA 1 
HEPES 10 HEPES 10 
Glucose 10 Glucose 10 
pH 7.4 
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each staining procedure, a buffer without primary antibody was used as a negative control and 
cells were detected by nuclei-specific DAPI staining. 
2.7 Immunohistochemistry (IHC) 
Once fresh ganglia were collected, they were washed with 1x PBS and fixed with 4% ice-cold 
PFA for 1 hour. The ganglia were then embedded in 10% gelatin (Sigma), solution prepared 
with distilled water. Once solidified, the gelatin was cut into 1cm³ cubes, each cube containing 
a ganglion, and further incubated in 4% PFA for 6 to 10 hours at 4°C. The cubes were then 
washed with 1x PBS and stored in 0.1M phosphate buffer solution (PB, Sigma-Aldrich) at 
4°C. Using a microtome blade, DRG sections of approximately 40 µm were cut and wished 
with 1x PBS. The following steps including blocking and primary/secondary antibody staining 
were done in the same manner as above. The DRG slices were then mounted with Vectashield 
plus DAPI, covered with coverslips and sealed with polish prior to imaging. See Table 2.4 for 
information about the primary and secondary antibodies used for immunocyto- and 
immunohistochemistry experiments.  
To support the validity of the antibodies, control samples without primary antibody treatment 
were also prepared. Thus, cultured DRG neurons or whole DRG sections were incubated with 
the buffer alone. The following steps remained unchanged: incubation with secondary 
antibodies and mounting with Vectashield plus DAPI. Images of the no primary antibody 
samples were processed in the same way and presented alongside the positive staining in the 
following chapters. This ensures that the observed staining is due to detecting the antigen by 
the primary antibody.  
Antibodies against STIM, Orai, NF200 and TRPV1 explicitly characterized in previous 
studies were chosen (see Table 2.4 for details). 
At the time of the experiments, the antibodies against JPH proteins were not referenced in any 
published manuscripts. Therefore, the specificity of these antibodies was also determined by 
Western blot in tissue homogenates known to express each of the protein (e.g. skeletal muscle 
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lysate for JPH1, cardiac muscle lysate for JPH2 and cerebellum lysate for JPH3 and JPH4). 
Specificity of JPH4 antibody has been further confirmed by the JPH4 knockdown. More 
information can be found in Chapter 5 of this thesis. 
The expression of all STIM, Orai and JPH isoforms was investigated in fixed DRG sections. 
Using Zeiss ZEN software, the number of positively and negatively stained neurons was 
determined.  The mean fluorescence intensity of the whole DRG section was considered the 
threshold above which a neuron was positive. The cell diameter and mean intensity was 
calculated for each selected neuron. Further on, the cells were classed depending on the 
somatic diameter and presented as a frequency distribution. Data is shown as the number of 
positive neurons of different somatic sizes (± SEM) from the total number of neurons 
analysed. The somatic diameter intervals were: ˂10 µm, 10-15 µm, 15-20 µm, 20-25 µm, 25-
30 µm, 30-35 µm, 35-40 µm, 40-45 µm and >45 µm. 
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Antibody Dilution Supplier / Reference 
Rabbit anti-JPH1 1:200 Biorbyt 
Rabbit anti-JPH2 1:200 Biorbyt 
Rabbit anti-JPH3 1:200 Biorbyt 
Rabbit anti-JPH4 1:200 Biorbyt 
Rabbit anti-JPH4 1:200 Sigma-Aldrich 
Mouse anti-STIM1 1:200 Abcam / Hájková Z et al. 2011 
Rabbit anti-STIM2 1:500 Abcam / Bréchard S et al. 2009 
Mouse anti-Orai1 1:500 Abcam / Guzman R et al. 2014 
Rabbit anti-Orai1 1:500 Alomone / Qi Z et al. 2016  
Rabbit anti-Orai2 1:500 Alomone / Zheng B et al. 2017 
Rabbit anti-Orai3 1:500 Alomone / Sabourin J et al. 2016  
Mouse anti-NF200 1:2000 Sigma-Aldrich / Rose et al. 2011 
Guinea pig anti-TRPV1 1:500 Neuromics / Rose et al. 2011 
Donkey anti-mouse Alexa Fluor 488 1:1000 Invitrogen / Rose et al. 2011 
Donkey anti-mouse Alexa Fluor 555 1:1000 Invitrogen / Du X et al. 2017 
Donkey anti-rabbit Alexa Fluor 488 1:1000 Invitrogen / Li JX et al. 2016  
Donkey anti-rabbit Alexa Fluor 555 1:1000 Invitrogen / Du X et al. 2017 
Goat anti-guinea pig Alexa Fluor 488 1:1000 Invitrogen / Rose et al. 2011 
Table 2.4: Primary and secondary antibodies used for ICC / IHC  
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2.8 Proximity Ligation Assay (PLA) 
PLA is a highly specific proteomic tool that was first developed in 2002 by Fredriksson and 
colleagues. It aims at detecting and visualizing protein-protein interactions (Fredriksson et al. 
2002). PLA uses the principle of two oligonucleotide-labelled antibodies capable of binding 
when in close proximity (less than 40 nm apart). Two primary antibodies are used to bind the 
targeted proteins and two oligonucleotide-conjugated secondary antibodies are then used to 
bind the primary antibodies. When the proteins are found in close proximity, connector 
oligonucleotides facilitate the formation of a single-stranded DNA circle between the two 
secondary probes. The use of DNA polymerase promotes the formation of repeated DNA 
sequences (the ‘rolling-cycle amplification’) that are further targeted for fluorescent detection. 
Thus, acute dissociated DRG neurons were cultured on pre-coated glass microscope slides. 
Prior to seeding, a hydrophobic barrier pen (Vector Laboratories) was used to delimit a seeding 
area to approximately 1 cm². Two days post-seeding, a Duolink PLA kit (Sigma-Aldrich) was 
used to perform the experiment as per manufacturer’s instructions. Depending on the 
experimental design, some cells have been treated with the CRAC inhibitor YM58483 for 1 
hour and/or store-depleted with BK in Ca2+ free solution prior to fixation. 
Cells were then fixed with 4% ice-cold PFA for 20 minutes and treated with a permeabilization 
buffer (composed of 0.05% Tween 20 and 0.25% Triton X in PBS) for 1 hour at room 
temperature. Further on, the cells were treated with the provided blocking solution for 30 
minutes at 37°C, followed by incubation with a diluted primary antibody solution for 12 to 16 
hours at 4°C. Next step was to wash the samples and add in oligonucleotide-conjugated 
secondary antibodies (anti-mouse MINUS and anti-rabbit PLUS PLA probes, Sigma-Aldrich) 
for 1 hour at 37°C. Further on, the ligation was done by treating the neurons with a solution 
containing ligase and 5X ligation stock in purified water for 30 minutes at 37°C. Cells were 
then washed and the amplification step was performed by adding in a solution comprising of 
polymerase and 5X Amplification stock in purified water for 100 minutes at 37 °C.  Finally, 
the samples were washed and mounted with Duolink mounting medium with DAPI (Sigma-
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Aldrich) prior to being sealed. Imaging was performed using a Carl Zeiss LSM880 inverted 
confocal microscope and images processed by Zeiss ZEN software. Table 2.5 lists the pair of 
antibodies used to perform different PLA experiments within this thesis. 
To validate the PLA approach, I performed negative and positive controls using Orai1 as a 
target protein. As such, the positive control experiment meant using two primary antibodies 
against Orai1 (one raised in mouse, one in rabbit) as shown in Table 2.5. Both PLA probes, 
anti-rabbit PLUS and anti-mouse MINUS, attached to the primary antibodies that previously 
bound the same Orai1 protein. A PLA-specific fluorescent signal was detected as shown in 
Chapter 3. Furthermore, a negative control experiment revealed that using only one primary 
antibody (mouse anti-Orai1) would not suffice for the anti-mouse MINUS and anti-rabbit 
PLUS probes to bind and reveal any fluorescent puncta (Figure 3.12.A). 
 
Table 2.5: Antibodies and probes used for PLA experiments 
 
 
 
 
 
Antibody 1 Antibody 2 PLA probe 1 PLA probe 2 
Rabbit anti-JPH4 Mouse anti-Orai1 Anti-rabbit PLUS Anti-mouse MINUS 
Rabbit anti-JPH4 Mouse anti-STIM1 Anti-rabbit PLUS Anti-mouse MINUS 
Rabbit anti-Orai1 Mouse anti-STIM1 Anti-rabbit PLUS Anti-mouse MINUS 
Rabbit anti-Orai1 Mouse anti-Orai1 Anti-rabbit PLUS Anti-mouse MINUS 
- Mouse anti-Orai1 Anti-rabbit PLUS Anti-mouse MINUS 
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2.9 Western blot (WB) 
WB is a widely used analytical assay to detect protein expression within a sample of tissue 
homogenate and was introduced in 1979 (Towbin et al. 1979). It is also called immunoblotting 
and it uses SDS-polyacrylamide gel electrophoresis (SDS-PAGE) to trigger the protein 
separation within a sample. Once separated, the proteins are transferred on a nitrocellulose or 
polyvinylidene difluoride (PVDF) membrane and stained with primary and secondary 
antibodies. The proteins of interest are therefore revealed and the location and intensity of the 
specific antigen-antibody reaction is analysed. 
For the scope of this thesis, WB experiments were performed to determine the expression of 
JPHs within DRG lysates and to analyse the JPH4-KD efficacy as previously mentioned. 
Therefore, DRG neurons from two 7 days old Wistar rats were seeded on 6-well plates. Cells 
were lysed 48 hours post-seeding with lysis buffer (made of HEPES 50 mM, NaCl 150 mM, 
Na3VO4 183.9 mM, NaF 10 mM, Glycerol 10%, NP-40 1% and EDTA 1mM) supplemented 
with protease inhibitor. Lysis was boosted by mechanically damaging the cells’ membrane 
with a sterile pipetting tip. The mixture was centrifuged for 10 minutes at 13 000 rpm, at 4°C. 
To determine the protein concentration, 2µl of the lysate was mixed with 700 µl of diluted 
spectrophotometer dye (Bio-Rad). The absorbance was read at 595 nm using Jenway 6300 
Spectrophotometer and the protein concentration (µg / µl) was calculated using the formula 
C= Absorbance / 0.0562*2. Further on, an SDS lysate was prepared by mixing 1-part SDS 
sample buffer with 3-parts of lysate and boiled at 95°C for 5 minutes. The SDS sample buffer 
is a mixture of 50 µl β-mercaptoethanol (Sigma-Aldrich) and 950 µl 4X Laemmli sample 
buffer (Bio-Rad). Approximately 30 µg of each denatured protein samples and 8 µl protein 
marker (Precision Protein Plus, Bio-Rad) were loaded on Mini Protean gels TG (Bio-Rad). 
Using a Mini-Protean Tetra System connected to a power control (Power Pac HC, Bio-Rad), 
the samples were electrophoresed at 120 V for 1 hour and 15 minutes or until the marker dye 
migrated to the bottom of the gel. This step occurred in a running buffer composed of 25 mM 
Tris-base, 192 mM glycine, 0.1% SDS in purified water). 
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The proteins were then transferred on a methanol-activated PVDF membrane using a wet-
transfer method in transfer buffer (25 mM Tris-base, 192 mM glycine and 20% v/v methanol 
in purified water). Further on, the membrane was blocked in a 5% milk blocking buffer for 1 
hour at room temperature. The membrane was then probed with a diluted primary antibody 
solution (the required amount of antibody in 5% milk buffer) and incubated overnight on a 
shaker at 4°C. The following day, the membrane was washed with washing buffer and 
incubated with a diluted secondary antibody (Table 2.6) in 5% milk buffer for 45 minutes at 
room temperature. The horse radish peroxidase (HRP)-linked anti-rabbit or anti/mouse 
secondary antibody was further visualized on the membrane using an enhanced 
chemiluminescence substrate (Pierce ECL WB Substrate and Super Signal West Femto, 
Thermo-Scientific). The membrane was then exposed to a Kodak film for 10 seconds up to 10 
minutes depending on the assay sensitivity to the targeted proteins. All samples were re-
probed for β-actin as a loading control. To do so, the membranes were stripped with stripping 
buffer (Thermo Scientific) for 20 minutes at room temperature and washed, blocked and re-
probed with rabbit anti-β-actin antibody (Cell Signalling) and further performed the same 
steps as above.  
The exposed films were processed using an Xograph machine, scanned and analysed using 
Image J software. The mean intensity of each band was corrected to background and the band 
intensity of each targeted protein was made relative to the corresponding loading control, β-
actin.  Antibody quality control was done using lysates from tissues known to express the 
protein of interest. In circumstances when it was difficult to interpret the WB results, the 
protocol was optimized to facilitate a better protein separation, increased the duration of 
blocking and or washed thoroughly. When needed, other antibodies against the same proteins 
were used as well as a blocking peptide to confirm the antibody specificity and determine the 
correct band.  
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Table 2.6: Primary and secondary antibodies used for WB and IP 
 
2.10 Co-immunoprecipitation 
Immunoprecipitation (IP) is a widely used technique to detect and purify a specific antigen, 
while the isolation of protein complexes is known as co-immunoprecipitation (Co-IP) 
(Phizicky and Fields, 1995). For Co-IP experiments, DRG lysates were prepared as previously 
described. A pre-cleaning step was done by adding 8 µl of beads (Protein A.G PLUS-Agarose, 
Santa Cruz Biotechnology) to 500 µg lysate and mixing for 30 minutes at 4°C to reduce the 
non-specific binding. The mixture was then centrifuged at 9000 rpm for 5 minutes at 4°C. The 
supernatant was collected and incubated with the appropriate primary antibody for 2 hours at 
Antibody Dilution Supplier 
For Western blot experiments: 
Rabbit anti-JPH1 1:500 Biorbyt 
Rabbit anti-JPH2 1:500 Biorbyt 
Rabbit anti-JPH3 1:500 Biorbyt 
Rabbit anti-JPH4 1:500 Biorbyt 
Rabbit anti-JPH4* 1:1000 Sigma-Aldrich 
*  Blocking peptide 1:1000 Sigma-Aldrich 
Rabbit anti-β-actin 1:1000 Cell Signaling 
HRP-linked anti-rabbit secondary antibody 1:1000 Cell Signaling 
HRP-linked anti-mouse secondary antibody 1:1000 Cell Signaling 
For Immunoprecipitation experiments: 
Mouse anti-STIM1 1:100 Abcam 
Rabbit anti-JPH4 1:500 Biorbyt 
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room temperature. Next day, 20 µl of IP beads were added to the mixture and incubated with 
rotation overnight at 4°C. The beads were then collected by centrifugation at 9000 rpm for 5 
minutes and washed with PBS 3 times. A volume of 60 µl SDS sample buffer was added over 
the beads followed by boiling them for 5 minutes at 95°C. The next step was to proceed with 
the gel loading, electrophoresis and transfer as described in the WB method.   
This technique was used to determine the interaction between STIM1 and JPH4 in DRG 
neurons upon SOCE activation (Chapter 6). For this reason, prior to lysis, the cultured neurons 
were store-depleted with 250 nM BK in Ca2+ free solution. Then, the lysate was 
immunoprecipitated with mouse anti-STIM1 antibody and immunoblotted with rabbit anti-
JPH4 antibody (Table 2.6). The membrane was exposed to a Kodak film as previously 
described, followed by a stripping step and re-probing for STIM1 to confirm the efficacy of 
the immunoprecipitation. 
2.11 Statistical analysis 
Student’s t-test (unpaired) was used to analyse the mean difference between a control and test 
group. One-Way ANOVA was used when comparing more than two groups. Statistical 
significance was established when the p value was ≤ 0.05. All results are provided as mean ± 
SEM. The n number is equal to the number of samples used for each experiment. Except for 
the Figure 4.9, three animals per data set were sacrificed to provide the corresponding n 
number stated in each figure legend (e.g. n= 6 individual samples from 3 different animals).  
For the imaging experiments, one sample is defined as the mean fluorescence intensity for all 
neurons analysed per that sample. 
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Chapter 3. Characterization of CRAC components in DRG 
neurons 
 
3.1 Introduction 
Neurons have the ability to deliver Ca2+ signals tailored at modulating specific neuronal 
functions (Berridge 1998). They use both intra- and extracellular Ca2+ sources to regulate Ca2+ 
dependent processes: i) Ca2+ influx from the extracellular space is controlled by plasma 
membrane Ca2+ channels, such as VGCCs or ROCs, and ii) Ca2+ release from the main 
intracellular Ca2+ source, the ER, is controlled by IP3R and RyR (Berridge 1998). SOCE, as 
previously described in Chapter 1, represents another type of Ca2+ entry. Initially it was shown 
to be activated in response to ER Ca2+ store depletion in non-excitable cells (Parekh and 
Putney 2005). Later, CRAC channels were described as carrying the Ca2+ current responsible 
for refilling the ER Ca2+ pool (Parekh and Putney 2005, Parekh 2010). For a long time SOCE 
was not considered to be a source of Ca2+ entry in neurons, as these are abundantly populated 
with VGCCs and ROCs that give access to the extracellular Ca2+ reservoir (Putney 2003). In 
early 2000’s a study reported that SOCE is present in hippocampal pyramidal neurons and 
that it controls neurotransmitter release and contributes to short- and long-term synaptic 
plasticity (Emptage et al. 2001). Furthermore, impaired SOCE was associated with 
neurodegenerative disorders such as Alzheimer’s or Huntington’s disease (Yoo et al. 2000, 
Wu et al. 2011) and the molecular components of SOCE have been identified to play an 
important role in synaptic transmission and cognition (Berna-Erro et al. 2009, Hartmann et al. 
2014, Klejman et al. 2009). 
Besides playing an important role in the central nervous system, the functionality of SOCE 
was also demonstrated in peripheral neurons. Interestingly, several studies reported that 
peripheral nerve injury disrupts cytosolic Ca2+ homeostasis in sensory neurons and elevated 
Ca2+ levels were linked to diabetic neuropathic pain and chronic inflammatory pain (Fuchs et 
al. 2005, Fuchs et al. 2007, Gemes et al. 2011, Huang et al. 2002). While the role of CRAC 
channels has been investigated mainly in dorsal horn neurons and astrocytes (Xia et al. 2014), 
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several recent studies demonstrated that molecular components of CRAC channels are also 
present in DRG neurons (Gemes et al. 2011, Gao et al. 2016). Moreover, Wei D and colleagues 
reported relative mRNA levels and protein expression of Orai and STIM family members in 
mice DRGs (Wei D et al. 2017). The authors also characterized the functional properties of 
CRAC channels in DRG neurons by performing Ca2+ imaging recordings to test the presence 
of thapsigargin-induced SOCE within neurons of different sensory modalities (Wei D et al. 
2017). Through knock-down experiments, they further highlighted the role of STIM1, STIM2, 
Orai1 and Orai 3 in modulating SOCE in DRGs and noticed that while Orai2 mRNA level is 
the highest among all Orai family members, knocking it down had no effect on SOCE (Wei 
D et al. 2017). Interestingly, both Orai1 and Orai3 are required for thapsigargin-induced 
neuronal excitability in DRG neurons and knocking-down both proteins prevents membrane 
depolarization (Wei D et al. 2017). To determine whether depletion of the ER Ca2+ pool 
triggers puncta formation of STIM isoforms, they transfected DRGs with STIM1- or STIM2-
YFP. Performing live cell confocal imaging, it was shown that in neurons store depleted with 
thapsigargin, both STIM isoforms translocated into puncta, but STIM2 to a lesser extent than 
STIM1 (Wei D et al. 2017). While these recent reports started to address functional role of 
SOCE and molecular composition of CRAC in sensory neurons, the full picture is still far 
from being complete. 
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3.2 Results 
Since several attempts were made to characterize the identity and role of CRAC components 
in peripheral sensory neurons (Wei D et al 2017, Qi et al. 2016, Duncan et al. 2013), this 
chapter is built to add missing pieces to the puzzle.  
Nociceptors are typically categorized based on fiber size and differentiated into groups 
depending on the type of the sensory stimuli they detect and how fast they conduct an action 
potential: i) Aβ large myelinated fibers (neuronal somatic diameter usually larger than 45 µm), 
ii) Aδ medium thinly myelinated fibers (somatic diameter between 25 and 45 µm), and iii) C 
small non-myelinated fibers (somatic diameter of less than 25 µm) (Basbaum et al. 2009).  
Since nociception is associated with Aδ- and C- nerve fibers (conducting fast pain and 
persistent pain, respectively), it seems reasonable to characterize the presence of SOCE 
components in DRG neuronal population, based on the somatic size (Suzuki et al. 2010, Rose 
et al. 2011). For this purpose, I prepared the DRG sections as described in Chapter 2 and used 
immunohistochemistry assay to characterize the distribution of Orai and STIM subunits in 
DRG. DAPI staining (blue) was used to identify nuclei. Tissue slices of 40 µm thickness were 
immunostained with Orai1, Orai2, Orai3, STIM1 and STIM2 antibodies (Table 2.4). To 
further confirm and characterize the putative role of these proteins, I co-stained the samples 
with an antibody against the neurofilamental marker NF200 to identify large myelinated 
neurons. NF200 also reveals positive staining in some, but not all, medium myelinated Aδ 
fibers. Similarly, to verify whether Orai and/or STIM family members are present in pain 
signaling C-fibers, I selected TRPV1 as a marker for heat sensitive small-diameter 
nociceptors.  
To ensure consistency and avoid bias, I considered a threshold above which a neuron is stained 
positively with the required antibody. I measured the mean fluorescence intensity of the whole 
tissue and used a rounded-up value as a threshold for positive staining (e.g. if the mean 
intensity is 17, anything above 20 would qualify as positive). I took this conservative approach 
as this value is already 3 times higher than the background itself (black area including noise). 
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Using this method will mainly highlight the protein distribution in medium and intense stained 
cells. It certainly excludes some of the weak (but still positive) stained cells, but importantly, 
it avoids false positive selection. I have selected the neurons based on their morphological 
properties: big round-shape cells surrounded by long and thin satellite glial cells.  
No primary antibody samples were also prepared as described in Chapter 2. Images were 
presented alongside positive staining. For co-expression experiments, the samples used as no 
primary controls were treated with two complimentary secondary antibodies (e.x. Donkey 
anti-mouse AlexaFluor 555 and Goat anti-guinea pig AlexaFluor 488) 
 
 
3.2.1 Orai and STIM isoforms are present in DRG neurons. 
Immunostaining of DRG sections demonstrated that all STIM and Orai isoforms, except 
Orai2, are expressed in DRG neurons (Figure 3.1). The nuclear staining of Orai2 was noticed 
in all samples, independent of antibody dilution (1:200, 1:500 and 1:1000 dilutions were used 
to test the antibody’s affinity to the PFA fixed samples). Further investigations are needed to 
determine if Orai2 is indeed absent in primary afferent neurons. 
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Figure 3.1. The protein expression of Orai and STIM isoforms within DRG neurons. Confocal 
micrographs for immunostaining with antibodies against Orai1 (B), Orai2 (C), Orai3 (D), STIM1 (E), 
STIM2 (F) and no-primary control (A). DAPI staining (blue) was used to identify nuclei. Scale bars = 
50 µm.  
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3.2.2 Expression of Orai1 and Orai3 in DRG neurons 
 
Immunohistochemistry experiments revealed that Orai1 was expressed in 74 ± 7% of all 
neurons. Also, the average somatic diameter of the Orai1-positive cells was 21.5 ± 0.9 µm, 
very similar to the mean somata size of all DRG neurons analyzed, 21.4 ± 1 µm. There was 
no evident preference of Orai1 expression in neurons of particular size (Figure 3.2). 
As expected, co-staining experiments with neuronal markers NF200 (for medium and large 
myelinated neurons, Figure 3.3) and TRPV1 (for heat-sensitive nociceptors, Figure 3.4) 
demonstrated that Orai1 is uniformly distributed within neurons of different sensory 
modalities.
 
Figure 3.2. The distribution of Orai1 in DRG neurons. A. The somatic diameter of Orai1-positive 
neurons was measured, presented as a frequency distribution (green) and showed alongside the total 
number of neurons (black). Data is shown as the number of neurons of different somatic sizes ± SEM, 
from a total of 1774 neurons analysed (cumulative data from n=10 individual DRG sections).  
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Figure 3.3 The expression of Orai1 in medium and large DRG neurons identified by NF200 
marker. A. No-primary antibody control, blue-stained nuclei with DAPI. B-D Confocal images of 
immunostaining with antibodies against NF200 (B, green), Orai1 (C, red) and Co-staining (D, merged). 
White arrows indicate Orai1 positive neurons, blue arrows indicate NF200 only positive neurons and 
orange arrows indicate neurons expressing both NF200 and Orai1. 
 
 
Figure 3.4 The expression of Orai1 in heat-sensing nociceptors identified by TRPV1 marker. A. 
No-primary antibody control, blue-stained nuclei with DAPI. B-D Confocal images of immunostaining 
with antibodies against TRPV1 (B, green), Orai1 (C, red) and Co-staining (D, merged). White arrows 
indicate Orai1 positive neurons, Orange arrows indicate neurons expressing both TRPV1 and Orai1. 
 
71 
 
 
Orai3 immunostainings demonstrated that this isoform was expressed in 47.6 ± 5.5% of all 
DRG neurons analyzed (Figure 3.5) and the mean somatic diameter of the Orai3-positive 
neurons was 22.67 ± 1.69 µm. Similar to Orai1, Orai3 seemed to be expressed uniformly in 
neurons of all sizes. 
Orai1-Orai3 co-staining experiments strengthen the above observations. Figures 3.6 and 3.7 
show that neither of the isoforms had a preferred distribution pattern and that Orai3 is less 
expressed than Orai1 in DRG neurons. Also, out of the total number of Orai1-positive neurons, 
56.8 ± 13.4 % of cells were positive for Orai3. 
 
Figure 3.5. The distribution of Orai3 in DRG neurons. A. The somatic diameter of Orai3-positive 
neurons was measured, presented as a frequency distribution (green) and showed alongside the total 
number of neurons (black).  Data is shown as the number of neurons of different somatic sizes ± SEM, 
from a total of 594 neurons analysed (cumulative data from n=5 individual DRG sections).  
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Figure 3.6. Co-localization of Orai1 and Orai3 in DRG neurons. Confocal micrographs of 
immunostaining with antibodies against Orai1 (A, red) and Orai3 (B, green) and co-staining (C, 
merged). White arrows indicate Orai1 only positive neurons, blue arrows indicate Orai3 only positive 
neurons and orange arrows indicate neurons that are positive for both Orai1 and Orai3. 
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Figure 3.7. The distribution of Orai1 and Orai3 in DRG neurons. A parallel representation of the 
Orai1 (dark green) and Orai3 (light green) distribution preference within DRG neurons. Data for each 
isoform represents the percentage of positively-stained neurons as showed in Figure 3.2 and Figure 3.5, 
respectively.  
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3.2.3 Expression of STIM1 and STIM2 in DRG neurons 
Immunohistochemistry experiments revealed that STIM1 was expressed in 57.4 ± 9.1% of all 
neurons (505 out of 931 neurons were positive). Furthermore, the mean somatic diameter of 
the STIM1-positive cells was 23.3 ± 1.2 µm, similar to the average somata size of all DRG 
neurons analyzed, 23.9 ± 1.5 µm. STIM1 immunostainings did not reveal a localization 
preference, being expressed uniformly in neurons of all sizes (Figure 3.8). 
Co-staining experiments with neuronal markers NF200 (Figure 3.9) and TRPV1 (Figure 3.10) 
confirmed that STIM1 is expressed in medium and large myelinated neurons, as well as in 
heat-sensitive nociceptors.  
 
 
Figure 3.8. The distribution of STIM1 in DRG neurons. A. The somatic diameter of STIM1-positive 
neurons was measured, presented as a frequency distribution (red) and showed alongside the total 
number of neurons (black). Data is shown as the number of neurons of different somatic sizes ± SEM, 
from a total of 931 neurons analysed (cumulative data from n=5 individual DRG sections).  
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Figure 3.9. Co-localization of STIM1 and NF200 in DRG neurons. A. No-primary antibody control, 
blue stained nuclei with DAPI. B-D. Confocal images of immunostaining with antibodies against 
NF200 (B, green), STIM1 (C, red) and co-staining (D, merged). White arrows indicate STIM1 positive 
neurons, blue arrows indicate NF200 only positive neurons and orange arrows indicate neurons 
expressing both NF200 and STIM1. Scale bars = 50 µm. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. Expression of STIM1 in nociceptors expressing TRPV1. A. No-primary antibody 
control, blue stained nuclei with DAPI. B-D. Confocal images of immunostaining with antibodies 
against TRPV1 (B, green), STIM1 (C, red) and co-staining (D, merged). White arrows indicate STIM1 
positive neurons, blue arrows indicate TRPV1 only positive neurons and orange arrows indicate 
neurons expressing both TRPV1 and STIM1.  
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STIM2 immunostainings demonstrated that 50.5 ± 9.5% of all DRG neurons analyzed 
expressed this protein (266 out of 612 neurons were positive) (Figure 3.11). The mean somatic 
diameter of the STIM2-positive neurons was 25.2 ± 2.6 µm, slightly greater than the overall 
average of 22.8 ± 2 µm. 
STIM1-STIM2 co-staining experiments revealed that 46.7 ± 8.6% of STIM1-positive neurons 
co-expressed STIM2. Furthermore, Figures 3.12 and 3.13 show that while STIM1 has a 
uniform distribution throughout neurons of different sizes, STIM2 seemed to be expressed 
greater in medium and large somata.  
 
 
Figure 3.11. The distribution of STIM2 in DRG neurons. A. The somatic diameter of STIM2-
positive neurons was measured, presented as a frequency distribution (red) and showed alongside the 
total number of neurons (black).  Data is shown as the number of neurons of different somatic sizes ± 
SEM, from a total of 612 neurons analysed (cumulative data from n=5 individual DRG sections).  
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Figure 3.12. Co-localization of STIM1 and STIM2 in DRG neurons. Confocal micrographs of 
immunostaining with antibodies against STIM1 (A, red) and STIM2 (B, green) and co-staining (C, 
merged). White arrows indicate STIM1 only positive neurons, blue arrows indicate STIM2 only 
positive neurons and orange arrows indicate neurons that are positive for both STIM1 and STIM2. 
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Figure 3.13. The distribution of STIM1 and STIM2 in DRG neurons. A parallel representation of 
the STIM1 (dark red) and STIM2 (light red) distribution preference within DRG neurons. Data for each 
isoform represents the percentage of positively-stained neurons as showed in Figure 3.8 and Figure 
3.11, respectively.  
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3.2.4 Orai1 and STIM1 are interacting during SOCE in DRG nociceptors 
The presence of SOCE in DRG neurons was demonstrated in several studies (Duncan et al. 
2013, Szteyn et al. 2015, Qi et al. 2016). Moreover, attempts were made to clarify which of 
the CRAC components are present and involved in SOCE. Similar to non-excitable cells, 
Orai1 and STIM1 were put forward as the main players, while STIM2 and Orai3 were 
suggested to play supporting roles; yet, these hypotheses require further clarification (Wei D 
et al. 2017, Gruszczynska-Biegala and Kuznicki 2013). Interestingly, Wei D and colleagues 
observed that knocking-down either STIM1 or STIM2 in acutely dissociated DRG neurons 
results in similar SOCE impairment, however, the authors did not mention what types of 
neurons (e.g. large/small, myelinated/non-myelinated etc.) were tested. Similarly, 
thapsigargin-induced SOCE was impaired in Orai1 and Orai3 knockdown neurons (Orai1 
siRNA proved the highest reduction) and not changed in Orai2 knockdown culture. 
Importantly, the protein levels of Orai1 and Orai3 in knockdown cultures was reduced only 
by 30% in this study. The same study also revealed that neurons transfected with STIM1-YFP 
showed a better puncta formation during SOCE as compared to STIM2-YFP. These findings 
suggest that between all 5 proteins, STIM1 and Orai1 are the main SOCE drivers in DRG 
neurons (Wei D et al. 2017). 
It is fair to highlight that some of the performed experiments were conducted in transfected 
cells. For this reason, to test whether the endogenous CRAC components, STIM1 and Orai1, 
co-localize into puncta to facilitate binding and CRAC pore opening, I performed proximity 
ligation assay (PLA) targeting endogenously expressed Orai1 and STIM1 proteins in acutely 
dissociated DRG neurons. This technique aims at detecting protein-protein interactions and is 
more sensitive than the traditional immunohistochemistry. The proteins of interest are targeted 
with oligonucleotide-labelled antibodies that are capable of binding when in close proximity 
(at 40 nm apart). When the proteins are found within 40 nm or less from each other, a 
fluorescent signal (puncta, dot) is detected by confocal microscopy. 
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To validate the PLA approach, I performed negative and positive controls using Orai1 as a 
target protein. The negative control test consisted of a PLA experiment with a single primary 
antibody against Orai1 (no paired primary antibody was used). Analysis of the PLA-treated 
probe showed no fluorescent puncta, suggesting that the established protocol does not allow 
secondary PLA probes to co-localize ‘by chance’ (Figure 3.14.A). 
Moreover, I also ran a positive control experiment where two different primary antibodies 
against Orai1 (one raised in mouse, one in rabbit) were used (Table 2.5). The reason for this 
approach is that both PLA probes (anti-mouse plus and anti-rabbit minus) attach to the 
previously bound antibodies against the same Orai1 protein. The results show fluorescent 
signals for Orai1-Orai1 PLA, demonstrating that the assay successfully recognizes the 
proximity of the secondary PLA probes once attached to the same target proteins (Figure 
3.14.B). 
After this validation, I used PLA as a tool to measure the proximity between Orai1 and STIM1 
within DRG nociceptors. DRG neurons were cultured on microscope slides as previously 
described. Before fixing the cells with 4 % PFA, samples were washed with pre-warmed EC 
solution containing 2mM Ca2+ (Table 2.3). One group of samples were kept in this EC 
solution, while the other group were bathed in a Ca2+ free solution (also containing EGTA) to 
wash extracellular Ca2+, followed by 5 minutes treatment with 250 nM BK solution (still in 
Ca2+ free conditions). The EC and BK solutions were removed from the control and SOCE 
induced cells respectively and replaced with 4 % PFA for 20 minutes. The purpose of this 
experiment was to fix the proteins into their specific cellular location during SOCE and 
compare the PLA signals to that of the cells with Ca2+ levels at rest. Therefore, I tested whether 
native STIM1 and Orai1 come in close proximity during SOCE as compared to Control (no 
store-depleted cells).   
For measurements, I counted the number of fluorescent puncta with an intensity higher than 
10 per each neuron. Then I divided this value by the cross-sectional area and reported the 
results as the mean number of puncta per µm² (Figure 3.15.C).  
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Figure 3.14. PLA protocol validation. A. Negative control based on using only one primary antibody 
against Orai1. B. Positive control based on Orai1-Orai1 PLA. Anti-Orai1 mouse and anti-Orai1 rabbit 
antibodies were paired to validate the positive PLA signal (green). Scale = 10 µm for all images. 
 
 
 
 
Figure 3.15. Orai1 and STIM1 are in contact during SOCE in DRG cultured neurons. A. 
Representative image of PLA experiments probing Orai1 and STIM1 proximity in small diameter DRG 
neurons. The Control group comprises of neurons with Ca2+ levels in the resting state. n=27 neurons, 
N=5 individual experiments. B. Representative image of PLA experiments probing Orai1 and STIM1 
proximity during SOCE. This group was treated with 250 nM BK in Ca2+ free solution prior to fixation. 
n=33 neurons, N=6 individual experiments. C. Plot showing the number of fluorescent puncta per µm² 
for Orai1-STIM1 proximity in control versus depleted neurons. Scale = 10 µm, unpaired Student’s t 
test, *p<0.05. 
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3.3 Discussion 
This chapter demonstrates the localization pattern of CRAC components within DRG neurons 
and confirms that endogenously expressed STIM1 and Orai1 isoforms are co-localizing into 
puncta upon ER Ca2+ store depletion. These observations are important in the context of pain 
research as it has been previously shown that upon nerve injury SOCE is increased and 
cytosolic Ca2+ levels are elevated (Duncan et al. 2013, Gao et al. 2015). 
 
3.3.1 STIM1, STIM2, Orai1 and Orai3 are expressed in DRG neurons 
Immunohistochemical characterization of STIM and Orai proteins in DRG sections was 
carried out and further analyzed based on somatic size and co-localization with nociceptive 
neuronal markers.  
Previous attempts were made to examine the CRAC components and SOCE in control and 
injured sensory neurons (Xia et al. 2014, Gao et al. 2015, Wei et al. 2017, Qi et al. 2016). 
While spinal cord dorsal horn neurons and have been the subject for several recent studies 
(Xia et al. 2014, Gao et al. 2015, Gemes et al. 2011), the presence of Orai and STIM isoforms 
within first-order neurons located in DRGs needed further clarification. DRG neurons express 
a variety of receptors and ion channels which modulate the membrane excitability but only 
recently an attempt was made to determine which STIM/Orai proteins are present and 
functional in DRGs (Qi et al. 2016, Wei et al. 2017). Relative mRNA levels and protein 
expression of each isoform has been determined and it was suggested that Orai1 and Orai3 
may form homomultimers and contribute to SOCE in DRG neurons (Wei et al. 2017). 
Moreover, the same study reported that knocking-down both proteins abolishes membrane 
depolarization and thapsigargin-induced spike frequency, suggesting that these proteins are 
required for SOCE-induced neuronal excitability (Wei et al. 2017).  
However, the exact preferred distribution of Orai and STIM family members within DRGs 
remained unelucidated. Therefore, this chapter brought evidence for the neuronal distribution 
of STIM/Orai proteins within DRGs based on different diameter neurons. Interestingly, 
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amongst SOC family (STIM and Orai isoforms), STIM1 and Orai3 seemed to be uniformly 
distributed throughout the DRG (Figures 3.5 and 3.8). Orai1 showed the highest overall 
expression of approximately 74% and it was identified in all large neurons that were analyzed, 
as opposed to Orai3 that showed a lower expression (Figure 3.7). While Wei and colleagues 
demonstrated that Orai1 and Orai3 together are responsible for SOCE in DRG neurons, my 
results revealed that some neurons express Orai3 alone which may lead to differences in SOCE 
activation and ISOC properties (Figure 3.6). Further investigations are needed to confirm the 
homo/heterogeneity of Orai isoforms within sensory neurons and to establish their functional 
role depending on the neuronal subset they populate. 
My attempts to investigate the expression of Orai2 failed to determine its distribution pattern 
in sensory neurons as the confocal images mainly revealed high nuclear staining. Wei and 
colleagues observed a high mRNA level of Orai2 in DRG, but knocking it down had no effect 
on SOCE (Wei et al. 2017). Future work might include testing the specificity of other 
antibodies against Orai2. 
 
3.3.2 STIM2 is highly expressed in large myelinated sensory neurons 
STIM2 distribution analysis demonstrated that while it was expressed only in 50% of all 
neurons analyzed, 34% of the small neurons (diameter <25 µm) revealed positive staining, 
while 80% of larger neurons (>40 µm) expressed this isoform (Figure 3.13). Hence, STIM2 
is preferentially expressed by the myelinated fibers within the DRG. By contrast, STIM1 was 
uniformly distributed in neurons of all sizes suggesting that it might facilitate SOCE in pain 
sensing neurons greater than STIM2, while STIM2 might have a role in touch sensation as it 
was highly expressed in large mechanosensory neurons. 
Other groups observed that STIM1 and STIM2 have a different Ca2+ sensitivity in such a way 
that STIM2 might restore Ca2+ levels only when there is a subtle decrease in the ER Ca2+ 
concentration (Gruszczynska-Biegala and Kuznicki 2013, Brandman et al. 2007). In contrary, 
a significant decrease (e.g. triggered by thapsigargin or a GPCR agonist) stimulates STIM1-
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Orai1 interaction. A reason for this might be that STIM1 clusters approximately 70-times 
faster than STIM2 and is able to saturate Orai1 binding sites before STIM2 does (Stathopulos 
et al. 2009). Similarly, another group reported that STIM2 associates with and promotes 
STIM1 puncta formation in acinar cells and enhances SOCE at low agonist concentrations 
(Ling Ong et al. 2015). Low levels of stimulations seem to be enough for STIM2 to produce 
a physiological response, which complements the fast STIM1 mobilization when ER Ca2+ 
stores are substantially depleted (Ling Ong et al. 2015). 
In conclusion, this ability of STIM2 to enable SOCE is relevant when there is less ER Ca2+ 
store depletion and when STIM1 diffuses freely within the ER membrane (Ling Ong et al. 
2015). These observations alongside my findings, may suggest that STIM2 alone could have 
a functional role in touch sensation through mechanoreceptors and associated with STIM1 in 
pain sensing nociceptors. More investigations are needed to validate this hypothesis in DRG 
neurons, but STIM2 is clearly not a negligible protein. 
 
3.2.4 Endogenous Orai1 and STIM1 are in contact during SOCE in DRG 
nociceptors 
Orai1 and STIM1 remain the most plausible candidates to form the CRAC amongst their 
family members as they were shown to be expressed and function in a wide range of cells, 
including DRG and dorsal horn neurons (Xia et al. 2014, Gao et al. 2015, Qi et al. 2016). 
While a number of studies reported puncta formation and protein mobilization into clusters in 
transfected sensory neurons (Wei et al. 2017, Gao et al. 2016), to my knowledge, no attempts 
to research the interaction between endogenously expressed Orai1 and STIM1 proteins in 
DRG neurons were made. 
Here I aimed at testing whether these proteins come in close apposition upon SOCE activation 
by running a PLA test that specifically two target proteins when these are within <40 nm of 
each other. The purpose of this experiment was to determine whether endogenously expressed 
Orai1 and STIM1 form complexes at the so-called ER-PM junctions of DRG neurons after 
BK-induced SOCE. 
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BK is a pro-inflammatory mediator released by immune cells after a tissue injury. In 
physio/pathological conditions, pro-inflammatory mediators (such as histamine or BK) act on 
the peripheral terminals of nociceptive afferents and either bind and activate specific receptors 
or sensitize them to other chemical or physical stimuli (Das V. 2015). BK has been shown to 
be a pain mediator in different organs and its effect is mediated via its receptors B1R and B2R 
(Steranka et al. 1988, Dray et al.1993). The stimulation of B2R is known to activate the PLC 
pathway which results in the release of IP3 and subsequent SOCE activation (Das V 2015).  
Here I demonstrated (Figure 3.15) that upon ER Ca2+ store depletion with BK in Ca2+ free 
solution, more STIM1-Orai1 PLA puncta is detected per neuron, suggesting that these proteins 
move closer to each other and presumably form contacts in order to trigger Ca2+ influx. This 
experiment is particularly important because it shows that endogenously expressed STIM1 
and Orai1 proteins are found within less than 40nm of each other after SOCE activation with 
BK. 
 
 
Here I characterized the expression of STIM and Orai family members in primary afferent 
neurons. The next chapter aims at investigating the effect of CRAC inhibitors on 
inflammatory-mediated SOCE in DRG neurons. 
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Chapter 4. Pharmacology of CRAC channel inhibitors 
YM58483 and Synta66 
 
4.1 Introduction 
Since their discovery, CRAC channels gained growing interest and became pharmacological 
targets in several therapeutic areas such as immunology, cancer or allergy (McCarl et al. 2009, 
Motiani et al. 2010, Calcimedica Inc, 2017). A general interest in developing CRAC channel 
modulators is confirmed by the high number of patents issued in the past 8 years (Pevarello et 
al.2014). The strong correlation between genetic defects in Orai and/or STIM proteins and 
disorders ranging from immunodeficiency syndromes to Huntington’s disease, triggered large 
investment in both academia and industry, into research in this area. Small biotech companies 
such as Synta Pharmaceuticals and Calcimedica are currently leading the way with several 
CRAC modulators in the pipeline however recently, large companies such as GSK and 
Hoffman-La Roche have also initiated major drug discovery initiatives in this field. 
Due to the complexity of the machinery behind CRAC channels, several tools to assess their 
properties have been made available in the last decade. Experimentally, activating SOCE is 
possible by stimulating ER Ca2+ store depletion with agents such as SERCA pump inhibitors 
(e.g. thapsigargin, cyclopiazonic acid), calcium ionophores (e.g. ionomycin) or by triggering 
GPCR-mediated processes such as the activation of PLC pathway (Bird et al. 2008, Putney 
2010). With growing knowledge regarding the molecular components of CRAC channels, an 
opportunity to investigate ways to inhibit SOCE led to the development of drugs that act either 
by blocking the Orai1 pore, or by interfering with the Orai1-STIM1 coupling machinery 
(Putney 2010, Parekh et al. 2010). 
Historically, lanthanides Gd3+ and La3+ were widely used to block SOCE. Another group of 
blockers is represented by the fairly non-selective compounds 2-APB (Putney 2010) and ML-
9 (a myosin light chain kinase inhibitor). 2-APB was shown to inhibit STIM1 translocation at 
the ER-PM junctions, but also to strongly inhibit ICRAC through Orai1 channels (Peinelt et al. 
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2008). Interestingly, whilst widely being used as an inhibitor at higher concentrations, 2-APB 
also potently activates SOCE at 3-10 µM (DeHaven et al. 2008). 
SOCE is a mediator of lymphocyte function with an important role in promoting inflammatory 
processes (Feske et al. 2012). Several pyrazole derivatives (BTP1, BTP2 and BTP3) have been 
shown to inhibit SOCE and the subsequent T-cell cytokine production (Trevillyan et al. 2001). 
Amongst them, BTP2 (also called YM58483, here referred to as YM) demonstrated the 
highest potency (Trevillyan et al. 2001). This drug has been proven to inhibit ICRAC in T-cells 
with an IC50 of 10nM (Ishikawa et al. 2003, Zitt et al. 2004). YM’s greater potency and channel 
selectivity resulted in a more preferential usage compared to 2-APB amongst research groups. 
For this reason, the current chapter investigated the SOCE inhibitory effect of this compound 
in DRG neurons. 
Interestingly, multiple studies reported distinct protocols designed to assess the efficacy of 
YM. Several groups used YM in an acute manner (e.g. during SOCE) (Ishikawa et al. 2003) 
whereas others have used YM for longer periods of time (Zitt et al. 2004). While it is not clear 
whether the potency of YM is dependent on the duration of treatment, specific application 
timepoint (e.g. before or after SOCE initiation) and/or the type of cells, an attempt to evaluate 
the time-dependence of this drug’s action has been made (Zitt et al. 2004). These authors 
preincubated Jurkat cells with YM for various periods of time and performed patch-clamp 
experiments to monitor ICRAC. They showed that at 200 nM YM needs at least 2 hours to 
develop full ICRAC inhibition, which contradicts the acute effect reported by Ishikawa and 
colleagues (Zitt et al. 2004, Ishikawa et al. 2003). 
The effect of YM on immune cells and cytokine production generated a wider interest to 
investigate whether this compound may have analgesic properties, given that pain is 
frequently associated with immune responses (Gao R et al. 2013, Gao XH et al. 2015, Xia et 
al. 2014). A comprehensive study reported that YM effectively relieves spared nerve injury 
(SNI) pain, formalin-induced nociception as well as pain generated by mechanical, thermal or 
chemical stimuli (Gao R. et al. 2013). Moreover, in a collagen-induced arthritis (CIA) model, 
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YM was able to prevent the onset of inflammation and reduce pain hypersensitivity (Gao XH 
et al. 2015). The ICRAC inhibitory effect of the drug was also tested on acutely dissociated DRG 
and dorsal horn neurons with results suggesting that YM is not only able to reduce the 
production and release of pro-inflammatory mediators, but also inhibits SOCE within pain-
sensing neurons (Gemes et al. 2011, Gao R et al. 2013, Wei et al. 2017). These cumulative 
observations on YM's effects on cytokine production and reducing SOCE in nociceptors 
suggest that this drug might be a plausible candidate for relieving pain in a clinical setting. 
Synta Pharmaceutical have also developed a range of SOCE inhibitors. Synta66 (Synta) has 
drawn a particular attention and has been tested in several studies (Putney 2010, Li et al. 2011). 
Similar to YM, Synta has been shown to down-regulate the production of cytokines and reduce 
thapsigargin-induced ICRAC in Jurkat T cells with an IC50 of ~1 µM (Sabatino et al. 2009). This 
molecule also demonstrated high ICRAC inhibition potency in vascular smooth muscle cells 
(VSMC), with an IC50 of 43 nM (Li et al. 2011). It was also proposed that Synta may have 
high CRAC specificity, proven by the lack of effect on TRPC1/5 channels or ATP receptors, 
which are known to contribute to SOCE in several cell types (Li et al. 2011). Moreover, 
experiments on VSMCs expressing YFP-tagged STIM1 showed that Synta does not affect the 
ER Ca2+ store discharge, the ability of STIM1 to sense Ca2+ depletion or STIM1 clustering 
into puncta (Li et al. 2011). 
The effect of Synta was also tested on thapsigargin-induced SOCE in DRG neurons and 
calcium imaging experiments revealed that acute application of 30 µM of this inhibitor 
reduced Ca2+ influx by approximately 35% (Wei et al. 2017). Interestingly, the same group 
reported that 10 µM YM also inhibits SOCE by ~30% when applied immediately once SOCE 
reached maximal levels (Wei et al. 2017). 
It is important to point out that the effects of YM, Synta and other similar SOCE inhibitors 
were mainly tested using patch-clamp techniques (to measure changes in ICRAC) or calcium 
imaging (to analyse changes of cytosolic Ca2+vonce store-depletion and subsequent SOCE 
occur). Therefore, these studies generally report the effect of CRAC inhibitors observed in the 
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cytoplasm, while lacking information about their effect on the ER Ca2+ levels. Tools to directly 
measure intraorganellar Ca2+ concentration were previously used in research, but to a lesser 
degree (Palmer et al. 2004). Recently, genetically encoded Ca2+ indicators (GECI) and the 
Ca2+-sensitive photoprotein aquaporin were described as tools to target Ca2+ within 
intracellular compartments (Bonora et al. 2013). The latest improved GECI are termed 
calcium-measuring organelle-entrapped protein indicators (CEPIA); they have a high dynamic 
range, better spatiotemporal resolution and are applicable to many cell types including neurons 
(e.g. Purkinje cells) (Suzuki et al. 2014). 
The aims of the experiments reported in this chapter are to investigate the effects of two CRAC 
inhibitors, YM and Synta on the SOCE process and dynamics of ER Ca2+ in sensory neurons. 
Primarily, the protocols were optimised in an established cell line and subsequently the effects 
of the drugs were investigated in cultured DRG neurons. 
 
4.2 Results 
To test the effect of YM and Synta on the ER Ca2+ pool refill, I used R-CEPIA1er or G-
CEPIA1er indicators to run intraorganellar Ca2+ imaging. The delivery of cDNA in CHO cells 
was done according to the manufacturer’s recommendations and the protocol is detailed in 
Chapter 2. Time-dependence of transfection efficiency of R-CEPIA1er plasmid was 
determined by incubating the cells for 24, 48 and 72 hours at 37°C and 5% CO2. Direct 
visualization of the transfected cells revealed that the optimal cell density and transfection 
efficiency (30% fluorescent cells, 60-70% cell confluence) was achieved after 48 hours of 
incubation. 
A pilot experiment was run to determine whether SOCE activation by inhibiting SERCA 
pumps or by stimulating endogenous GPCRs reveal different store depletion/refill patterns. 
CHO cells expressing R-CEPIA1er were treated with 1 µM thapsigargin in Ca2+ free solution 
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to activate SOCE followed by re-introduction of 2 mM Ca2+ into the extracellular solution to 
promote store-operated Ca2+ influx (Figure 4.1). 
CHO cells endogenously express purinergic receptors P2Y which are coupled with Gq/11-
proteins and are activated by ATP (Erb et al 2012). Once stimulated, a PLC-dependent cascade 
generates the formation of IP3 which further triggers the ER Ca
2+ release through IP3R. Thus, 
I also investigated the effect of ATP on the Ca2+ store depletion and refill. For this purpose, I 
stimulated SOCE by treating the cells with 30 µM ATP in Ca2+free solution, followed by the 
re-addition of 2 mM Ca2+ (Figure 4.2). 
The first experimental protocol revealed that thapsigargin depleted the ER stores slowly and 
incompletely, which is in line with what is known about SERCA inhibitors; they act as ER 
Ca2+ uptake blockers and generate a slow passive Ca2+ leakage into the cytosol modulated by 
RyR (Chelu and Wehrens 2007). Once exposed back to Ca2+, only several cells revealed a 
partial store refill, while the others did not indicate any Ca2+ uptake back into the ER. 
Interestingly, depleting the stores by activating endogenous P2Y receptors with ATP 
demonstrated a much stronger and faster (within 30 s) store depletion. Once Ca2+ was re-
introduced into the extracellular solution, it was up-taken rapidly and reached a plateau after 
2 minutes.  
The results of this pilot experiment suggest that stimulating Gq/11-coupled GPCR provides a 
better way of controlling the ER Ca2+ content as compared to thapsigargin. 
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Figure 4.1. Thapsigargin-induced ER Ca2+store depletion in CHO cells expressing R-CEPIA1er. 
Left panel, calcium imaging traces of individual cells (grey) and average (red). Right panel, 
representative image of the ER Ca2+ fluorescence at rest (time = 0s), during store depletion (time = 480 
s) and during Ca2+ exposure to activate SOCE (time = 900 s). 
 
 
 
 
 
Figure 4.2. ATP-induced ER Ca2+store depletion in CHO cells expressing R-CEPIA1er. Left 
panel, calcium imaging traces of individual cells (grey) and average (red). Right panel, representative 
image of the ER Ca2+ fluorescence at rest (time = 0s), during store depletion (time = 300 s) and during 
Ca2+ exposure to activate SOCE (time = 600 s). 
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4.2.1 YM58483 and Synta66 reduce the ER Ca2+ store refill in a time-
dependent manner 
Several studies have highlighted that CRAC inhibitors reveal a more pronounced effect when 
cells are treated for longer (Zitt et al. 2004). According to Zitt and colleagues, 200 nM YM 
demonstrated maximal SOCE inhibition when Jurkat T cells were treated for two hours prior 
to store-depletion. Multiple groups also revealed that CRAC inhibitors have a spontaneous 
effect when applied immediately after SOCE activation (Ishikawa et al. 2003). 
To clarify these scenarios, I further investigated if the inhibitory effect of YM and Synta varies 
depending on the stage of the experiment: i) during SOCE, ii) during ER Ca2+ store depletion, 
or iii) when Ca2+ levels are at rest (pre-treatment for 1 hour prior to store depletion) 
To do so, CHO cells were transfected with R-CEPIA1er as previously described and 1 µM 
YM and 3 µM Synta were used as indicated in Figures 4.4 and 4.6. The pre-incubation 
experiment was performed in EC solution containing either of the drugs. SOCE was induced 
with 30 µM ATP in Ca2+ free solution (treatment for 5 minutes). 
The refill/depletion ratio in these three scenarios was compared with that of the control cells 
(no YM treatment; n=6). The refill/depletion ratio was determined as the maximum 
normalised fluorescence intensity (F/F0) corresponding to the refill stage divided by the 
minimum normalised fluorescence intensity (F/F0) corresponding to the depletion phase 
(Figure 4.3). 
 Figure 4.5. highlights that YM reduced the ER Ca2+ levels by 13.5 % in cells treated during 
SOCE, by 27.8 % in cells treated at store depletion and by 48.6 % in pre-incubated cells (n=6, 
p=0.009 Student’s t test). 
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Figure 4.3. Representative image revealing the calculation for the Refill/Depletion ratio. Baseline 
(B) represents the F/F0 at t=50s (before Ca2+ free solution was applied), Depletion (D) represents the 
minimal F/F0 value during ATP treatment (ER Ca2+ pool depletion) and Refill (R) is the maximal F/F0 
value recorded during the Ca2+ re-addition phase (SOCE). Refill/Depletion ratio= (R-D)/(B-D). This 
calculation was used to represent data in Figures 4.5 (for YM) and 4.7 (for Synta). 
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Figure 4.4. The state-dependence effect of YM on the ER Ca2+ store refill after ATP-induced 
SOCE. CHO cells overexpressing R-CEPIA1er revealed an unaltered ER Ca2+ uptake upon SOCE in 
non-treated group (A). Cells treated with YM revealed a variable ER replenishment depending on the 
time of administration: during SOCE only (B), during ER Ca2+ depletion phase and further on (C) and 
when pre-incubated for 1 hour prior to store depletion and for the duration of the experiment (D). Grey 
lines are individual experiments (n=6 for all data sets), black traces represent the mean for control and 
YM treated groups, respectively. 
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Figure 4.5. YM significantly inhibits the ER Ca2+ store recharge in a time-dependent manner. 
Analysis of experiments shown in Figure 4.4. Data is shown as Refill/Depletion ratio. Black marks are 
individual experiments (n=6 for each group) and green marks are mean values. *, p<0.05, One-Way 
ANOVA. 
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Similarly, 3 µM Synta was used to treat CHO cells expressing R-CEPIA1er in the same three 
different scenarios. Thus, cells were exposed to Synta during SOCE (Figure 4.6. B), when 
store-depletion was stimulated (Figure 4.6. C) and for 1 hour prior to experiment, including 
the duration of the recording (Figure 4.6. D).  
The effect of this drug on the ER Ca2+ refill is summarised in Figure 4.7 where the 
refill/depletion ratio is shown. When cells were treated with Synta during the store refill 
period, ER Ca2+ uptake was reduced by 30.7 % (n=6, p=0.008, Student’s t test), when applied 
during the whole discharge-recharge phase it decreased the store uptake by 45.0 % (n=6, 
p=0.0017, Student’s t test) and when cells were pre-treated with Synta for 1 hour they revealed 
a reduced ER Ca2+uptake by 53.70 % (n=6, p=0.00019, Student’s t test). 
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Figure 4.6. The state-dependence effect of Synta on the ER Ca2+ store refill after ATP-induced 
SOCE. CHO cells overexpressing R-CEPIA1er revealed an unaltered ER Ca2+ uptake upon SOCE in 
non-treated group (A). Cells treated with Synta revealed a slightly variable ER replenishment depending 
on the time of administration: during SOCE only (B), during ER Ca2+ depletion phase and further on 
(C) and when pre-incubated for 1 hour prior to store depletion, including during the duration of the 
experiment (D). Grey lines are individual experiments (n=6 for all data sets), black traces represent the 
mean for control and YM treated groups, respectively. 
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Figure 4.7. Synta significantly inhibits the ER Ca2+ store recharge in a time-dependent manner. 
Analysis of experiments shown in Figure 4.6. Data is shown as Refill/Depletion ratio. Black marks are 
individual experiments (n-6 for each group) and green marks are mean values. ***, p<0.001 One-Way 
ANOVA. 
 
 
 
 
 
 
101 
 
4.2.2 YM58483 and Synta66 reduce the ER Ca2+ store refill in BK treated 
cells.  
One of the pro-inflammatory mediators released after a tissue injury is BK. Not only is BK a 
potent vasodilator able to reduce the peripheral vascular resistance, but it also contributes to 
the release of prostaglandin E2 by binding to B2 receptors (Shin et al. 2002). Pain sensing 
neurons highly express B2R and BK contributes to pain signalling by triggering PLC-
dependent intracellular cascades, followed by the ER Ca2+ store depletion upon IP3R 
stimulation. To investigate whether YM and Synta inhibit SOCE and subsequent ER Ca2+ 
refill in BK- treated DRG neurons, I optimized the experimental protocol based on the results 
presented above. Firstly, I transfected HEK293 cells with G-CEPIA1er and B2R and 
incubated them for 48 hours prior to the experiment day. To maximize the effect of CRAC 
inhibitors observed in ATP experiments, I pre-treated the cells with either 1 µM YM or 3 µM 
Synta for 1 hour. Cells were also continuously exposed to each of the drugs during the 
recording. SOCE was induced with 250 nM BK in Ca2+ free solution, followed by the re-
addition of 2 mM Ca2+ (Figure 4.8. A). 
Both YM and Synta significantly reduced the ER Ca2+ uptake shown as Refil/Depletion ration 
± SEM (Unpaired Student’s t-test, p<0.05, n=6 for all three groups) (Figure 4.8. B).  
Interestingly, this experiment reveals a higher inhibitory potency of both drugs in BK-treated 
G-CEPIA1er-HEK cells over-expressing B2R as compared to ATP-treated CHO cells 
expressing R-CEPIA1er. In the BK scenario, YM and Synta reduced the ER Ca2+ uptake by 
71.5 % and 62.36 %, respectively, which is 22.9 % higher for YM and 8.7 % higher for Synta 
as compared to the ATP experiments. 
In conclusion, differences between the cell type, the Ca2+ indicator and the SOCE activator 
may generate some variability in Ca2+ measurements even in identical experimental designs 
and unchanged drug concentrations.   
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Figure 4.8 YM and Synta significantly inhibit the ER Ca2+ store refill after the BK-induced store 
depletion. A. Calcium imaging traces of HEK293 cells co-transfected with the G-CEPIA1er and B2R 
in control conditions (black), and after the 1 hr pre-treatment with YM (green) or Synta (red); shown 
are mean F/F0± SEM (n=6 for each group). B. ER Ca2+ content upon SOCE shown as a Refill/Depletion 
ratio. Values represent mean ± SEM; *, p ≤ 0.05, One-Way ANOVA. 
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4.2.3 YM58483 and Synta66 alter SOCE in small diameter DRG neurons 
To test whether YM and Synta demonstrate the same inhibitory effect in cultured sensory 
neurons, I transfected acutely dissociated DRGs with G-CEPIA1er or R-CEPIA1er as 
described in Chapter 2. Both genetically encoded Ca2+ indicators were successfully expressed 
in glial cells, but only G-CEPIA1er was present in a very small proportion of neurons. The 
transfection of primary neurons has been proven challenging and for this reason, only a small 
number of individual experiments were successfully completed.  
The highlights of this attempt are that DRG neurons pre-treated with 1 µM YM revealed a 
reduced ER Ca2+ uptake upon BK-induced SOCE (Figure 4.9). YM potently inhibited SOCE 
such that the ER Ca2+ levels after Ca2+ add-back recovered to 37.4 % of the levels seen in the 
Control group (*, p= 0.04, Unpaired Student’s t test, n=3 experiments for each group). 
To further confirm the effect of both CRAC inhibitors in DRG neurons, I measured changes 
in the cytosolic Ca2+ load by the ratiometric dye fura-2. Similar with the previous experiments, 
I induced SOCE with 250 nM BK in Ca2+ free solution for 4 minutes, followed by re-addition 
of 2 mM Ca2+ to the extracellular solution to facilitate ICRAC. Both YM and Synta were applied 
1 hour prior to calcium imaging and this incubation was done simultaneously with the fura-2 
loading. CRAC inhibitors were also applied throughout the recording. Neurons were initially 
selected based on their morphological properties and after running the experimental protocol, 
only those responsive to BK were included in the analysis.  
Intriguingly, neither YM nor Synta altered the Ca2+ release from the ER pool induced by BK 
(Figure 4.10.B), but as expected, both drugs drastically reduced Ca2+ influx in DRG neurons 
(Figure 4.10.C). More precisely, YM inhibited SOCE by 93.0 % while Synta by 85.1 %. 
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Figure 4.9 YM significantly inhibits the ER Ca2+ store refill after the BK-induced store depletion 
in DRG neurons. A. Calcium imaging traces offura2-AM loaded DRG neurons in control conditions 
(black), and after the 1 hr pre-treatment with YM (green) shown are mean F/F0± SEM (n=3 for each 
group). B. ER Ca2+ content upon SOCE shown as a Refill/Depletion ratio. Values represent mean ± 
SEM; *, p<0.05, compared with Control group by unpaired Student’s t-test. 
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Figure 4.10 YM and Synta significantly inhibit SOCE in DRG neurons. A. Calcium imaging traces 
of the BK-induced store depletion and Ca2+ add-back-induced SOCE in DRG neurons of control 
neurons (black) and neurons pre-treated with YM (green) or Synta (red); shown are mean R/R0 ± SEM 
(n=6 for each group). B. The effect of YM and Synta on the BK-dependent Ca2+ release from the ER 
pool. C. The effect of YM and Synta on BK-induced SOCE. Values represent mean ± SEM; ***, 
p≤0.001 One-Way ANOVA. 
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4.2.4 Lack of effect of YM on STIM1-Orai1 dynamics at ER-PM junctions 
An important mechanism behind the activation of SOCE is the coupling between STIM1 and 
Orai1 at ER-PM junctions (Parekh and Putney 2005). This happens once ER Ca2+ levels drop 
enough to trigger STIM1 into extending, clustering and binding to the PM resident Orai1 
(Parekh and Putney 2005, Putney 2010). The presence of both proteins in DRG neurons has 
been detailed in Chapter 3 of this thesis. As demonstrated, YM is a potent SOCE inhibitor that 
prevents ER Ca2+ store recharge in various cells, including DRG neurons. As demonstrated 
above, the maximal SOCE inhibition efficacy of either YM or Synta was achieved only after 
pre-incubation of the cells prior to store depletion, while acute application of either drug 
during SOCE had limited effect. This ‘state-dependence’ of the effect argued against simple 
ion channel pore block as a main mechanism of the CRAC inhibitors. Therefore, I also tested 
whether pre-treatment with YM affects STIM1-Orai1 coupling using the proximity ligation 
assay. 
DRG neurons were cultured on microscope slides as previously described. Before PFA 
fixation, cells were pre-incubated for 1 hour with 1 µM YM, while the control group was kept 
in fresh extracellular solution. Both control and treated cells were subjected to store-depletion 
with 250 nM BK in Ca2+ free solution to stimulate STIM1-Orai1 coupling and subsequent 
SOCE activation. PLA signal was determined with LSM880 Zeiss microscope. The number 
of fluorescent puncta per µm2 in YM treated cells was compared to the control group (Figure 
4.11). The results showed prominent STIM1-Orai1 PLA signal in both groups with no 
significant difference in the number or fluorescent puncta. This result is in good agreement 
with the lack of effect of YM (or Synta) on the BK-induced Ca2+ release from the ER (Figure 
4.10.B) and suggests that YM does not affect the ability of STIM1 to sense the Ca2+ discharge, 
nor its re-arrangement and movement closer to the PM where Orai1 resides. It is therefore 
unlikely that YM impairs SOCE by interfering with CRAC channel forming mechanism. The 
mechanism of the YM (or Synta) action remains to be elucidated; perhaps it interferes with 
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the assembly of the functional CRAC even though STIM1-Orai1 interaction still occurs, 
alternatively, these compounds may block the CRAC channel at a very slow rate. 
 
 
 
Figure 4.11. YM does not affect the Orai1 - STIM1 coupling in DRG neurons.  Representative 
image of Orai1-STIM1 PLA signal in small diameter DRG neurons in control group, (A, store-depleted 
and non-treated with CRAC inhibitor, n=5) and YM-treated group (B, store-depleted and pre-treated 
with YM for 1 hour, n=5). 
 
C 
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4.3 Discussion 
This chapter aimed at investigating the effect of two widely used CRAC inhibitors in DRG 
neurons: YM58483 and Synta66. Firstly, I optimized the drug application protocol to 
determine their effects on ER Ca2+ loading in SOCE-induced scenarios, in CHO cells 
transfected with R-CEPIA1er. Secondly, I investigated the effect of these CRAC inhibitors 
on BK-induced SOCE in DRG neurons and whether YM alters the STIM1-Orai1 interaction 
in nociceptors. 
4.3.1 YM58483 and Synta66 reduces the ER Ca2+ store refill in a ”state”-
dependent manner 
Several groups reported that CRAC inhibitors, including YM, demonstrate a spontaneous 
inhibitory effect on SOCE which was not evident in my experiments (data not shown). For 
this reason, I hypothesized that the efficacy of inhibition may depend on the state of the 
STIM1-Orai1 complex. Hence, I designed an experimental paradigm to test how the effect of 
YM and Synta varies dependent on the time of drug application (Figure 4.4 and 4.6). Zitt and 
colleagues attempted to demonstrate the dose and time-dependence of YM in Jurkat T cells 
and showed that whilst a spontaneous SOCE-inhibitory effect was still observed, the maximal 
inhibition happened after 2 hours of treatment with 200 nM YM. Their results were achieved 
by measuring cytosolic Ca2+ levels, however this current chapter focuses on the effects of both 
YM and Synta on the ER Ca2+ content specifically, given by ER targeted Ca2+ imaging.  When 
cells were only treated during SOCE or during store-depletion, a reduced level of ER Ca2+ 
refill was noticed, but to a lower degree as compared to when the cells were pre-treated for 1 
hour prior to store-depletion (Figures 4.5 and 4.7). This finding suggests that CRAC inhibitors 
might interfere with the STIM/Orai machinery or may simply require a longer duration of 
treatment for a greater effect. A partial effect on the ER Ca2+ refill may still result in 
subsequent SOCE activation, whereas preventing store replenishment completely would 
impair further Ca2+ influx generated by CRAC channels.  
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4.3.2 YM58483 and Synta66 reduce the ER Ca2+ store refill in BK treated 
cells.  
In order to mimic an inflammatory-pain signalling scenario, I used BK as a model for GPCR-
induced SOCE. BK is an endogenously released compound with pro-algesic and pro-
inflammatory properties. Amongst other mediators (ATP, Histamine, Substance P), it is 
synthetized locally, once a tissue is injured. To measure the effect of pro-longed treatment 
with YM and Synta on BK-induced store-depletion, I over-expressed B2R and G-CEPIA1er-
in HEK cells and showed that both drugs significantly prevented the restoration of the ER Ca2+ 
levels. This experiment also confirms the previous results obtained with the ATP-induced 
SOCE scenario and serves as a pilot prior to investigating the effect of CRAC inhibitors in 
pain sensing neurons.  
4.3.3 YM58483 and Synta66 alter SOCE in pain sensing DRG neurons 
Transfecting acutely dissociated DRG neurons with either R-or G-CEPIA1er proved to be 
challenging, therefore a limited number of cells were recorded and only the effect of YM on 
DRG neurons was tested. Despite of these limitations, a significant reduction in the ER Ca2+ 
uptake induced by YM preincubation was observed (Figure 4.9.B). To continue investigating 
the effect of CRAC inhibitors in this paradigm, a new transfection method (or even viral gene 
delivery) should be considered to better deliver the vectors inside the neurons.  
To further strengthen the results observed at the ER Ca2+compartment in DRG neurons, I also 
measured the Ca2+ dynamics at the cytosolic level. Wei and colleagues recently reported that 
10 µM YM and 30 µM Synta inhibit thapsigargin-induced SOCE in DRG neurons (Wei et al. 
2017). Interestingly, both drugs were applied acutely, immediately after maximal SOCE was 
reached. Using this methodology, YM and Synta demonstrated an inhibitory effect of 
approximately 30 % (Wei et al. 2017). The findings detailed in this chapter demonstrate that 
even at 10-times lower concentration (as compared to that used by Wei and colleagues), 1 
hour pre-incubation with 1 µM YM and 3 µM Synta revealed SOCE inhibition by 93.04 % 
and 85.14 %, respectively (Figure 4.10.C). Moreover, neither YM nor Synta affected the Ca2+ 
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release from the stores during BK application (Figure 4.10.B), suggesting that these drugs 
interfere only with mechanisms underlying SOCE (either by blocking the channel’s pore at a 
slower rate, or by affecting the CRAC channel formation). 
4.3.4 Lack of effect of YM on STIM1-Orai1 movement at ER-PM junctions 
A widely accepted mechanism for SOCE activation is through STIM1 sensing the ER Ca2+ 
store discharge, its extension and clustering at ER-PM junctions. This is followed by its 
binding to PM resident Orai1 protein and forming the CRAC channels that open and allow 
Ca2+ influx (Putney 2010, Luik et al. 2006). This is a reversible process, as when the ER Ca2+ 
pool recharges, STIM1 and Orai1 unbind and return to their resting states diffusing freely in 
the ER and plasma membrane, respectively (Luik et al. 2006, Park et al. 2009). Since SOCE 
inhibition by either YM or Synta observed in the present study was most efficacious in a 
scenario when cells were preincubated with the drugs prior to store depletion and SOCE 
activation, it is logical to hypothesise that the mechanism of the drug action in this case could 
be the interference with the CRAC channel assembly.  
To test whether YM may interfere with STIM1-Orai1 coupling, I investigated if pre-treatment 
of small-diameter DRG neurons for 1 hour with YM reduces formation of STIM1-Orai1 
complexes (as detected with the PLA assay). For this experiment, all cells were store-depleted 
and SOCE-induced with BK, for consistency with calcium imaging experiments. 
Interestingly, YM did not demonstrate an inhibitory effect on Orai1-STIM1 puncta formation 
(Figure 4.11). This suggests that the drug may not affect the ability of STIM1 to sense store 
depletion (the latter process is actually not affected by either of the drugs), nor its movement 
closer to PM to recruit Orai1 proteins. These results are consistent with a recent study 
investigating the effects of Synta on STIM1 clustering in vascular smooth muscle cells (Li et 
al. 2011). The authors reported that Synta may not act by affecting store depletion, its sensing 
by STIM1 nor inhibiting the re-arrangement and subsequent movement of STIM1 at the ER-
PM junctions (Li et al. 2011) Having said that, the resistance of STIM1-Orai1 machinery to 
YM and Synta (as assessed with PLA in this study and with fluorescence microscopy by Li 
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and colleagues) does not rule out a possibility that the drugs may interfere in some way with 
the physical coupling between the proteins and formation of functional ion channel pore. From 
a pharmacological perspective, CRAC channels inhibitors such as YM and Synta reveal a high 
therapeutic potential in chronic and inflammatory pain conditions. They have the ability to 
impair cytokine release at tissue injury (Gao R. et al. 2013), to inhibit SOCE and subsequent 
ER Ca2+ refill as demonstrated in the current study and further preventing and reducing 
different types of pain as seen in animal models (Gao XH et al. 2015, Rigaud et al. 2009, Gao 
R. et al. 2013).  
 
The previous sections revealed the identity of CRAC components and confirmed the presence 
of BK-mediated SOCE in pain sensing neurons. CRAC channels are formed at the ER-PM 
junctions, thus the following chapter aims at identifying and characterizing the junctional 
proteins that might facilitate the channel assembly and subsequent SOCE activation in primary 
afferent neurons. 
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Chapter 5. Characterization of Junctophilin proteins in 
DRG neurons 
 
5.1 Introduction 
Junctional membrane complexes (JMCs) between the PM and the ER are common structures 
of all excitable cells (Landstorm et al 2014).  Their main role is to promote the communication 
between ion channels residing in these membranes (Takeshima et al. 2000, Kakizawa et al. 
2008). They are highly important in facilitating SOCE as STIM1 translocation and its 
interaction with Orai1 happens at the already formed ER-PM junctions (Fahrner et al. 2013).  
The junctophilin (JPH) family of proteins was discovered almost two decades ago and since 
then, their critical role in coordinating JMCs was intensely studied (Landstorm et al. 2014).  
Four JPH family members have been identified to date and their expression profiles were 
found to be tissue-specific (Landstorm et al. 2014).  
JPH1 is highly expressed in skeletal muscle and to a lower degree in cardiomyocytes (Murphy 
et al. 2013). Despite of being itself a structural support to the JMCs, JPH1 also interacts 
directly with caveolin-3 (Cav3), which is an important structural component of the muscle 
cells that forms invaginations of the sarcolemmal membrane (Gazzero et al. 2010). At the ER, 
JPH1 interacts with RyR1 which modulates the Ca2+ release from the sarcoplasmic reticulum 
(SR), while at the PM it interacts with the L-type calcium channels (LTCC) (Landstorm et al. 
2014). Lack of JPH1 has been associated with the development of muscular dystrophy, 
including respiratory failure leading to early death in mice (Ito et al. 2001).  
JPH2 is highly expressed in cardiac muscle cells, also binding Cav3 and co-localizing with 
LTCC and RyR2 in rat cardiomyocytes (Minamisawa et al. 2004). It plays an important role 
in maintaining the dyadic ultrastructure of cardiac muscle cells and a reduced expression of 
JPH2 has been linked to hypertrophic cardiomyopathy and arrhythmia in mice models as well 
as in humans (Landstorm et al. 2011). 
JPH3 and JPH4 are present in neurons of the brain (Landstorm et al. 2014). They are involved 
in Ca2+ homeostasis and facilitate   the crosstalk between N-methyl D-aspartate (NMDA) and 
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RyR in hippocampal neurons and Purkinje cells (Moriguchi et al. 2006). Furthermore, the 
impaired Ca2+ dynamics in JPH3/4 knock-out mice was linked to memory loss, a reduced 
exploratory activity and irregular limb reflexes (Moriguchi et al. 2006). In humans, a strong 
correlation between JPH3 and Huntington-disease like syndrome (HDLS) has been described 
(Landstorm et al. 2014, Holmes et al. 2001). A recent study in Venezuela reported that 25% 
of the subjects with HDLS had JPH3 mutations (Paradisi et al. 2013). While the cohort of this 
study was small (16 patients in total), larger studies would be beneficial to clarify the link 
between JPH3 and HDLS.  
Allen Spinal Cord Atlas, a comprehensive map of gene expression through the mouse spinal 
cord, revealed that JPH3 and JPH4 might be present within young mouse spinal cord and 
DRGs (http://mousespinal.brain-map.org/). To my knowledge, no other attempt to investigate 
the JPHs’ expression and functional role within sensory neurons has been done, thus this 
chapter aims at verifying and further on characterizing the presence of JPH family members 
in DRG neurons. 
 
5.2 Results 
Since literature holds no evidence of JPH proteins being expressed in DRG neurons, I 
attempted to investigate the protein levels of JPHs using Western blot (WB) and 
immunohistochemistry (IHC) assays.  
Acutely dissociated DRG neurons were lysed and further prepared as described in Chapter 2. 
As a positive control for the WB experiments, I simultaneously prepared other tissue lysates 
as follows: a skeletal muscle sample as a positive control for JPH1, a cardiac muscle sample 
for JPH2 and a cerebellum sample for JPH3 and JPH4.  
For the IHC experiments, DRGs were collected, fixed and sliced as previously described. 
Antibodies against JPH1, 2, 3 and 4 (Table 2.4) were used to stain DRG slices at different 
dilutions (1:200, 1:500 and 1:1000) to optimize the IHC protocol. A dilution of 1:200 for each 
anti-JPH antibody was found to be optimal and consistent with the manufacturer 
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recommendations. The overall approach was similar to the previous chapter where I 
characterized the expression of CRAC components within DRGs. Here, I counted the number 
of positively stained neurons (for anti-JPH1, 3 and 4 antibodies) and presented my findings as 
the percentage of neurons expressing each specific JPHs out of the total neuronal population, 
based on the somatic diameter. I also co-stained with neuronal markers NF200 and TRPV1 to 
identify medium/large myelinated neurons, as well as heat-sensitive small-diameter 
nociceptors.  
 
5.2.1 JPH1, JPH3 and JPH4 are expressed in DRG neurons 
To determine whether junctophilin proteins might be expressed in DRGs, I first performed a 
Western blot analysis and found that all JPH proteins were detected in their specific control 
tissues (Figure 5.1) and bands were of the predicted molecular weight (with the exception of 
that for JPH4, see below).  JPH1, 3 and 4 were detected in DRG while JPH2 was not present 
(Figure 5.1.B). Interestingly, JPH4 antibody revealed a double band in the DRG, one of which 
was of the predicted molecular weight (66 kDa), yet, only a lighter band was detected in the 
brain sample. (Figure 5.1.D). These results suggest the presence of an alternatively spliced 
gene product or a post-transcriptional modification of the JPH4 in the brain. The experiments 
were repeated as follows: preparations from 3 animals were used with 6 different lysates per 
tissue sample; all the repeats returned similar results. Moreover, using a different antibody 
against JPH4 (Sigma, Table 2.6) revealed the same differences between brain and DRG lysates 
and all bands were eliminated by using a blocking peptide (Table 2.6). Further confirmation 
of the JPH4 antibody specificity was obtained using the siRNA knock-down approach (see 
next chapter). 
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Figure 5.1. The protein expression of JPH isoforms within DRG neurons. Left panel - 
Representative confocal images of immunostaining with antibodies against JPH1 (A), JPH2 (B), JPH3 
(C) and JPH4 (D). Right panel- Western blot analyses of the JPH family members in DRG and positive 
control tissue lysates (Skeletal muscle, SM, for JPH1, Heart for JPH2 and Brain for JPH3 and 4). These 
are representative results of n=6 individual experiments. Red is JPH labelling and Blue is nuclei 
labelling with DAPI. 
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5.2.3 Expression of JPH1 in DRG neurons 
Immunostaining of DRG sections demonstrated that JPH1 is expressed in 50.5 ± 3.1 % of all 
neurons and the average somatic diameter of the positively-stained cells was 22.5 ± 1.2 µm. 
This was similar to the mean size of all measured DRG neurons, 21.8 ± 0.7 µm; there was no 
apparent preference in JPH1 expression in neurons of particular size (Figure 5.2.). A 
representative image of the localization of JPH1 within PFA-fixed DRG sections is also shown 
in Figure 5.1.A. Furthermore, co-staining experiments demonstrated that JPH1 co-localizes 
with NF200 in 68.9 ± 9.1 % of the medium and large myelinated neurons (n=3, Figure 5.3 is 
a representative example) and is expressed within 70.2 ± 10.2 % of the TRPV1-postive 
nociceptors (n=3, Figure 5.4 is a representative example). Taken together, these observations 
suggest that JPH1 is expressed in neurons of different sensory modalities, including heat-
sensitive nociceptors.  
 
Figure 5.2 The distribution of JPH1 in DRG neurons. The somatic diameter of JPH1-positive 
neurons was measured, presented as a frequency distribution (green) and showed alongside the total 
number of neurons (black). Data is shown as the number of neurons of different somatic sizes ± SEM, 
from a total of 882 neurons analysed (cumulative data from n=6 individual DRG sections). 
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Figure 5.3 The expression of JPH1 in medium and large DRG neurons identified by NF200 
marker. A. No-primary antibody control, blue-stained nuclei with DAPI. B-D Confocal images of 
immunostaining with antibodies against NF200 (B, green), JPH1 (C, red) and Co-staining (D, merged). 
 
 
 
Figure 5.4 The expression of JPH1 in heat-sensing nociceptors identified by TRPV1 marker. A. 
No-primary antibody control, blue-stained nuclei with DAPI. B-D Confocal images of immunostaining 
with antibodies against TRPV1 (B, green), JPH1 (C, red) and Co-staining (D, merged). 
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5.2.4 Expression of JPH3 in DRG neurons 
Immunohistochemistry experiments revealed that 38.37 ± 4.83 % of DRG neurons express 
JPH3 protein, thus this isoform seems to be less abundant in this tissue as compared to JPH1. 
The mean size of JPH3-positive neurons was 20.8 ± 0.6 µm, similar to the overall mean 
somatic diameter in these samples: 20.5 ± 0.4 µm. The somatic size comparison revealed that 
JPH3 is similarly expressed in neurons of various sensory modalities (Figure 5.5). Moreover, 
co-staining experiments with neuronal markers demonstrated that JPH3 is expressed within 
55.8 ± 10.1 % of NF200-positive neurons and within 55.1 ± 19 % of heat-sensitive nociceptors  
 
Figure 5.5 The IHC distribution of JPH3 in DRG neurons. The somatic diameter of JPH3-positive 
neurons was measured, presented as a frequency distribution (green) and showed alongside the total 
number of neurons analysed (black). Data is shown as the number of neurons of different somatic sizes 
± SEM, from a total number of 882 neurons (cumulative data from n=6 individual DRG sections). 
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Figure 5.6 The expression of JPH3 in medium/large DRG neurons identified by NF200 marker. 
A. No-primary antibody control, blue-stained nuclei with DAPI. B-D Confocal images of 
immunostaining with antibodies against NF200 (B, green), JPH3 (C, red) and Co-staining (D, merged). 
 
 
Figure 5.7 The expression of JPH3 in heat-sensing nociceptors identified by TRPV1 marker. A. 
No-primary antibody control, blue-stained nuclei with DAPI. B-D Confocal images of immunostaining 
with antibodies against TRPV1 (B, green), JPH3 (C, red) and Co-staining (D, merged). 
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5.2.5 Expression of JPH4 in DRG neurons 
Interestingly, JPH4 immunostainings showed that this protein is expressed in 71.5 ± 6% of 
DRG neurons with a uniform distribution amongst somas of all sizes (Figure 5.8), making 
JPH4 the most abundantly expressed JPH isoform in DRG. NF200 and TRPV1 co-localization 
experiments demonstrated that JPH4 is highly co-expressed with these neuronal markers, 
therefore it is present in 75.1 ± 10 % of the medium and large myelinated Aδ fibers (n=3, 
Figure 5.9 is a representative example) as well as in 84 ± 6.3 % of the heat-sensitive C-fibers 
(n=3, Figure 5.10 is a representative example). Similar to the other isoforms, the average 
somatic diameter of JPH4, 22.2 ± 0.8 µm, did not differ to that of the overall neuronal 
population (21.88 ± 0.7 µm), further confirming that JPH4 does not reveal a preferred 
distribution pattern. 
 
  
Figure 5.8 The IHC distribution of JPH4 in DRG neurons. The somatic diameter of JPH4-positive 
neurons was measured, presented as a frequency distribution (green) and showed alongside the total 
number of neurons (black). Data is shown as the number of neurons of different somatic sizes ± SEM, 
from a total number of 882 neurons (cumulative data from n=6 individual DRG sections). 
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Figure 5.9 Expression of JPH4 in medium/large DRG neurons identified by NF200 marker. A. 
No-primary antibody control, blue-stained nuclei with DAPI. B-D Confocal images of immunostaining 
with antibodies against NF200 (B, green), JPH4 (C, red) and Co-staining (D, merged). 
 
 
Figure 5.10 Expression of JPH4 in heat-sensing nociceptors identified by TRPV1 marker. A. No-
primary antibody control, blue-stained nuclei with DAPI. B-D Confocal images of immunostaining 
with antibodies against TRPV1 (B, green), JPH4 (C, red) and Co-staining (D, merged). 
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5.3 Discussion 
JPH proteins have been previously shown to have an important role in supporting SOCE in 
excitable cells (Takeshima et al. 2000, Landstorm et al. 2014). Since the presence of JPH3 and 
4 within the brain has been confirmed (Nishi et al. 2003) and their mutations were correlated 
with impaired Ca2+ influx leading to neurodegenerative disorders (Seixas et al. 2012), I aimed 
at investigating whether JPHs are also expressed in primary sensory neurons. The presence of 
JPHs at ER-PM junctions of nociceptors may offer a supportive role for activating and/or 
maintaining SOCE in the context of pain signaling. Thus, this chapter also investigated the 
localization patterns of JPHs within DRG neurons of different sensory modalities. 
 
5.3.1 JPH proteins are present in first order sensory neurons 
Western blot analysis was carried out to determine the protein expression of JPH family 
members within DRG cultured neurons. The relative expression of these isoforms is shown in 
Figure 5.1 and the results suggest that JPH4 might be expressed at the highest level, followed 
by JPH1, JPH3 and JPH2 (the last isoform did not reveal any evident band as compared to its 
positive controls). To further investigate the protein levels and the preferred distribution of 
JPHs, IHC assay was performed. This experiment revealed that JPH4 isoform is expressed in 
a higher number of neurons (71%) as compared to JPH1 (50%) and JPH3 (38%) (p<0.0001, 
2 test). No positive staining for JPH2 has been determined, suggesting that this protein might 
not be present in DRGs. These findings are consistent with the mRNA levels reported in the 
Allen Spinal Cord Atlas (http://mousespinal.brain-map.org/). However, the expression of 
JPH1 was thought to be specific for muscle cells (skeletal and to a lesser degree, cardiac) 
(Landstorm et al. 2014). Surprisingly, the experiments reported in this chapter revealed some 
expression of JPH1 in DRG by Western blot and Immunohistochemistry approaches. This 
finding should be further investigated to confirm its presence and most importantly its role 
within DRG neurons.  
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5.3.2 JPH1, 3 and 4 are uniformly distributed within neurons of different 
sensory modalities 
A previous attempt to determine the expression of JPH3 and 4 within the brain was made 
(Nishi et al. 2003) but less is known about the presence of junctional proteins within DRG 
neurons. Thus, once the expression of JPHs within primary sensory neurons was confirmed, I 
aimed at determining their localization pattern in this tissue. Interestingly, JPH1, 3 and 4 
revealed a uniform distribution within nociceptors of different sizes (Figures 5.2, 5.5, 5.8). 
This observation suggests that JPHs might facilitate Ca2+ dynamics independent of the 
stimulus type (from light touch to noxious stimuli). In addition, the mean somatic diameter 
for JPH1 (21.8 µm), JPH3 (20.8 µm) and JPH4 (22.2µm) did not differ from the mean overall 
neuronal size, further confirming an invariable distribution within DRG neurons.  
 
5.3.3 JPH1, 3 and 4 are expressed in heat-sensitive nociceptors 
As mentioned in previous chapters, SOCE is present in DRG neurons and the overexpression 
of CRAC components might be correlated to different types of pain (Wei et al. 2017). Orai 
and STIM proteins are localized uniformly within neurons of different sizes, except STIM2 
who demonstrated a preference towards the medium-large somata. To determine whether 
junctophilin proteins might facilitate SOCE in Aδ and C-fibers, I co-stained with neuronal 
markers NF200 and TRPV1. The results revealed that JPH4 and JPH1 have a strong co-
localization pattern with both markers, while JPH3 demonstrated a lower co-expression. 
However, these observations are based on a dataset comprising of 3 individual experiments 
per IHC pair and more images are required to clarify the co-expression of JPHs with specific 
neuronal markers in peripheral sensory neurons This finding suggests that JPH4, JPH1 and, 
to a lower degree, JPH3 might be involved in facilitating STIM-Orai coupling at ER-PM 
junctions in DRG neurons. The overall conclusion of the experiments reported above is that 
in TRPV1-positive nociceptors, which are believed to be the main type of DRG neurons 
mediating inflammatory pain responses, the major JPH isoform is JPH4. While the expression 
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of JPH1 and JPH3 should not be neglected, the following chapter will attempt to investigate 
the functional role of JPH4 in relation to inflammatory pain.  
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Chapter 6. The role of Junctophilin 4 in primary sensory 
neurons  
6.1 Introduction 
SOCE was initially reported as the main source for Ca2+ entry in non-excitable cells (Parekh 
AB and Putney JW, 2005) and since then, the role of Orai/STIM proteins in inflammation and 
inflammatory pain has been intensely studied (Yamashita et al. 2007, Feske et al 2006, 2009, 
Xia et al. 2014, Gemes et al 2011). Thus, disrupting SOCE in T-cells was shown to affect the 
release of pain-generating cytokines (Gao X et al. 2016).  However, it was soon discovered 
that the role of SOCE in inflammatory pain is not only limited to non-excitable cells. For 
instance, it was shown that silencing CRAC components or inhibiting CRAC channels in DRG 
and dorsal horn neurons directly affects the excitability of nociceptors (Gao X et al. 2016, 
Gemes et al 2011). These two somehow synergic mechanisms culminate with an overall 
reduced painful sensation. The role of junctional proteins that facilitate the communication 
between STIM and Orai in neurons was less studied. While the presence of JPH3 and JPH4 
in brain tissue was described (Nishi et al 2003, Moriguchi et al. 2006), no further evidence of 
their expression in sensory neurons was reported.  
The previous chapter demonstrated that amongst the Junctophilin family members, JPH1, 3 
and 4 are expressed in primary-afferent neurons and JPH4 is expressed to a higher degree in 
nociceptors. Interestingly, the role of JPH4 in facilitating SOCE in T-cells was recently 
reported (Woo et al. 2016). Firstly, the authors demonstrated that JPH4 is located within the 
ER-PM junctions of T-cells and, secondly, it interacts with STIM1. To investigate the 
interaction, JPH4 and STIM1 were overexpressed in T cells and Co-Immunoprecipitation, 
Total Internal Reflection Fluorescence (TIRF) as well as Ca2+ imaging experiments were 
performed (Woo et al. 2016). The results highlight that JPH4 might modulate SOCE by 
forming protein complex with junctate. Both JPH4 and junctate have the ability to interact 
with STIM1 (junctate by its ER-luminal terminus and JPH4 by its cytoplasmic region) (Woo 
et al. 2016, Treves et al. 2004). Interestingly, high expression of JPH4 promoted STIM1 
clustering even when Ca2+ levels were at rest, but without affecting these levels. In addition, 
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STIM2 may also interact with JPH4 for maintaining the basal ER Ca2+ levels. Further studies 
are required to determine the exact role of STIM2 and whether it is also recruited by 
JPH4/junctate complex at ER-PM junctions. Woo and colleagues provided supporting 
information about the role of JPH4 in recruiting STIM1 and promoting SOCE in T cells. 
Previous chapters of this thesis demonstrated that Orai1, STIM1 and JPH4 are highly 
expressed in DRG neurons, including pain-sensing nociceptors. Therefore, this chapter aims 
at investigating the role of JPH4 in primary afferent neurons, its interaction with STIM1 and 
its function as a SOCE facilitator in relation to inflammatory pain. 
 
6.2 Results 
Previous chapter have brought evidence of the expression of JPH4 in DRG neurons. As Orai1 
and STIM1, the main CRAC components in primary sensory neurons, are expressed in a 
similar pattern to that of JPH4, I hypothesized that JPH4 co-localizes with either of these 
proteins in DRG neurons and that it might facilitate SOCE by promoting STIM1 to ER-PM 
junctions.  
6.2.1 JPH4 co-localizes with Orai1 and STIM1 in DRG neurons 
To test this, DRG sections were prepared and immunostained with antibodies against JPH4 
and Orai1 or STIM1. Figures 6.1.A and 6.2.A show that neurons positive for JPH4 are also 
positive for Orai1 or STIM1. Interestingly, JPH4 reveals a filament-like intracellular structure 
with a preferred distribution towards the PM rather than being randomly diffused in the 
cytoplasm (Figure 6.1.C). JPH4 and Orai1 are co-expressed in cultured DRG neurons and, 
interestingly, reveal a relatively similar intracellular distribution pattern as shown in Figure 
6.1.B. JPH4 and STIM1 are also co-expressed in cultured neurons. Interestingly. while STIM1 
prefers a diffused intracellular location (being an ER membrane resident), JPH4 was largely 
visible at the PM and to a lesser extent in the deeper cellular volume (Figure 6.2.B). These 
observations suggest that JPH4 might be present at the ER-PM junctions of DRG neurons, 
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while STIM1 and Orai1 are more likely to be uniformly distributed throughout the ER and 
PM, respectively. 
 
 
Figure 6.1. JPH4 is co-expressed with Orai1 in DRG neurons. A. Immunohistochemical 
identification of Orai1 (green) and JPH4 (red) in PFA-fixed DRG sections. B. Immunocytochemical 
identification of Orai1 and JPH4 in small cultured DRG neuron (left panel) and the fluorescence 
intensity line scan to illustrate the localization for each protein (right panel). C. Airyscan image (Z-
stack of 1 µm optical sections) of a cultured DRG neuron revealing a specific cisternae-like localization 
of JPH4 (red) near the plasma membrane. C-right panel is a 3D representation of the same neuron. 
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Figure 6.2. JPH4 is co-expressed with STIM1 in DRG neurons. A. Immunohistochemical 
identification of STIM1 (green) and JPH4 (red) in PFA fixed DRG sections. B. Immunocytochemical 
identification of STIM1 and JPH4 in small cultured DRG neuron (left panel) and the fluorescence 
intensity line scan to illustrate the localization for each protein (right panel).  
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6.2.2 JPH4 interacts with STIM1 to promote SOCE 
To further investigate the role of JPH4 in sensory neurons, I performed a co-
immunoprecipitation (Co-IP) experiment to determine if JPH4 and STIM1 physically interact 
during SOCE. Acutely dissociated DRG neurons were treated with extracellular buffer (the 
control group) and with BK in Ca2+ free solution (the SOCE stimulated group). Cells were 
then prepared for Co-IP as described in Chapter 2.  
Immunoprecipitates from DRG neurons endogenously expressing JPH4 and STIM1 revealed 
a weak interaction between the two proteins when Ca2+ levels were at rest. This could be 
caused by protein interactions during cell lysis, but further investigations are needed to 
confirm. A thicker and darker band for STIM1 was detected once SOCE was activated, 
suggesting a substantial increase in JPH4-STIM1 interaction upon ER Ca2+ store depletion 
(Figure 6.3.A). 
To confirm this interaction, I also investigated if the fluorescent PLA signal between JPH4 
and STIM1 is enhanced upon SOCE activation. The experimental protocol was similar to the 
one described in Chapter 3, where I demonstrated that Orai1 and STIM1 cluster and 
presumably form contacts after BK-induced SOCE in DRG nociceptors. The results 
demonstrate that PLA signal between STIM1 and JPH4 is significantly enhanced by the SOCE 
activation (Figure 6.3 B and C). This suggests that while some JPH4 and STIM1 molecules 
are already in close proximity at rest, the amount of interacting molecules is greatly increased 
after BK-induced ER Ca2+ store depletion, further suggesting that JPH4 might facilitate SOCE 
by recruiting STIM1 at the ER-PM junctions.  
Interestingly, PLA experiments aiming at the interaction between JPH4 and Orai1 also 
demonstrated that upon BK-induced SOCE, the two proteins revealed a higher number of 
fluorescent puncta (Figure 6.4).  
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Immunoprecipitation experiments for detecting a direct interaction between JPH4 and Orai1 
were not performed. An optimized protocol should be used to accommodate the overlapping 
molecular weight of Orai1 (a 33 kDa protein) to the heavy chain fragment (dark thick bands 
seen at 50 kDa in Figure 6.3.A) in the IP experiment.  
Figure 6.3. JPH4 interacts with STIM1 in DRG neurons. A. JPH4 co-immunoprecipitates with 
STIM1. Immunoprecipitation was performed with the anti-STIM1 antibody from DRG neurons and 
immunoblotted for the detection of JPH4 (the band within the green box) and STIM1 (the band within 
the red box). Cells were left untreated (Control) or treated with BK in Ca2+ free solution to induce store-
depletion before lysis. B, C. Fluorescent PLA signals between STIM1 and JPH4 in cultured DRG 
neurons: representative example (B), number of fluorescent puncta per 100 µm² (C), Data shown as 
mean ± SEM, p<0.001, Student’s t-test. 
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Figure 6.4. Orai1 moves closer to JPH4 upon BK-induced SOCE in DRG neurons. Fluorescent 
PLA signals between Orai1 and JPH4 in cultured DRG neurons, before and after store depletion with 
BK. A, representative example; B, number of fluorescent puncta per 100 µm². Data shown as mean ± 
SEM, p<0.001, Student’s t-test. 
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6.2.3 Silencing JPH4 in DRG neurons disrupts Orai1-STIM1 interaction 
Previous experiments suggested that STIM1 might interact with JPH4 after Ca2+ store 
depletion, prior to Orai1 binding. Thus, I investigated if silencing JPH4 in DRG neurons 
disrupts the Orai1-STIM1 machinery. For this purpose, I optimized an experimental protocol 
to silence JPH4 in cultured DRG neurons. I transfected cultured cells with Lipofectamine 
RNAiMAX and Silencer Select (Ambion) siRNA oligonucleotides against JPH4 (see Table 
2.1) under the manufacturer’s recommendations. I also used a scrambled oligomer as a 
negative control. Two different siRNA products targeting JPH4 were used at various 
concentrations in both single use and combination to optimize the protocol. I also tested 
different exposure times to the transfection mixture and determined the silencing effect by 
both IHC and WB. Silencer Select s175511 (here called siRNA2) demonstrated the highest 
efficacy of reducing JPH4 protein expression in DRG neurons 48 hours post transfection and 
at the highest recommended dose. Figure 6.5 shows a reduction in JPH4 expression by 
approximately 60% in WB analysis and by 40% in IHC assay. 
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Figure 6.5. Silencing JPH4 in DRG neurons. A. Western blot analysis demonstrating that siRNA2 
reduces the expression of JPH4 higher than siRNA1 or combination treatment. B. Immunocytochemical 
assay of Scrambled oligomer (as a negative control) versus JPH4-siRNA2 treated DRG neurons reveals 
a decreased JPH4 antibody-specific fluorescence by confocal microscopy. Data shown as mean ± SEM, 
n=6 for both data sets.  
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Even though this experiment does not provide a complete JPH4 depletion, I decided to test 
whether silencing JPH4 in DRG neurons using the optimized protocol with siRNA2 would 
reveal any disruption between Orai1 and STIM1 after BK-induced SOCE. 
Thus, PLA experiments aiming at the interaction between Orai1 and STIM1 were performed 
on JPH4 silenced DRG neurons and compared with the negative control. Upon SOCE 
activation, Orai1-STIM1 PLA signals revealed a higher number of fluorescent puncta as 
compared to non-depleted cells in the negative control group (Figure 6.6). This is consistent 
with my previous finding described in Chapter 3. Interestingly, in the JPH4 silenced group, 
no significant difference between the number of puncta in store-depleted and non-depleted 
neurons was detected (Figure 6.7). This experiment was performed with the help of Dr. Shihab 
Shah.  
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Figure 6.6. Orai1 and STIM1 translocate at ER-PM junctions after BK-induced SOCE in the 
negative control group. A. Representative example of fluorescent PLA signals between Orai1 and 
STIM1 in cultured DRG neurons. B. The number of fluorescent puncta per 100 µm². Data shown as 
mean ± SEM, p<0.001, Student’s t-test, Control n=5, SOCE n-6.  
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Figure 6.7. Orai1 and STIM1 translocation is disrupted in JPH4-KD sensory neurons. A. 
Representative example of fluorescent PLA signals between Orai1 and STIM1 in cultured DRG 
neurons. B. The number of fluorescent puncta per 100 µm². Data shown as mean ± SEM, p<0.001, 
Student’s t-test, Control n=5, SOCE n=6.  
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6.2.4 Silencing JPH4 impairs SOCE but does not affect the ER Ca2+ levels at 
rest in DRG neurons 
Calcium imaging experiments were then performed to determine whether reducing the 
expression of JPH4 in DRG neurons has any impact on BK-induced SOCE. To do so, I 
transfected the neurons with JPH4-siRNA2 (using Lipofectamine RNAiMAX as a vehicle) as 
described previously. Similarly, Scrambled Oligomer transfections were used as a negative 
control. Two days post-transfection, cells were loaded with Fura-2AM for 1 hour and washed 
with extracellular buffer thereafter. For consistency, the experimental design was kept in line 
with all previous experiments focused on inducing SOCE in DRG neurons. Thus, Ca2+ stores 
were depleted with 250 nM BK in Ca2+ free solution and Fura2 fluorescent levels were 
measured. Figure 6.8 shows that silencing JPH4 in DRG neurons reduces the BK-induced 
SOCE by approximately 45% (p<0.05, Student T test). Interestingly, the amplitudes of the 
cytosolic Ca2+ transients induced by BK during store depletion did not significantly differ 
between the two groups, although a reduction of 14% in JPH4-siRNA treated cells was noticed 
(p<0.05, Student’s t test; Figure 6.8.B). 
These results suggest that JPH4 might be involved in facilitating SOCE yet, the basal ER Ca2+ 
levels could be maintained even with such partial SOCE impairment.  
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Figure 6.8. JPH4-KD impairs SOCE in DRG neurons. A. Representative example of Fura2 calcium 
imaging recording of typical store depletion/Ca2+ add back experiments in control and JPH4-KD cells, 
as indicated. B, C summary data for experiments as these shown in A; the effect of JPH4 KD on the 
amplitude of the BK-induced Ca2+ transients (B) and SOCE during the Ca2+ re-addition phase (C). Data 
is shown as mean ± SEM, p<0.05 Student’s t test.  
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The previous experiment demonstrated that silencing JPH4 in DRG neurons generated a 
reduced SOCE and, presumably, a lower ER Ca2+ uptake. To determine the impact of the 
reduced Ca2+ store refill on subsequent SOCE activation, I designed an experimental protocol 
where two rounds of store depletion were applied in sequence.  To avoid desensitization and 
tachyphylaxis common for the Gq/11 coupled receptors, the DRG neurons were treated with 
two different GPCR-agonists. Thus, cultured cells were initially treated with 30 µm ATP to 
activate endogenous Gq/11-coupeld P2Y receptors expressed in DRG neurons (Gerevich et al. 
2004), Following a Ca2+ pool refill phase, BK was applied to stimulate again the IP3-dependent 
store depletion, this time by activating B2R. It has to be pointed out that while DRG neurons 
also express ionotropin P2X2/P2X3 receptors (Gerevich et al. 2004), the agonist application 
was performed in Ca2+ free conditions (in line with previous protocols), thus contribution of 
these receptors to intracellular Ca2+ levels was excluded by the experimental design. The aim 
of this experiment was to investigate the role of JPH4 in an active store refill in intensive DRG 
stimulation scenarios (as e.g. under the persistent tissue inflammation). Figure 6.9 shows that 
the secondary (BK-induced) Ca2+ release from the stores was indeed reduced by 40% in JPH4-
silenced neurons as compared to control.  
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Figure 6.9. JPH4-KD impairs the ER Ca2+ pool refill with consequences on the subsequent store 
depletion. A. Representative example of Fura2 calcium imaging recording in sensory neurons. First 
store depletion was induced by ATP (30 M) in the Ca2+ free buffer; Ca2+ was then added back to the 
extracellular buffer and secondary IP3-dependent store depletion with BK (250 nM) was performed. B. 
Fura-2 measurements of BK-induced store depletion in Scrambled Oligomer treated (negative control) 
and JPH4-KD (siRNA2 treated) DRG neurons. Data is shown as mean ± SEM, p<0.05 Student’s t-test.  
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6.3 Discussion 
JPH4 has been recently shown to have an important role in facilitating SOCE in T cells and, 
alongside JPH3, to modulate Ca2+ dynamics in hippocampal neurons (Woo et al 2016, 
Takeshima et al 2003). Chapter 5 of this thesis demonstrated the expression of JPH4 in DRG 
neurons of different sensory modalities, including small pain-sensing nociceptors. As STIM1 
and Orai1 have a similar expression pattern to that of JPH4, the current chapter aimed at 
investigating whether JPH4 might function as a SOCE promoter in DRG neurons. 
 
6.3.1. JPH4 is co-expressed with Orai1 and STIM1 in primary sensory neurons 
The IHC/ICC experiments demonstrated that JPH4 was co-expressed with both Orai1 and 
STIM1 in primary afferent neurons. Interestingly, ICC experiments highlighted that JPH4 
reveals a filament-like staining pattern in the PM, wrapping the neuron as shown in Figure 
6.1. It is likely that it might follow the ER cisternae that runs alongside the PM. This image 
was recorded at different sections through the neuron: starting from the lowest Z level, 
followed by moving the optical focus up by 1 µm until I reached the other edge of the cell. 
This pattern has been observed in repeated experiments and further investigations are needed 
to determine the exact nature of the JPH4-positive cisternae in DRG neurons. 
Co-staining with an antibody against STIM1 revealed that JPH4 was expressed mainly at the 
PM level, while STIM1 populated the intracellular space as expected. It is important to 
mention that JPH4 is residing in the ER, but its MORN motifs interact with the PM and thus 
contribute to forming the ER-PM junctions.  By contrast, when Ca2+ levels are at rest, STIM1 
moves freely in the ER membrane reason why a diffused intracellular distribution was 
observed. Woo and colleagues also demonstrated that after thapsigargin-induced store 
discharge, STIM1-YFP move into pre-formed junctions detected by mCh-JPH4 in Jurkat T 
cells.  
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6.3.2 JPH4 interacts with STIM1 in DRG neurons 
The Co-IP experiments (immunoblotting JPH4 in a STIM1 immunoprecipitate sample, Figure 
6.3.A) revealed that STIM1 and JPH4 directly interacted upon SOCE stimulation with BK. 
This finding suggests that discharging the ER Ca2+ pool in DRG neurons triggers the 
translocation of STIM1 at the ER-PM junctions and its binding to JPH4.  
This result was consistent with those reported by Woo and colleagues. The authors transfected 
HEK293 cells with FLAG-STIM1 and GFP-JPH4 and immunoprecipitated with either anti-
STIM1 or anti-JPH4 antibody, while blotting for the detection of JPH4 (with anti-GFP 
antibody) or STIM1 (with anti-FLAG antibody), respectively. Similar with my observations, 
thapsigargin-induced store depletion generated STIM1-JPH4 interaction, also confirmed by 
GST pulldown analyses (Woo et al. 2016). Moreover, the same authors reported that JPH4 
colocalizes with junctate at the ER-PM junctions of T-cells, form a protein complex and both 
bind STIM1 in order to facilitate SOCE (Woo et al. 2016). Junctate is an IP3R- associated 
protein with a role in modulating ER Ca2+ release and facilitating SOCE by recruiting STIM1 
into ER-PM junctions (Treves et al. 2004, Srikanth et al. 2012). Previous studies demonstrated 
that junctate has a structural role into sustaining the ER-PM junctions of T cells where STIM1 
and Orai1 cluster, interact and form CRAC channels (Srikanth et al. 2012). To my knowledge, 
there is no evidence of the expression of this protein in rodent DRG neurons in the literature 
or in the Allen Mouse Spinal Cord atlas. But mouse cloning studies demonstrated that it is 
present in brain, heart, spleen, lung, kidney, liver and stomach (Hong et al 2001). Whether 
JPH4 on its own is sufficient to promote the CRAC channel assembly in DRG neurons remains 
to be determined. As other junctophilin proteins also seem to be expressed in this tissue (such 
as JPH1 and JPH3), but to a lesser degree, it is appealing to investigate a putative role of these 
in SOCE further. 
Moreover, PLA analysis further confirmed that both STIM1 and Orai1 come in closer 
proximity to JPH4 in DRG neurons after BK-induced store depletion. Detecting fluorescent 
PLA signal between JPH4-STIM1 and JPH4-Orai1 in the non-treated cells demonstrated that 
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a number of these proteins are already found at the ER-PM junctions (the distance between 
the inner leaflet of the PM and the ER membrane at junctions is of approximately 20nm), but 
once the ER Ca2+ discharge was induced, further movement and clustering into junctions was 
revealed by a stronger PLA signal (Figures 6.3 and 6.4). Whether Orai1 directly interacts with 
JPH4 or further scaffolds are necessary remains to be determined. 
 
6.3.3 Silencing JPH4 in DRG neurons disrupts Orai1-STIM1 interaction 
Chapter 3 of this thesis reported that Orai1 and STIM1 come in closer proximity once store 
depletion is triggered in DRG neurons. Experiments in the current chapter suggested that 
STIM1 might be recruited by JPH4 at ER-PM junctions, presumably prior to coupling to 
Orai1. To investigate its role in promoting the formation of CRAC channels, small interfering 
RNA (siRNA) was used to reduce the expression of JPH4 in DRG neurons. Further on, 
changes in the fluorescent PLA signal between Orai1-STIM1 were determined. Figures 6.6 
and 6.7 demonstrate that downregulation of JPH4 expression reduces Orai1-STIM1 PLA 
signal in BK-treated neurons as compared to control. These results suggest that lacking JPH4 
may impair STIM1 recruitment at ER-PM junctions, further disrupting the CRAC machinery 
and, presumably, inhibiting SOCE. Taken together, these results strongly suggest that JPH4 
is indeed an important component of CRAC channel complex assembly in DRG neurons. 
 
6.3.4 Silencing JPH4 in DRG neurons inhibits SOCE and further impairs the 
ER Ca2+ store refill  
To investigate further the role of JPH4 in SOCE, ER store refill and GPCR-induced Ca2+ 
signalling in DRG neurons, JPH4-silenced neurons were store-depleted with BK in the 
extracellular Ca2+ free solution (for consistency, all BK-induced SOCE experiments reported 
in this thesis were performed by applying the same protocol design). Interestingly, reducing 
the expression of JPH4 did not alter the basal Ca2+ pool levels (Figure 6.8.B), but it 
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significantly impaired SOCE as shown by a reduced Ca2+ influx as compared to control 
(Figure 6.8.C). 
Alongside the BK, other inflammatory mediators released after tissue injury are histamine, 5-
hydroxytriptamine (5-HT), adenosine triphosphate (ATP), nitric oxide and ions such as K+ or 
H+ (Kidd and Urban 2001). ATP is also involved in peripheral pain signalling by activating 
ligand-gated P2X receptors as well as metabotropic P2Y receptors in small nociceptive 
neurons (Liang et al. 2010, Gerevich and Illes 2004). Previous studies reported that GPCR-
activated SOCE demonstrated an oscillatory behaviour as the ER Ca2+ pool depletes and refills 
continuously upon IP3R or RyR activation (Suzuki et al. 2014). Thus, if a disruption in the 
Ca2+ store uptake occurs, further SOCE-activating processes should be inhibited. Figure 6.9 
reveals that a lower expression of JPH4 in DRG neurons impairs ATP-induced SOCE, 
followed by a decrease in the ER Ca2+ uptake and, further on, a reduced BK-induced Ca2+ 
transients. As expected, lower intraorganellar Ca2+ levels would subsequently generate lower 
Ca2+ release levels. Moreover, the JPH4-KD was achieved only partially, thus a slow ER Ca2+ 
refill could be expected. Even in this condition, a strong and repetitive stimulation could lead 
to a deficiency in the recovery of the ER Ca2+ levels and, further on, to a reduced neuronal 
excitability. 
An attempt to reduce the expression of JPH4 protein in vivo was made by collaborators at 
Hebei Medical University. The aim of this experiments was to determine changes in the 
nocifensive behaviour in JPH4 knockout mice as compared to naïve mice. JPH4-KD did not 
modify the basal thermal or mechanical sensitivity but reduced the BK-induced nociception 
(data not shown, manuscript in preparation).   
All these observations taken together strengthen the hypothesis that JPH4 may have a 
functional role in recruiting STIM1 at ER-PM junctions, facilitating the CRAC channel 
assembly and thus mediating inflammatory-related SOCE in pain-sensing neurons. CRAC 
components have been previously reported as attractive targets for novel analgesic or anti-
inflammatory compounds. The results presented in this chapter may lead the road to further 
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investigations to determine whether junctional proteins, such as JPH4, might be considered as 
pharmacological targets for inflammatory pain as well. 
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Chapter 7. General discussion 
This study aimed at identifying the CRAC components in DRG neurons, investigating the 
effects of CRAC inhibitors and determining the role of junctophilin proteins to modulate 
SOCE in the context of inflammatory pain. 
7.1 SOCE is driven mainly by the STIM1/Orai1 machinery in pain-
sensing DRG neurons 
Neurons use intra- and extracellular Ca2+ sources to generate intricate Ca2+ signals and the 
main intracellular Ca2+ pool is the ER. Ca2+ levels in this organelle are controlled by IP3R, 
RyR and SERCA pumps (Berridge 1998). Elevated SOCE was previously associated with 
neuropathic and inflammatory pain and the presence of molecular components of CRAC 
channels were reported in primary afferent neurons (Fuchs et al. 2007, Gemes et al. 2011, Wei 
et al. 2017).  
Amongst STIM and Orai family members, it has been suggested that all except Orai2 are 
expressed and mediate SOCE in DRGs (Wei et al. 2017). Current clamp recordings on Orai1 
and Orai3 double knock-down neurons showed a reduced thapsigargin-induced membrane 
depolarization and spike frequency as compared to control (Wei et al. 2017). This suggests 
that Orai1 and Orai3 play a key role in SOCE-mediated excitability in peripheral sensory 
neurons. 
Furthermore, fura-2 experiments revealed that thapsigargin-induced SOCE was negatively 
correlated with the somatic diameter, thus a more robust Ca2+ influx occurred in smaller 
neurons, frequently associated with nociceptors (Wei et al. 2017).  
In this thesis I investigated the distribution pattern of STIM and Orai isoforms by 
immunohistochemistry (Chapter 3) and demonstrated that all proteins except Orai2 are indeed 
expressed in DRG neurons, which is in line with the observations of Wei and colleagues. 
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Moreover, the immunostainings revealed that STIM1 and Orai1 remain the most plausible 
candidates for the CRAC channel as they were expressed to a higher degree in DRG neurons 
as compared to STIM2 and Orai3. Would this imply they are involved in inflammatory pain 
signalling? To answer this, I determined whether endogenously expressed STIM1 and Orai1 
proteins co-localize into puncta upon BK-induced SOCE, as to my knowledge, attempts to 
investigate similar scenarios were made only in sensory neurons transiently overexpressing 
these SOCE components (Gao et al. 2016, Wei et al. 2017). BK, amongst other inflammatory 
mediators that are released upon tissue injury, acts on the peripheral nerve terminals by 
activating or sensitizing specific receptors (Das V. 2015). The stimulation of B2R is known to 
activate the PLC pathway which results in the release of IP3 and DAG from PIP2 (Das V 2015). 
The main role of IP3 is to trigger ER Ca
2+ store depletion through IP3R, and the lowering in 
Ca2+ levels is further sensed by the ER resident STIM1. Further on, STIM1 clusters and 
interacts with Orai1 at the ER-PM junctions to mediate SOCE (Liou et al. 2005). Here I 
reported that BK-induced SOCE triggers the STIM1-Orai1 protein mobilization at the ER-PM 
junctions in DRG neurons, and therefore this process might have a functional role in 
inflammatory pain signalling. 
7.2 STIM2 is expressed highly in large mechanosensory neurons 
Interestingly, immunohistochemistry experiments revealed that STIM1, Orai 1 and Orai 3 are 
uniformly distributed throughout DRG neurons of all sizes, without any obvious bias towards 
neurons of a particular size. By contrast, the STIM2 distribution analysis demonstrated that 
only 34% of the smaller somata (diameter <25 µm) express STIM2, while 80% of larger 
neurons (>40 µm) revealed positive staining. Hence, STIM2 is preferentially expressed by the 
myelinated fibers within the DRG. 
Previous studies reported that STIM2 could mediate SOCE when a partial ER Ca2+ store 
depletion occurs (and STIM1 is at rest). Moreover, STIM1 was shown to be 70 times faster to 
saturate Orai1 binding sites as compared to STIM2 and it responds quicker to a significant ER 
148 
 
Ca2+ drop (Stathopulos et al. 2009, Gruszczynska-Biegala and Kuznicki 2013). Considering 
these observations and my findings, it could be hypothesized that: i) in small pain sensing 
neurons STIM1 is mainly responsible for mediating SOCE, and ii) in large mechanosensory 
neurons STIM2 could enable SOCE and thus having a role in touch sensation. More 
investigations are needed to validate the different functions of STIM isoforms in DRG 
neurons. 
Wei and colleagues also reported that thapsigargin induced-SOCE is more robust in small and 
medium-sized neurons (Wei et al.2017). The reason for this could be the higher expression of 
STIM1 as compared to STIM2 in small pain sensing nociceptors and the opposite for large 
myelinated neurons. 
7.3 CRAC inhibitors reduce BK-induced SOCE in pain sensing neurons 
Since the discovery of the CRAC channel, CRAC inhibitors were developed and widely used 
as tools for research. Biotech and pharmaceutical companies developed a range of small 
molecules to inhibit SOCE (McCarl et al. 2009). Several CRAC modulators are now in the 
pipeline with positive outcomes observed in Phase I clinical trials in immunology and allergy 
(Calcimedica Inc, 2017). SOCE plays a key role in inflammatory processes and its inhibition 
is associated with a decrease in cytokine production and subsequent pain alleviation as 
observed in in vivo studies (Gao XH et al. 2015). This thesis revealed that CRAC inhibitors 
YM and Synta potently reduced BK-induced SOCE in DRG neurons.  Wei and colleagues 
recently reported that 10 µM YM and 30 µM Synta inhibited thapsigargin-induced SOCE by 
30% in primary afferent neurons (Wei et al. 2017). In another study cyclopiazonic acid (CPA)-
induced SOCE was reduced by approximately 50% when DRG neurons where treated with 3 
µM YM and by approximately 15% when treated with 1 µM YM (Gao R et al. 2013). Both 
research groups applied the drugs acutely, immediately after maximal SOCE was reached. In 
this study I report that 1 µM YM and 3 µM Synta inhibited BK-induced SOCE by 
approximately 90%. The concentration I used was 10 times lower as compared to that used by 
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Wei and colleagues, but neurons were treated for 1 hour prior to store depletion. CHO cells 
experiments with the ER Ca2+ indicator R-CEPIA1er demonstrated that YM and Synta inhibit 
SOCE (and subsequent ER Ca2+ refill) greater in the pre-incubation paradigm, as compared to 
cells being treated during store depletion or during SOCE. Furthermore, PLA experiments 
revealed that even though YM shows a greater effect when cells were pre-incubated, it may 
not interfere with processes such as STIM1 Ca2+ sensing, its re-arrangement or movement to 
junctions. Similar results were reported for Synta in vascular smooth muscle cells (Li et al. 
2011). This being said, the resistance of STIM1-Orai1 coupling machinery to either of the 
drugs does not rule out a possibility that YM or Synta may interfere with the formation of the 
ion channel pore or interfere with the STIM1-Orai1 interaction in such a way that while not 
affecting clustering, it nevertheless inhibits the formation of functional STIM1-Orai1 
complex. The slow kinetics of YM and Synta and the necessity of pre-treatment do suggest 
that, unlike most ion channel inhibitors, these compounds are unlikely to block SOCE via a 
simple pore blocking mechanism. This is a novel finding that warrant further investigation, 
especially in light potential therapeutic applications of the SOCE inhibitors. Indeed, both YM 
and Synta demonstrated a high therapeutic potential in both neuropathic and inflammatory 
pain (Gao XH et al. 2015, Wei et al. 2017). They were shown to alter the cytokine release at 
tissue injury and to alleviate acute and chronic pain in animal models (Sabatino et al. 2009, 
Wei et al. 2017, Gao XH et al. 2015, Qi et al. 2016, Gemes et al. 2011). In conclusion, this 
current study provides evidence that YM and Synta complimentary inhibit SOCE in primary 
afferent neurons this effect is in good agreement with previously reported reduction of 
cytokine release by these compounds  
7.4 Junctophilin proteins are expressed in DRG neurons 
Junctional membrane complexes (JMC) between the ER and PM are structures that mediate 
the communication between proteins residing in these membranes (Takeshima et al. 2000). 
Junctophilin (JPH) proteins are important components of JMCs and they promote STIM1 
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translocation at the already formed ER-PM junctions. Thus, the interaction with Orai1 is 
facilitated and SOCE can be triggered (Fahrner et al. 2013). The expression of JPHs has been 
observed to be tissue-specific: JPH1 has been identified in skeletal muscle and to a lower 
degree in cardiomyocytes (Murphy et al. 2013), JPH2 in cardiac muscle cells (Minamisawa et 
al. 2004), JPH3 and JPH4 in neurons of the brain (Landstorm et al. 2014) and, to date, JPH4 
has been the only family member identified in T cells (Landstorm et al. 2014).  In both rodents 
and humans, lack of JPH proteins has been linked to muscular dystrophy (JPH1), arrhythmia 
(JPH2) and Hungtington-disease like syndrome (JPH3/4) (Ito et al. 2001, Minamisawa et al. 
2004, Moriguchi et al. 2006, Paradisi et al. 2013). To my knowledge, literature holds no 
evidence of JPH proteins being expressed in peripheral sensory neurons, only the Allen Spinal 
Cord Atlas showing JPH3 and 4 gene expression mapped across the mouse spinal cord and 
DRGs (http://mousespinal.brain-map.org/). 
This thesis for the first time reports the expression of JPH3 and 4 proteins in primary afferent 
neurons. Surprisingly, JPH1, thought to localize preferentially in skeletal muscle, has been 
also identified in approximately 50% of DRG neurons. All three proteins showed a uniform 
distribution within neurons of different sensory modalities, suggesting they might facilitate 
SOCE induced by a variety of stimuli. Furthermore, I demonstrated that these proteins are 
expressed in heat-sensitive nociceptors, with JPH4 to express at a higher degree than JPH1 
and JPH3. TRPV1-positive nociceptors are believed to be the main type of primary afferent 
neurons that mediate inflammatory responses, thus I hypothesize that all three proteins might 
mediate Ca2+ dynamics in pain-sensing neurons.  
7.5 JPH4 facilitates STIM1-Orai1 coupling in pain sensing neurons 
Out of the three JPH proteins identified in DRG neurons, JPH4 was found to be expressed at 
the highest levels (assuming that the affinities of the JPH antibodies used in this study are 
comparable). Moreover, it was identified in approximately 80% of heat-sensitive nociceptors 
further suggesting that it might facilitate SOCE in inflammatory-pain scenarios. Here I 
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reported that STIM1 and Orai1 are co-expressed with JPH4 in DRG neurons and that both co-
localized with JPH4 after store depletion. Interestingly, JPH4 revealed a filament-like 
localization with a preferred distribution towards the PM. It is likely to follow the ER cisternae 
that run alongside the PM. When Ca2+ levels are at rest, JPH4 co-localized partially with Orai1 
towards the PM, but no co-localization of JPH4 and STIM1 was observed. As expected, 
STIM1 diffuses freely in the ER membrane and only when store depletion occurs it 
translocates at the ER-PM junctions. 
Woo and colleagues recently reported that JPH4 mediates SOCE in T cells by forming a 
complex with junctate and recruiting STIM1 at the ER-PM junctions. Similarly, I 
demonstrated that STIM1 directly interacted with JPH4 after stimulation with BK, further 
suggesting that JPH4 might have a functional role in promoting the formation of CRAC 
channels in nociceptors. 
To strengthen these observations, knock-down experiments revealed that STIM1-Orai1 
interaction is disrupted in neurons lacking JPH4, thus this junctional protein is an important 
component of the CRAC channel complex assembly in pain sensing neurons. 
Woo and colleagues demonstrated that both JPH4 and junctate bind STIM1 to facilitate SOCE 
in T cells. To my knowledge, there is no evidence of the expression of junctate in DRG 
neurons, but a research group identified it in brain (Hong et al. 2001). Whether JPH4 acts on 
its own to promote the CRAC channel assembly or if other scaffolding or supporting 
molecules are recured remains to be determined.   
7.6 JPH4 facilitates SOCE in relation to inflammatory pain 
My experiments demonstrated that silencing JPH4 disrupts STIM1-Orai1 interaction in pain 
sensing neurons. As a consequence of this disruption, in conditions of BK stimulation, a 
decreased SOCE was observed. Importantly, the basal Ca2+ levels remained unaffected. A 
limitation of this experiment was that only partial knock-down of JPH4 was achieved and this 
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could be the reason why SOCE was not completely abolished. Also, other junctional proteins 
might facilitate the CRAC channel assembly alongside JPH4. Therefore, in conditions of 
vigorous stimulation, similar to that occurring in the inflammatory milieu, neurons expressing 
less JPH4 were still able to refill their stores, albeit at a slower rate. Partial store replenishment 
affects subsequent SOCE and thus contributes to a decreased neuronal excitability in relation 
to inflammatory-mediated pain. 
 
Figure 7.1. Schematic representation of STIM1 recruitment by JPH4. After ER Ca2+ pool 
depletion, STIM1 expands and clusters at the ER-PM junctions where it interacts with junctional 
proteins such as JPH. JPH4 has been shown to promote STIM1 recruitment in DRG neurons and to 
offer a supportive role to BK-induced SOCE.  
 
Importantly, these observations were confirmed in the in vivo JPH4 knockdown experiments 
conducted in collaboration with researchers at Hebei Medical University. In these 
experiments, unilateral in vivo knock down of JPH4 in rats was performed using an intrathecal 
injection of cholesterol-conjugated JPH4 siRNA (the same sequence as the siRNA#2 used in 
this study). Knocking-down JPH4 in mice DRGs did not alter the basal thermal or mechanical 
sensitivity but significantly reduced the BK-induced pain-related (‘nocicefensive’) behaviour 
(data not shown, manuscript in preparation).   
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In conclusion, the work presented in this thesis brings evidence for: 
a) the expression pattern of STIM/Orai components in DRG neurons of distinct sensory 
modalities,  
b) the presence of inflammatory mediator (e.g. BK) - induced SOCE in DRG neurons,  
c) the CRAC state-dependence effect of SOCE inhibitors YM and Synta 
d) the identity and localization pattern of JPH proteins in primary afferent neurons and 
e) the functional role of JPH4 in promoting CRAC channel assembly and mediating BK-
induced SOCE in primary afferent neurons. 
 
7.7 Future directions  
The data presented in this study strengthen the importance of SOCE in inflammatory pain 
signalling and addressed some of the controversial issues surrounding the efficacy of CRAC 
inhibitors. The above-mentioned results are also fascinating observations regarding the 
putative role of JPHs (and JPH4 in particular) in facilitating pain signalling during 
inflammation. 
SOCE is a complex and reversible mechanism that offers the possibility to target a range of 
proteins to develop novel therapies. Either CRAC channel components or their interacting 
partners are plausible candidates for future anti-inflammatory and/or analgesic drugs.  
STIM 2, Orai 2 and Orai 3 are the isoforms that did not get as much attention from researchers 
as the other family members did. The impact they may have on facilitating SOCE in a range 
of scenarios (e.g. STIM2 have been reported to trigger SOCE when a partial ER Ca2+ store 
depletion occurs) should make them attractive for further research. For example, due to the 
distinct localization pattern of STIM isoforms, I speculate that STIM2 might be involved in 
mediating SOCE at lower pain thresholds as compared to STIM1. 
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Here I also reported that JPH4 promotes SOCE in stimulated primary afferent neurons. 
Whether JPH1 and/or 3 also play a key role in inflammatory pain signalling remains to be 
determined. One way to investigate this could involve knocking down JPH1 and JPH3 in vitro 
and in vivo, running Co-IP and PLA experiments to determine if JPHs form protein complexes 
upon SOCE stimulation, or if they function individually.   
To summarise, the findings reported in this thesis provided evidence for the importance of 
CRAC components and brought to the surface the role of JPH proteins in the context of 
inflammatory pain. While researchers are continuously looking to better understand the 
mechanisms of pain signalling and to find novel pharmacological targets for analgesics, these 
results will hopefully contribute to building up knowledge in this field.    
7.8 Study limitations 
The current study has several limitations that could be addressed in future research, as follows: 
The DRG neurons were used as a model of SOCE in relation to inflammatory pain signalling. 
While primary afferent neurons are widely used in vitro in all types of pain models (Xiao et 
al. 2007), the main caveat for using them is that DRG dissociation requires axotomy, thus 
limiting the results interpretation to the isolated cells (Malin et al. 2007). However, for 
confirming the hypothesis that JPH4 is important in inflammatory pain signalling, in vivo 
experiments using different pain models were performed by collaborators at Hebei University 
as described in Chapter 6. 
Widely used in molecular biology research, CHO and HEK cell lines were used as analogues 
of SOCE and intracellular signalling of DRGs. The main reason to experiment on these 
established cell lines was to reduce the number of sacrificed animals. However, as compared 
to DRG neurons, these are non-excitable cells and the results may differ due to the lack of 
specific neuronal proteins such as voltage activate channels. 
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Bradykinin (250 nM) was used as a mechanism of depleting the ER luminal Ca2+ and 
stimulating SOCE. The concentration I used was tested and confirmed by previous lab 
members in DRG neurons, however I have not performed any other dosing regimens. It is 
indeed possible that higher doses of bradykinin could deplete the ER stores better or faster. 
Proximity ligation assay (PLA) is a proteomic technique that uses the principle of two 
oligonucleotide-labelled antibodies that are capable to bind when are found within 40 nm of 
each other. While the technique is believed to be sensitive due to the detection of the amplified 
DNA, its sensitivity can be modulated by adjusting the incubation time during the rolling 
circle amplification. However, for the purpose of this study, I have followed the 
manufacturer’s instructions, but different results may be obtained if amplification conditions 
would be tuned. Furthermore, there is a risk of not detecting several protein pairs due to the 
spatial uncertainty introduced by the IgG (primary and secondary) complex, which can be 10-
20 nm in size itself, adding further distance to that between the target proteins. Also, already 
formed CRAC channels may not be detected.  
For PLA analysis, I counted the number of puncta with an intensity higher than 10 per each 
neuron and presented the results as the number of puncta per 100 μm2. I chose an intensity 
threshold of 10 as less than that was showing as diffused fluorescence. However, a weak 
intensity may still be a positive signal, but I took a conservative approach to avoid false 
negative results.  
Similarly, the Immunohistochemistry (IHC) experiments were analysed by selecting the mean 
fluorescence intensity per DRG section. Indeed, this approach limits the number of neurons 
counted as positive as those with weak intensity were not considered. Furthermore, there is a 
limited blinding (assessing the Orai and STIM protein expression) that might have biased the 
analysis for the IHC, even though the same approach was used throughout all experiments and 
my findings are similar to what other groups reported (see Chapter 3).  
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The main limitation of the Co-immunoprecipitation (Co-IP) experiment is that the result 
mainly suggests that STIM1 and JPH4 are precipitating together as part of a protein complex. 
Whether they bind directly or indirectly through other proteins cannot be elucidated solely by 
this method. However, the Co-IP result alongside the PLA in JPH4 KD DRG neurons strongly 
suggest that JPH4 is involved in the mechanism of SOCE either as a direct or indirect partner 
with the CRAC components. 
The experimental design for optimising the YM and Synta66 application (time) protocol has 
its limitations as well. Mainly, the design was based on previous literature (see Chpater 4), 
however a time-exposure variability would have been more appropriate to determine if  i) YM 
and/or Synta are dependent on the state of SOCE, and if ii) YM and/or Synta are dependent 
on the treatment duration. The current experiment revealed that both drugs are more efficient 
if incubated 1h prior to store depletion, but whether an incubation time longer than 1h provides 
a better depletion (or even Ca2+ store abolition), remains to be determined.  
YM and Synta are pyrazole-derivative drugs that were developed as SOCE inhibitors. 
However, their mechanism of action remains unknown. Recent literature determined that YM 
can interact with other Ca2+ handling proteins such as TRPM4 channels (Takezawa et al. 
2006). The potency of YM as an agonist of TRPM4 is thought to be 100 times higher than that 
of CRAC channels, as shown in T-cells (Putney et al. 2010). To my knowledge, the selectivity 
of Synta against a panel of proteins was not yet tested. If YM or Synta activate plasma 
membrane Ca2+ channels, this may contribute to a depolarization and a reduced Ca2+ entry 
through CRAC channels. Thus, it cannot be ruled out that other proteins may contribute to the 
results presented in this thesis. Knock-down experiments and using specific inhibitors may 
provide further evidence about the drugs’ selectivity. Furthermore, the basal Ca2+ levels could 
also be measured to determine if the drugs influence the overall ER loading during the 
incubation phase as compared to the acute treatment.  
For testing the ER Ca2+ fluctuations I used CEPIA sensors as described in Chapter 2.5 
However, I have not tested other ER Ca2+ indicators and therefore I relied on the specificity 
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and transfection efficacy as described by Suzuki and colleagues. Another limitation would be 
not measuring the dye saturation and not calculating the Ca2+ concentration which may affect 
the overall depletion/refill ratio. Moreover, to determine whether the fluorescence intensity 
decreases with time, running an experiment to determine the bleaching time of the Ca2+ 
indicator would be necessary.  
Two STIM1 splice variants have been observed: STIM1S (S for small, 90 kDa) and STIM1L 
(L for long, 115 kDa) (Darbellay et al. 2011). While STIM1S slowly clusters to form CRAC 
channels in response to ER Ca2+ depletion, STIM1L was shown to colocalize with Orai1, 
interact with actin and form permanent clusters independent of SOCE (Darbellay et al. 2011). 
To my knowledge, the different expression of STIM1L and STIM1S in DRG neurons was not 
determined yet, however the PLA experiments presented in this thesis revealed fluorescent 
puncta between Orai1 and STIM1 when Ca2+ levels are at rest. This may be due to the 
permanent clusters formed between STIM1L and Orai1 as described by Darbellay and 
colleagues. To test this hypothesis, specific antibodies can be used to determine the expression 
(and role) of the two STIM1 splice variants in DRG neurons. 
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